GB Sciences (GBLX) S-1 17 Sep 21 2022 Q1 IPO registration Financial data

Document And Entity Information

Document And Entity Information	3 Months Ended
	Jun. 30, 2021
Document Information [Line Items]
Entity Central Index Key	0001165320
Entity Registrant Name	GB SCIENCES INC
Amendment Flag	false
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Document Type	S-1
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	59-3733133
Entity Address, Address Line One	3550 W. Teco Avenue
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89118
City Area Code	866
Local Phone Number	721-0297
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020
Cash and cash equivalents	$ 582,971	$ 793,040	$ 2,406
Prepaid expenses and other current assets	296,081	256,251	18,776
Current assets from discontinued operations	2,248,757	2,494,564	1,755,275
TOTAL CURRENT ASSETS	3,127,809	3,543,855	7,000,880
Property and equipment, net	21,895	25,022	37,821
Intangible assets, net of accumulated amortization of $43,096 and $12,287 at March 31, 2021 and 2020, respectively	1,797,920	1,706,762	1,128,702
Long term assets from discontinued operations	5,383,005	5,530,415	6,185,465
TOTAL ASSETS	10,330,629	10,806,054	14,352,868
CURRENT LIABILITIES:
Accounts payable	1,463,806	1,412,459	1,913,049
Accrued interest	521,145	493,741	366,865
Accrued liabilities	1,031,003	957,946	813,618
Notes and convertible notes payable and line of credit, net of unamortized discount of $272,122 and $296,504 at June 30, 2021 and March 31, 2021, respectively	3,619,186	3,594,804
Indebtedness to related parties	84,913	84,913	586,512
Current liabilities from discontinued operations	1,987,787	2,054,585	1,999,062
TOTAL CURRENT LIABILITIES	8,707,840	8,598,448	10,885,757
Convertible notes payable, net of unamortized discount of $154,590 and $0 at March 31, 2021 and 2020, respectively	305,877	292,410	0
Long term liabilities from discontinued operations	3,347,363	3,389,124	3,555,605
TOTAL LIABILITIES	12,361,080	12,279,982	14,441,362
Commitments and contingencies (Note 11)
STOCKHOLDERS' EQUITY/(DEFICIT):
Common Stock, $0.0001 par value, 600,000,000 shares authorized, 315,340,411 and 275,541,602 outstanding at March 31, 2021 and 2020, respectively	31,743	31,534	27,554
Additional paid-in capital	102,619,471	102,380,770	97,271,157
Accumulated deficit	(104,681,665)	(103,886,232)	(97,387,205)
TOTAL STOCKHOLDERS' DEFICIT	(2,030,451)	(1,473,928)	(88,494)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 10,330,629	$ 10,806,054	$ 14,352,868

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020	Aug. 15, 2019	Apr. 08, 2018	Mar. 31, 2018
Intangible assets, accumulated amortization	$ 57,322	$ 43,096	$ 12,287
Unamortized discount, current	272,122	296,504	608,580
Unamortized discount, noncurrent	$ 141,123	$ 154,590	$ 0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	600,000,000	600,000,000	600,000,000	600,000,000	400,000,000	250,000,000
Common stock, shares issued (in shares)	317,429,078	315,340,411	275,541,602
Common stock, shares outstanding (in shares)	317,429,078	315,340,411	275,541,602

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021	Mar. 31, 2020
Sales revenue	$ 0	$ 0	$ 0	$ 0
Cost of goods sold	0	0	0	0
Gross profit	0	0	0	0
General and administrative expenses	493,405	515,253	2,001,617	5,741,514
LOSS FROM OPERATIONS	(493,405)	(515,253)	(2,001,617)	(5,741,514)
OTHER EXPENSE
Interest expense	(65,254)	(662,370)	(1,285,460)	(1,109,031)
Debt default penalty	0	(286,059)	(286,059)	0
Other expense	0	11,182	0	179,368
Total other expense	(65,254)	(959,611)	(1,331,233)	992,455
LOSS BEFORE INCOME TAXES	(558,659)	(1,474,864)	(3,332,850)	(4,749,059)
Income tax expense	0	0	0	0
LOSS FROM CONTINUING OPERATIONS	(558,659)	(1,474,864)	(3,332,850)	(4,749,059)
Loss from discontinued operations	(73,758)	(371,836)	(392,177)	(8,362,626)
NET LOSS	(632,417)	(1,846,700)	(3,725,027)	(12,373,579)
Net loss attributable to common stockholders of GB Sciences, Inc.
Continuing operations	(558,659)	(1,474,864)	(3,332,850)	(4,749,059)
Discontinued operations	(73,758)	(371,836)	(392,177)	(7,624,520)
Net loss	$ (632,417)	$ (1,846,700)	$ (3,725,027)	$ (12,373,579)
Net loss per common share – basic and diluted
Continuing operations (in dollars per share)	$ 0	$ (0.01)	$ (0.01)	$ (0.02)
Discontinued operations (in dollars per share)	0	0	0	(0.03)
Net loss (in dollars per share)	$ 0	$ (0.01)	$ (0.01)	$ (0.05)
Weighted average common shares outstanding - basic and diluted (in shares)	315,675,539	277,968,516	285,190,729	258,450,641

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
OPERATING ACTIVITIES:
Net loss	$ (632,417)	$ (1,846,700)
Loss from discontinued operations	(73,758)	(371,836)
Net loss from continuing operations	(558,659)	(1,474,864)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	17,354	5,562
Stock-based compensation	19,500	0
Amortization of debt discount and beneficial conversion feature	37,849	510,885
Debt default penalty	0	286,059
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(39,830)	0
Accounts payable	(10,304)	34,739
Accrued expenses	(126,943)	(141,102)
Accrued interest	27,404	158,806
Indebtedness to related parties	0	60,291
Net cash used in operating activities of continuing operations	(633,629)	(559,624)
Net cash provided by/(used in) operating activities of discontinued operations	(2,954)	235,779
Net cash used in operating activities	(636,583)	(323,845)
INVESTING ACTIVITIES:
Advancement of proceeds from sale of Nevada subsidiaries	200,000	0
Acquisition of intangible assets	(50,000)	0
Net cash provided by investing activities of continuing operations	150,000	0
Net cash provided by investing activities of discontinued operations	7,435	0
Net cash provided by investing activities	157,435	0
FINANCING ACTIVITIES:
Gross proceeds from warrant exercises	62,660	151,202
Proceeds of note payable	0	150,000
Brokerage fees for warrant exercises	0	(15,121)
Net cash provided by financing activities of continuing operations	62,660	286,081
Net cash used in financing activities of discontinued operations	(33,478)	(12,772)
Net cash provided by financing activities	29,182	273,309
Net change in cash and cash equivalents	(449,966)	(50,536)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	1,145,633	151,766
CASH AND CASH EQUIVALENTS AT END OF PERIOD	695,667	101,230
Less: cash and cash equivalents classified as discontinued operations	(112,696)	(50,135)
CASH AND CASH EQUIVALENTS AT END OF PERIOD FROM CONTINUING OPERATIONS	582,971	51,095
Cash paid for interest	0	0
Cash paid for income tax	0	0
Non-cash investing and financing transactions:
Depreciation capitalized in inventory (discontinued operations)	134,511	164,654
Patent drafting and filing costs capitalized in intangible assets	55,385	78,226
Brokerage fees from warrant exercises in accounts payable	6,266	0
Induced dividend from warrant exercises	163,016	17,236
Discount on note payable attributable to warrant modification	$ 0	$ 150,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Mar. 31, 2019	240,627,102
Balance at Mar. 31, 2019	$ 24,063	$ 93,020,015	$ (84,743,836)	$ 17,155,999
Exercise of warrants for stock, net of issuance costs (in shares)	17,563,000			17,563,000
Exercise of warrants for stock, net of issuance costs	$ 1,756	1,155,971	0	$ 1,157,727
Share based compensation expense	0	287,260	0	287,260
Inducement dividend from warrant exercises	0	262,240	(262,240)	0
Net loss	$ 0	0	(12,373,579)	(12,373,579)
Balance (in shares) at Mar. 31, 2020	275,541,602
Balance at Mar. 31, 2020	$ 27,554	97,271,157	(97,387,205)	(88,494)
Exercise of warrants for stock, net of issuance costs (in shares)	4,991,084
Exercise of warrants for stock, net of issuance costs	$ 500	135,581	0	136,081
Inducement dividend from warrant exercises	0	17,263	(17,263)	0
Net loss	0	0	(1,846,700)	(1,846,700)
Discount on convertible note payable from warrant modification	$ 0	150,000	0	150,000
Balance (in shares) at Jun. 30, 2020	280,532,686
Balance at Jun. 30, 2020	$ 28,054	97,574,001	(99,251,168)	(1,649,113)
Balance (in shares) at Mar. 31, 2020	275,541,602
Balance at Mar. 31, 2020	$ 27,554	97,271,157	(97,387,205)	(88,494)
Exercise of warrants for stock, net of issuance costs (in shares)	35,798,809
Exercise of warrants for stock, net of issuance costs	$ 3,580	964,443	0	968,023
Share based compensation expense	0	436,349	0	436,349
Inducement dividend from warrant exercises	0	2,774,000	(2,774,000)	0
Net loss	$ 0		(3,725,027)	(3,725,027)
Balance (in shares) at Mar. 31, 2021	315,340,411
Balance at Mar. 31, 2021	$ 31,534	102,380,770	(103,886,232)	(1,473,928)
Exercise of warrants for stock, net of issuance costs (in shares)	2,088,667
Exercise of warrants for stock, net of issuance costs	$ 209	56,185	0	56,394
Share based compensation expense	0	19,500	0	19,500
Inducement dividend from warrant exercises	0	163,016	(163,016)	0
Net loss	$ 0	0	(632,417)	(632,417)
Balance (in shares) at Jun. 30, 2021	317,429,078
Balance at Jun. 30, 2021	$ 31,743	$ 102,619,471	$ (104,681,665)	$ (2,030,451)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 582,971	$ 793,040	$ 2,406
Prepaid expenses and other current assets	296,081	256,251	18,776
Note receivable		0	5,224,423
Current assets from discontinued operations	2,248,757	2,494,564	1,755,275
TOTAL CURRENT ASSETS	3,127,809	3,543,855	7,000,880
Property and equipment, net	21,895	25,022	37,821
Intangible assets, net of accumulated amortization of $43,096 and $12,287 at March 31, 2021 and 2020, respectively	1,797,920	1,706,762	1,128,702
Long term assets from discontinued operations	5,383,005	5,530,415	6,185,465
TOTAL ASSETS	10,330,629	10,806,054	14,352,868
CURRENT LIABILITIES:
Accounts payable	1,463,806	1,412,459	1,913,049
Accrued interest	521,145	493,741	366,865
Accrued liabilities	1,031,003	957,946	813,618
Notes and convertible notes payable, net of unamortized discount of $296,504 and $608,580 at March 31, 2021 and 2020, respectively		3,594,804	5,054,728
Indebtedness to related parties	84,913	84,913	586,512
Note payable to related party		0	151,923
Current liabilities from discontinued operations	1,987,787	2,054,585	1,999,062
TOTAL CURRENT LIABILITIES	8,707,840	8,598,448	10,885,757
Convertible notes payable, net of unamortized discount of $154,590 and $0 at March 31, 2021 and 2020, respectively	305,877	292,410	0
Long term liabilities from discontinued operations	3,347,363	3,389,124	3,555,605
TOTAL LIABILITIES	12,361,080	12,279,982	14,441,362
Commitments and contingencies (Note 11)
STOCKHOLDERS' EQUITY/(DEFICIT):
Common Stock, $0.0001 par value, 600,000,000 shares authorized, 315,340,411 and 275,541,602 outstanding at March 31, 2021 and 2020, respectively	31,743	31,534	27,554
Additional paid-in capital	102,619,471	102,380,770	97,271,157
Accumulated deficit	(104,681,665)	(103,886,232)	(97,387,205)
TOTAL STOCKHOLDERS' DEFICIT	(2,030,451)	(1,473,928)	(88,494)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 10,330,629	$ 10,806,054	$ 14,352,868

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020	Aug. 15, 2019	Apr. 08, 2018	Mar. 31, 2018
Intangible assets, accumulated amortization	$ 57,322	$ 43,096	$ 12,287
Unamortized discount, current	272,122	296,504	608,580
Unamortized discount, noncurrent	$ 141,123	$ 154,590	$ 0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	600,000,000	600,000,000	600,000,000	600,000,000	400,000,000	250,000,000
Common stock, shares issued (in shares)	317,429,078	315,340,411	275,541,602
Common stock, shares outstanding (in shares)	317,429,078	315,340,411	275,541,602

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	Nov. 15, 2019	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021	Mar. 31, 2020
Sales revenue		$ 0	$ 0	$ 0	$ 0
Cost of goods sold		0	0	0	0
Gross profit		0	0	0	0
General and administrative expenses		493,405	515,253	2,001,617	5,741,514
LOSS FROM OPERATIONS		(493,405)	(515,253)	(2,001,617)	(5,741,514)
OTHER EXPENSE
Gain/(loss) on extinguishment				467,872	(216,954)
Gain on settlement of accounts payable				422,414	0
Gain on deconsolidation	$ 4,393,242			0	4,393,242
Interest expense		(65,254)	(662,370)	(1,285,460)	(1,109,031)
Loss on modification of line of credit				650,000	0
Loss on note receivable modification				0	1,895,434
Debt default penalty		0	(286,059)	(286,059)	0
Other expense		0	11,182	0	179,368
Total other expense		(65,254)	(959,611)	(1,331,233)	992,455
LOSS BEFORE INCOME TAXES		(558,659)	(1,474,864)	(3,332,850)	(4,749,059)
Income tax expense		0	0	0	0
LOSS FROM CONTINUING OPERATIONS		(558,659)	(1,474,864)	(3,332,850)	(4,749,059)
Loss from discontinued operations		(73,758)	(371,836)	(392,177)	(8,362,626)
NET LOSS				(3,725,027)	(13,111,685)
Loss attributable to non-controlling interest				0	(738,106)
NET LOSS		(632,417)	(1,846,700)	(3,725,027)	(12,373,579)
Net loss attributable to common stockholders of GB Sciences, Inc.
Continuing operations		(558,659)	(1,474,864)	(3,332,850)	(4,749,059)
Discontinued operations		(73,758)	(371,836)	(392,177)	(7,624,520)
Net loss		$ (632,417)	$ (1,846,700)	$ (3,725,027)	$ (12,373,579)
Net loss per common share – basic and diluted
Continuing operations (in dollars per share)		$ 0	$ (0.01)	$ (0.01)	$ (0.02)
Discontinued operations (in dollars per share)		0	0	0	(0.03)
Net loss (in dollars per share)		$ 0	$ (0.01)	$ (0.01)	$ (0.05)
Weighted average common shares outstanding - basic and diluted (in shares)		315,675,539	277,968,516	285,190,729	258,450,641

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity/(Deficit) - USD ($)	Cumulative Effect, Period of Adoption, Adjustment [Member]Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Noncontrolling Interest [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Mar. 31, 2019						240,627,102
Balance (Accounting Standards Update 2016-02 [Member]) at Mar. 31, 2019	$ 0	$ 0	$ (7,550)	$ 0	$ (7,550)
Balance at Mar. 31, 2019						$ 24,063	$ 93,020,015	$ (84,743,836)	$ 8,855,757	$ 17,155,999
Issuance of stock for debt conversion (in shares)						7,583,333
Issuance of stock for debt conversion						$ 758	524,242	0	0	$ 525,000
Exercise of warrants for stock, net of issuance costs (in shares)						17,563,000				17,563,000
Exercise of warrants for stock, net of issuance costs						$ 1,756	1,155,971	0	0	$ 1,157,727
Issuance of stock for services (in shares)						2,100,000				2,100,000
Issuance of stock for services						$ 210	213,790	0	0	$ 214,000
Share based compensation expense						$ 0	287,260	0	0	287,260
Issuance of stock for cash, net of issuance costs (in shares)						7,668,167
Issuance of stock for cash, net of issuance costs						$ 767	717,929	0	0	718,696
Beneficial conversion feature on notes payable						0	829,737	0	0	829,737
Contributions from non-controlling interest						0	0	0	590,000	590,000
Compensation warrants						0	132,914	0	0	132,914
Induced Dividend from Warrant Exercises						0	262,240	(262,240)	0	0
Induced conversions of accrued interest on notes payable						0	127,059	0	0	127,059
Deconsolidation of GB Sciences Louisiana, LLC						0	0	0	(8,707,651)	(8,707,651)
Net loss						0	0	(12,373,579)	0	(12,373,579)
Loss attributable to non-controlling interest						$ 0	0	0	(738,106)	(738,106)
Balance (in shares) at Mar. 31, 2020						275,541,602
Balance at Mar. 31, 2020						$ 27,554	97,271,157	(97,387,205)	0	(88,494)
Exercise of warrants for stock, net of issuance costs (in shares)						4,991,084
Exercise of warrants for stock, net of issuance costs						$ 500	135,581	0		136,081
Induced Dividend from Warrant Exercises						0	17,263	(17,263)		0
Net loss						$ 0	0	(1,846,700)		(1,846,700)
Balance (in shares) at Jun. 30, 2020						280,532,686
Balance at Jun. 30, 2020						$ 28,054	97,574,001	(99,251,168)		(1,649,113)
Balance (in shares) at Mar. 31, 2020						275,541,602
Balance at Mar. 31, 2020						$ 27,554	97,271,157	(97,387,205)	0	(88,494)
Issuance of stock for debt conversion (in shares)						4,000,000
Issuance of stock for debt conversion						$ 400	159,600	0	0	160,000
Exercise of warrants for stock, net of issuance costs (in shares)						35,798,809
Exercise of warrants for stock, net of issuance costs						$ 3,580	964,443	0	0	968,023
Share based compensation expense						0	436,349	0	0	436,349
Beneficial conversion feature on notes payable						0	543,886	0	0	543,886
Compensation warrants						0	231,335	0	0	231,335
Induced Dividend from Warrant Exercises						0	2,774,000	(2,774,000)	0	0
Net loss						$ 0		(3,725,027)	0	(3,725,027)
Loss attributable to non-controlling interest										0
Balance (in shares) at Mar. 31, 2021						315,340,411
Balance at Mar. 31, 2021						$ 31,534	102,380,770	(103,886,232)	$ 0	(1,473,928)
Exercise of warrants for stock, net of issuance costs (in shares)						2,088,667
Exercise of warrants for stock, net of issuance costs						$ 209	56,185	0		56,394
Share based compensation expense						0	19,500	0		19,500
Induced Dividend from Warrant Exercises						0	163,016	(163,016)		0
Net loss						$ 0	0	(632,417)		(632,417)
Balance (in shares) at Jun. 30, 2021						317,429,078
Balance at Jun. 30, 2021						$ 31,743	$ 102,619,471	$ (104,681,665)		$ (2,030,451)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021	Mar. 31, 2020
OPERATING ACTIVITIES:
Net loss			$ (3,725,027)	$ (13,111,685)
Loss from discontinued operations	$ (73,758)	$ (371,836)	(392,177)	(8,362,626)
Net loss from continuing operations	(558,659)	(1,474,864)	(3,332,850)	(4,749,059)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	17,354	5,562	47,353	125,502
Stock-based compensation	19,500	0	436,349	287,260
Stock issued for services			0	214,000
Compensation warrants			231,335	132,914
Amortization of debt discount and beneficial conversion feature	37,849	510,885	776,122	1,150,995
Debt default penalty	0	286,059	286,059	0
Interest expense on conversion of notes payable			0	84,354
Loss on modification of line of credit			650,000	0
Loss/(gain) on extinguishment			(467,872)	216,954
Gain on settlement of accounts payable			(422,414)	0
Loss on disposal of assets and termination of operating lease			0	147,953
Loss on induced conversion of note payable			0	127,059
Loss on note receivable modification			0	1,895,434
Gain on deconsolidation			0	(4,393,242)
Interest income receivable and amortization of discount on note receivable			0	(509,265)
Changes in operating assets and liabilities:
Accounts receivable			0	150,137
Prepaid expenses and other current assets	(39,830)	0	(237,475)	20,932
Decrease in deposits and other noncurrent assets			0	110,485
Inventory			0	83,750
Accounts payable	(10,304)	34,739	(248,115)	739,415
Accrued expenses	(126,943)	(141,102)	166,828	697,429
Accrued interest	27,404	158,806	549,703	464,279
Indebtedness to related parties	0	60,291	(501,599)	738,435
Net cash used in operating activities of continuing operations	(633,629)	(559,624)	(2,066,576)	(2,264,279)
Net cash provided by/(used in) operating activities of discontinued operations	(2,954)	235,779	(118,644)	(2,215,434)
Net cash used in operating activities	(636,583)	(323,845)	(2,185,220)	(4,479,713)
INVESTING ACTIVITIES:
Proceeds of note receivable			5,051,923	0
Acquisition of intangible assets	(50,000)	0	(292,675)	(91,862)
Net cash provided by investing activities of continuing operations	150,000	0	4,759,248	(91,862)
Net cash provided by investing activities of discontinued operations	7,435	0	(103,729)	(446,922)
Net cash provided by investing activities	157,435	0	4,655,519	(538,784)
FINANCING ACTIVITIES:
Proceeds from issuance of common stock			0	790,225
Gross proceeds from warrant exercises	62,660	151,202	1,075,396	1,274,790
Proceeds of note payable	0	150,000	725,000	2,630,000
Proceeds from line of credit			375,000	0
Principal payment on notes payable and operating lease obligation			(3,156,014)	(84,869)
Principal payment on related party note			(151,923)	0
Brokerage fees for warrant exercises	0	(15,121)	(107,373)	(188,593)
Fees for issuance of convertible notes			(74,750)	(175,000)
Net cash provided by financing activities of continuing operations	62,660	286,081	(1,314,664)	4,246,553
Net cash used in financing activities of discontinued operations	(33,478)	(12,772)	(161,768)	741,655
Net cash provided by financing activities	29,182	273,309	(1,476,432)	4,988,208
Net change in cash and cash equivalents	(449,966)	(50,536)	993,867	(30,289)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	1,145,633	151,766	151,766	182,055
CASH AND CASH EQUIVALENTS AT END OF PERIOD	695,667	101,230	1,145,633	151,766
Less: cash and cash equivalents classified as discontinued operations	(112,696)	(50,135)	(352,593)	(149,360)
CASH AND CASH EQUIVALENTS AT END OF PERIOD FROM CONTINUING OPERATIONS	582,971	51,095	793,040	2,406
Cash paid for interest	0	0	241,014	451,040
Cash paid for income tax	0	0	0	0
Non-cash investing and financing transactions:
Accrued liabilities forgiven in connection with Wellcana Note settlement			172,500	0
Depreciation capitalized in inventory (discontinued operations)	134,511	164,654	532,785	811,508
Accrued interest capitalized in convertible note principal			223,094	0
Property capitalized under operating leases			0	182,624
Patent drafting and filing costs capitalized in intangible assets	55,385	78,226	319,939	247,646
Stock options issued for preparing patent applications			168,000	0
Stock issued upon conversion of notes payable			160,000	525,000
Induced dividend from warrant exercises	$ 163,016	$ 17,236	2,774,000	262,240
Cumulative effect of the new lease standard			0	7,550
Convertible Notes Payable [Member]
Non-cash investing and financing transactions:
Beneficial conversion feature on notes payable			$ 543,886	$ 829,737

Note 1 - Background and Signifi

Note 1 - Background and Significant Accounting Policies	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	Note 1 Background and Significant Accounting Policies GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) is a phytomedical research and biopharmaceutical drug development company whose goal is to create patented formulations of plant-inspired, complex therapeutic mixtures for the prescription drug market that target a variety of medical conditions. The Company is engaged in the research and development of plant-based medicines and plans to produce plant-inspired, complex therapeutic mixtures based on its portfolio of intellectual property. Through its wholly owned Canadian subsidiary, GBS Global Biopharma, Inc. (“GBSGB”), the Company is engaged in the research and development of plant-based medicines, primarily cannabinoid medicines, with virtual operations in North America and Europe. GBSGB’s assets include a portfolio of intellectual property containing both proprietary cannabinoid-containing formulations and our AI-enabled drug discovery platform, as well as critical research contracts and key supplier arrangements. GBSGB’s intellectual property covers a range of medical conditions and several programs are in the pre-clinical animal stage of development including Parkinson’s disease, neuropathic pain, and cardiovascular therapeutic programs. GBSGB runs a lean drug development program and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses through strategic partnerships with Universities and Contract Research Organizations (“CROs”). GBSGB’s intellectual property portfolio includes five nine one 35 Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2022. March 31, 2021 not 10 March 31, 2021. Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. In particular, the assets, liabilities, profit and loss, and cash flows of GB Sciences Nevada LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC, have been separated from the comparative period amounts to conform to the current period presentation as discontinued operations as the result of the pending sale of the Company's Nevada operations. The reclassifications had no Discontinued Operations See Note 3. Long-Lived Assets We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not June 30, 2021. Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, 00 27, No. 98 5 first 718 The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source is part of discontinued operations and derives from sales of cannabis and cannabis products, distinct physical goods. Under ASC 606, may may one 606 not Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company operates in the State-licensed cannabis industry through the Nevada Subsidiaries, it is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E. Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 160,314,865 and 164,049,941 potentially dilutive common shares at June 30, 2021 March 31, 2021, not Recent Accounting Pronouncements Standards Not In May 2021, No. 2021 04, 2021 04 April 1, 2022. 2021 04 not On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2024. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not	Note 1 Business GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) is a phytomedical research and biopharmaceutical drug development company whose goal is to create patented formulations of plant-inspired, complex therapeutic mixtures for the prescription drug market that target a variety of medical conditions. The Company is engaged in the research and development of plant-based medicines and plans to produce plant-inspired, complex therapeutic mixtures based on its portfolio of intellectual property. Through its wholly owned Canadian subsidiary, GBS Global Biopharma, Inc. (“GBSGB”), the Company is engaged in the research and development of plant-based medicines, primarily cannabinoid medicines, with virtual operations in North America and Europe. GBSGB’s assets include a portfolio of intellectual property containing both proprietary cannabinoid-containing formulations and our AI-enabled drug discovery platform, as well as critical research contracts and key supplier arrangements. GBSGB’s intellectual property covers a range of medical conditions and several programs are in the pre-clinical animal stage of development including Parkinson’s disease, neuropathic pain, and cardiovascular therapeutic programs. GBSGB runs a lean drug development program and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses through strategic partnerships with Universities and Contract Research Organizations (“CROs”). GBSGB’s intellectual property portfolio includes five nine one 35 We were incorporated in the State of Delaware on April 4, 2001, March 28, 2008, On April 4, 2014, December 12, 2016, Effective April 8, 2018, August 15, 2019, 400,000,000 Recent Developments Sale of Membership Interest in GB Sciences Louisiana, LLC On November 15, 2019, December 16, 2020, 13 Convertible Note Payable to Iliad Research and Trading, L.P. On April 23, 2019, April 22, 2020, July 14, 2020, On November 20, 2020, December 8, 2020, 6 Intellectual Property Portfolio On October 14th, 2020, In Silico in silico On September 23rd, no January 31, 2018 December 8, 2020, 10,857,107. On April 7th, 2020, May 19, 2020, 10,653,640. On May 12th, 2020, July 14, 2020, 10,709,670. Planned Divestiture of Nevada Cannabis Operations On November 15, 2019, March 24, 2020, 14 On November 27, 2019, August 10, 2020, October 23, 2017, 14 The sales of the Teco and Nopah Subsidiaries are expected to close upon the successful transfer of the Nevada cannabis cultivation and production licenses held by those subsidiaries. The transfer of cannabis licenses in the State of Nevada was subject to an indefinite moratorium beginning in October 2019. July 21, 2020, 90 19

Note 2 - Going Concern

Note 2 - Going Concern	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 2 Going Concern The Company’s financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $104,681,665 at June 30, 2021. June 30, 2021, March 31, 2021, three June 30, 2021, three June 30, 2020. Management has been able, thus far, to finance the losses through a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no Furthermore, Management believes the COVID- 19 may three June 30, 2020, not 19 In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying financial statements do not may	Note 2 The Company’s consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $103,886,232 at March 31, 2021. March 31, 2021, March 31, 2020. March 31, 2021, March 31, 2020. Management has been able, thus far, to finance the losses through a public offering, private placements of debt and equity, and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no Furthermore, Management believes the COVID- 19 may not 19 In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying consolidated financial statements do not may

Note 3 - Discontinued Operation

Note 3 - Discontinued Operations	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	Note 3 Discontinued Operations Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. The Company has included its subsidiaries GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC in discontinued operations due to the pending sale of the Company's Nevada cultivation and extraction facilities 9 The assets and liabilities associated with discontinued operations included in our condensed consolidated balance sheets as of June 30, 2021 March 31, 2021 June 30, 2021 March 31, 2021 Continuing Discontinued Total Continuing Discontinued Total ASSETS CURRENT ASSETS Cash $ 582,971 $ 112,696 $ 695,667 $ 793,040 $ 352,593 $ 1,145,633 Accounts receivable, net - 643,594 643,594 - 400,175 400,175 Inventory, net - 1,462,009 1,462,009 - 1,689,304 1,689,304 Prepaid and other current assets 296,081 30,458 326,539 256,251 52,492 308,743 TOTAL CURRENT ASSETS 879,052 2,248,757 3,127,809 1,049,291 2,494,564 3,543,855 Property and equipment, net 21,895 4,736,272 4,758,167 25,022 4,876,247 4,901,269 Intangible assets, net 1,797,920 571,264 2,369,184 1,706,762 571,264 2,278,026 Deposits and other noncurrent assets - 75,469 75,469 - 82,904 82,904 TOTAL ASSETS $ 2,698,867 $ 7,631,762 $ 10,330,629 $ 2,781,075 $ 8,024,979 $ 10,806,054 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,463,806 $ 385,320 $ 1,849,126 $ 1,412,459 $ 509,477 $ 1,921,936 Accrued interest 521,145 49,211 570,356 493,741 49,211 542,952 Accrued expenses 1,031,003 122,714 1,153,717 957,946 105,421 1,063,367 Notes payable, net 3,619,186 485,000 4,104,186 3,594,804 485,000 4,079,804 Indebtedness to related parties 84,913 - 84,913 84,913 - 84,913 Income tax payable - 793,292 793,292 - 761,509 761,509 Finance lease obligations, current - 152,250 152,250 - 143,967 143,967 TOTAL CURRENT LIABILITIES 6,720,053 1,987,787 8,707,840 6,543,863 2,054,585 8,598,448 Convertible notes payable 305,877 - 305,877 292,410 - 292,410 Finance lease obligations, long term - 3,347,363 3,347,363 - 3,389,124 3,389,124 TOTAL LIABILITIES $ 7,025,930 $ 5,335,150 $ 12,361,080 $ 6,836,273 $ 5,443,709 $ 12,279,982 Discontinued Operations - Revenues and Expenses The revenues and expenses associated with discontinued operations included in our condensed consolidated statements of operations for the three June 30, 2021 2020 For the Three Months Ended June 30, 2021 2020 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 1,342,586 $ 1,342,586 $ - $ 551,197 $ 551,197 Cost of goods sold - (1,219,041 ) (1,219,041 ) - (491,795 ) (491,795 ) Gross profit/(loss) - 123,545 123,545 - 59,402 59,402 General and administrative expenses 493,405 84,078 577,483 515,253 289,455 804,708 INCOME/(LOSS) FROM OPERATIONS (493,405 ) 39,467 (453,938 ) (515,253 ) (230,053 ) (745,306 ) OTHER EXPENSE Interest expense (65,254 ) (102,331 ) (167,585 ) (662,370 ) (132,943 ) (795,313 ) Debt default penalty - - - (286,059 ) - (286,059 ) Other income/(expense) - 20,889 20,889 (11,182 ) - (11,182 ) Total other expense (65,254 ) (81,442 ) (146,696 ) (959,611 ) (132,943 ) (1,092,554 ) LOSS BEFORE INCOME TAXES (558,659 ) (41,975 ) (600,634 ) (1,474,864 ) (362,996 ) (1,837,860 ) Income tax expense - (31,783 ) (31,783 ) - (8,840 ) (8,840 ) NET LOSS $ (558,659 ) $ (73,758 ) $ (632,417 ) $ (1,474,864 ) $ (371,836 ) $ (1,846,700 ) Discontinued Operations - Inventory Raw materials consist of supplies, materials, and consumables used in the cultivation and extraction processes. Work-in-progress includes live plants and cannabis in the drying, curing, and trimming processes. Finished goods includes completed cannabis flower, trim, and extracts in bulk and packaged forms. Inventory is included in current assets from discontinued operations in the Company's unaudited condensed consolidated balance sheets at June 30, 2021 March 31, 2021. June 30, 2021 March 31, 2021 Raw materials $ 112,857 $ 86,076 Work in progress 814,166 743,844 Finished goods 601,807 866,195 Subtotal 1,528,830 1,696,115 Allowance to reduce inventory to net realizable value (66,821 ) (6,811 ) Total inventory, net $ 1,462,009 $ 1,689,304 Discontinued Operations - Leases The Company evaluates all finance and operating leases, and they are measured on the balance sheet with a lease liability and right-of-use asset (“ROU”) at inception. ROU assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 not The Company's only remaining lease commitment is a finance lease for the Teco Facility, which is classified as discontinued operations in the Company's unaudited condensed consolidated financial statements. This lease has a remaining non-cancelable term that ends December 31, 2025 December 31, 2030. Finance leases are included in property and equipment (long term assets from discontinued operations), finance lease obligations, short term (current liabilities from discontinued operations), and finance lease obligations, long term (long term liabilities from discontinued operations), on the unaudited condensed consolidated balance sheets. During the three June 30, 2021, The future minimum lease payments of lease liabilities as of June 30, 2021, Year Ending March 31, Finance Leases 2022 (9 months) $ 409,235 2023 560,625 2024 577,444 2025 594,767 2026 612,610 Thereafter 3,168,492 Total minimum lease payments 5,923,173 Less: Amount representing interest (2,423,560 ) Present value of minimum lease payments 3,499,613 Less: Current maturities of capital lease obligations (152,250 ) Long-term capital lease obligations $ 3,347,363 Discontinued Operations - 8% Line of Credit dated November 27, 2019 In connection with the Binding Letter of Intent dated November 27, 2019 ( 9 not March 31, 2021, December 29, 2020, no November 30, 2020. June 30, 2021	Note 4 Discontinued Operations Discontinued operations comprise those activities that were disposed of during the period, or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. The Company has included its subsidiaries GB Sciences Louisiana, LLC, GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC in discontinued operations due to the sale of the Company's Louisiana cultivation and extraction facility (Note 13 14 There were no assets and liabilities from discontinued operations attributable to GB Sciences Louisiana, LLC at March 31, 2021 2020. March 31, 2021 2020 March 31, 2021 March 31, 2020 Continuing Discontinued Nevada Subsidiaries Total Continuing Discontinued Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 793,040 $ 352,593 $ 1,145,633 $ 2,406 $ 149,360 $ 151,766 Accounts receivable, net - 400,175 400,175 - 117,967 117,967 Inventory, net - 1,689,304 1,689,304 - 1,445,839 1,445,839 Prepaid and other current assets 256,251 52,492 308,743 18,776 42,109 60,885 Note receivable - - - 5,224,423 - 5,224,423 TOTAL CURRENT ASSETS 1,049,291 2,494,564 3,543,855 5,245,605 1,755,275 7,000,880 Property and equipment, net 25,022 4,876,247 4,901,269 37,821 5,496,012 5,533,833 Intangible assets, net 1,706,762 571,264 2,278,026 1,128,702 571,264 1,699,966 Deposits and other noncurrent assets - 82,904 82,904 - 91,504 91,504 Operating lease right-of-use assets, net - - - - 26,685 26,685 TOTAL ASSETS $ 2,781,075 $ 8,024,979 $ 10,806,054 $ 6,412,128 $ 7,940,740 $ 14,352,868 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,412,459 $ 509,477 $ 1,921,936 $ 1,913,049 $ 646,865 $ 2,559,914 Accrued interest 493,741 49,211 542,952 366,865 30,787 397,652 Accrued expenses 957,946 105,421 1,063,367 813,618 74,394 888,012 Notes and convertible notes payable, net 3,594,804 485,000 4,079,804 5,054,728 480,000 5,534,728 Indebtedness to related parties 84,913 - 84,913 586,512 - 586,512 Note payable to related party - - - 151,923 - 151,923 Income tax payable - 761,509 761,509 - 592,982 592,982 Finance lease obligations, current - 143,967 143,967 - 166,769 166,769 Operating lease obligations, current - - - - 7,265 7,265 TOTAL CURRENT LIABILITIES 6,543,863 2,054,585 8,598,448 8,886,695 1,999,062 10,885,757 Convertible notes payable, net 292,410 - 292,410 - - - Operating lease obligations, long term - - - - 22,515 22,515 Finance lease obligations, long term - 3,389,124 3,389,124 - 3,533,090 3,533,090 TOTAL LIABILITIES $ 6,836,273 $ 5,443,709 $ 12,279,982 $ 8,886,695 $ 5,554,667 $ 14,441,362 The revenues and expenses associated with discontinued operations included in our consolidated statements of operations for the years ended March 31, 2021 2020, For the Year Ended March 31, For the Year Ended March 31, 2021 2020 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 4,110,456 $ 4,110,456 $ - $ 3,689,697 $ 3,689,697 Cost of goods sold - (3,506,722 ) (3,506,722 ) - (4,576,627 ) (4,576,627 ) Gross profit (loss) - 603,734 603,734 - (886,930 ) (886,930 ) General and administrative expenses 2,001,617 276,986 2,278,603 5,741,514 2,034,612 7,776,126 Loss on impairment of long-lived assets - - - - 4,645,054 4,645,054 LOSS FROM OPERATIONS (2,001,617 ) 326,748 (1,674,869 ) (5,741,514 ) (7,566,596 ) (13,308,110 ) OTHER INCOME/(EXPENSE) Gain/(loss) on extinguishment 467,872 - 467,872 (216,954 ) - (216,954 ) Gain on settlement of accounts payable 422,414 54,958 477,372 - - - Gain on deconsolidation - - - 4,393,242 - 4,393,242 Interest expense (1,285,460 ) (486,481 ) (1,771,941 ) (1,109,031 ) (694,313 ) (1,803,344 ) Loss on modification of line of credit (650,000 ) - (650,000 ) - - - Loss on modification of note receivable - - - (1,895,434 ) - (1,895,434 ) Debt default penalty (286,059 ) - (286,059 ) - - - Other expense - (118,875 ) (118,875 ) (179,368 ) (14,880 ) (194,248 ) TOTAL OTHER INCOME/(EXPENSE) (1,331,233 ) (550,398 ) (1,881,631 ) 992,455 (709,193 ) 283,262 NET LOSS BEFORE INCOME TAXES (3,332,850 ) (223,650 ) (3,556,500 ) (4,749,059 ) (8,275,789 ) (13,024,848 ) Income tax expense - (168,527 ) (168,527 ) - (86,837 ) (86,837 ) NET LOSS $ (3,332,850 ) $ (392,177 ) $ (3,725,027 ) $ (4,749,059 ) $ (8,362,626 ) $ (13,111,685 ) The components of revenues and expenses associated with discontinued operations included in our consolidated statements of operations for the years ended March 31, 2021 2020 For the Year Ended March 31, For the Year Ended March 31, 2021 2020 Nevada Louisiana Total Nevada Louisiana Total Sales revenue $ 4,110,456 $ - $ 4,110,456 $ 3,120,620 $ 569,077 $ 3,689,697 Cost of goods sold (3,506,722 ) - (3,506,722 ) (4,002,083 ) (574,544 ) (4,576,627 ) Gross profit (loss) 603,734 - 603,734 (881,463 ) (5,467 ) (886,930 ) General and administrative expenses 276,986 - 276,986 741,999 1,292,613 2,034,612 Loss on impairment of long-lived assets - - - 4,645,054 - 4,645,054 LOSS FROM OPERATIONS 326,748 - 326,748 (6,268,516 ) (1,298,080 ) (7,566,596 ) OTHER INCOME/(EXPENSE) Gain on settlement of accounts payable 54,958 - 54,958 - - - Interest expense (486,481 ) - (486,481 ) (516,173 ) (178,140 ) (694,313 ) Other expense (118,875 ) - (118,875 ) (14,880 ) - (14,880 ) TOTAL OTHER INCOME/(EXPENSE) (550,398 ) - (550,398 ) (531,053 ) (178,140 ) (709,193 ) NET LOSS BEFORE INCOME TAXES (223,650 ) - (223,650 ) (6,799,569 ) (1,476,220 ) (8,275,789 ) Income tax expense (168,527 ) - (168,527 ) (86,837 ) - (86,837 ) NET LOSS $ (392,177 ) $ - $ (392,177 ) $ (6,886,406 ) $ (1,476,220 ) $ (8,362,626 ) Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on aging and subsequent collections. During the year ended March 31, 2021, March 31, 2021 2020. Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first Raw materials consist of supplies, materials, and consumables used in the cultivation and extraction processes. Work-in-progress includes live plants and cannabis in the drying, curing, and trimming processes. Finished goods includes completed cannabis flower, trim, and extracts in bulk and packaged forms. Inventory is included in current assets from discontinued operations in the Company's consolidated balance sheets at March 31, 2021 2020. March 31, 2021 March 31, 2020 Raw materials $ 86,076 $ 91,465 Work in progress 743,844 1,166,511 Finished goods 866,195 466,319 Subtotal 1,696,115 1,724,295 Allowance to reduce inventory to NRV (6,811 ) (278,456 ) Total inventory, net $ 1,689,304 $ 1,445,839 Deposits and Noncurrent Assets Deposits and noncurrent assets from discontinued operations were $82,904 and $91,504 at March 31, 2021 2020, March 31, 2021 2020. Leases In February 2016, 2016 02, 842 Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the standard. Lease payments do not April 1, 2019. not The Company adopted the New Lease Standard using the modified retrospective transition approach as of the effective date as permitted by the amendments in ASU 2018 11, 842 not April 1, 2019. The Company determines if an arrangement is a lease at inception and has had lease agreements for warehouses, office facilities, and equipment. As a result of the adoption of ASC 842 April 1, 2019, All of the Company's lease commitments previously recorded as operating leases have terminated as of March 31, 2021. March 31, 2021, March 31, 2021 2020. December 31, 2025 December 31, 2030. Operating leases are included in discontinued operations as operating lease right-of-use assets, operating lease obligations, current, and operating lease obligations, long term on the Company's balance sheets. Finance leases are included in property and equipment, finance lease obligations, current, and finance lease obligations, long term, on the Company's balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. The rates used to discount finance leases previously recorded as capital leases range from 10.2% to 11.5%. Operating leases were discounted at a rate of 17.0%. Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 not The lease costs recorded in the Company's financial statements for the years ended March 31, 2021 2020 March 31, Classification on the Statements of Operations 2021 2020 Discontinued operations: Finance leases - amortization of ROU assets Loss from discontinued operations $ 154,699 $ 252,973 Finance leases - interest on lease liabilities Loss from discontinued operations 414,993 426,374 Operating leases Loss from discontinued operations 3,243 13,648 Total lease cost, discontinued operations 572,935 692,995 Operating leases, continuing operations General and administrative expense - 61,658 Total lease cost $ 572,935 $ 754,653 The future minimum lease payments of lease liabilities, including the costs of the lease extension, classified as discontinued operations at March 31, 2021, Year Ending March 31, Finance Leases 2022 $ 544,296 2023 560,625 2024 577,444 2025 594,767 2026 612,610 Thereafter 3,168,492 Total minimum lease payments 6,058,234 Less: Amount representing interest (2,525,143 ) Present value of minimum lease payments 3,533,091 Less: Current maturities of capital lease obligations (143,967 ) Long-term capital lease obligations $ 3,389,124

Note 4 - Notes Payable and Line

Note 4 - Notes Payable and Line of Credit	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 4 Notes Payable and Line of Credit 0% October 23, 2017 On October 23, 2017, one three January 1, 2018. To date, the Company has made principal payments totaling $330,555 and the principal balance of the note was $369,445 at June 30, 2021. June 30, 2021, On August 10, 2020, 9 July 31, 2021, no no 8% July 24, 2020 On July 24, 2020, "July 24 may 8% February 28, 2019. July 24 July 24 may 9 On December 29, 2020, three $325,000 July 24 July 24 one not November 30, 2020. not July 24 March 31, 2021 ( two $325,000 $325,000 July 24 June 30, 2021, $325,000 March 31, 2021, June 30, 2021. June 30, 2021. Summary of Notes and Convertible Notes Payable As of June 30, 2021, As of June 30, 2021 Short-Term Notes Payable Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 4) $ 369,445 $ - $ 369,445 8% Line of Credit dated November 27, 2019 (Note 3) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 4) 1,025,000 - 1,025,000 6% Convertible promissory notes payable (Note 5) 1,060,000 - 1,060,000 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 5) 1,111,863 - 1,111,863 6% Convertible notes payable due January 18, 2022 (Note 5) 325,000 (272,122 ) 52,878 Total short-term notes and convertible notes payable 4,376,308 (272,122 ) 4,104,186 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short-term notes payable classified as continuing operations $ 3,891,308 $ (272,122 ) $ 3,619,186 6% Convertible promissory notes payable due September 30, 2023 (Note 5) 197,000 (37,204 ) 159,796 6% Convertible note payable due December 31, 2023 (Note 5) 250,000 (103,919 ) 146,081 Total long-term notes payable classified as continuing operations $ 447,000 $ (141,123 ) $ 305,877	Note 5 Notes Payable and Line of Credit 0% October 23, 2017 On October 23, 2017, one three January 1, 2018. To date, the Company has made principal payments totaling $330,555 and the principal balance of the note was $369,445 at March 31, 2021. March 31, 2021, March 31, 2021, On August 10, 2020, 14 July 31, 2021, no no 8% November 27, 2019 In connection with the Binding Letter of Intent dated November 27, 2019 ( 14 not March 31, 2021, March 31, 2021, March 31, 2021. 8% May 7, 2020 On May 7, 2020, first March 31, 2021, October 5, 2020, 8% July 24, 2020 On July 24, 2020, "July 24 may 8% February 28, 2019. July 24 July 24 may 14 On December 29, 2020, three $325,000 July 24 July 24 one not July 24 two $325,000 $325,000 July 24 $325,000 March 31, 2021. March 31, 2021. Summary of Notes Payable As of March 31, 2021, As of March 31, 2021 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ - $ 369,445 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 5) 1,025,000 - 1,025,000 6% Convertible promissory notes payable (Note 6) 1,060,000 - 1,060,000 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,111,863 - 1,111,863 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 (296,504 ) 28,496 Total short-term notes and convertible notes payable 4,376,308 (296,504 ) 4,079,804 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 3,891,308 $ (296,504 ) $ 3,594,804 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (40,561 ) $ 156,439 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (114,029 ) 135,971 Total long term convertible notes payable classified as continuing operations $ 447,000 $ (154,590 ) $ 292,410 As of March 31, 2020, As of March 31, 2020 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ (13,929 ) $ 355,516 8% Line of Credit dated November 27, 2019 (Note 5) 480,000 - 480,000 6% Convertible promissory notes payable (Note 6) 1,257,000 (155,340 ) 1,101,660 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,271,863 (409,481 ) 862,382 8% Convertible Promissory Note dated April 23, 2019 (Note 6) 2,765,000 (29,830 ) 2,735,170 Total short term notes and convertible notes payable 6,143,308 (608,580 ) 5,534,728 Less: Notes payable classified as discontinued operations (480,000 ) - (480,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 5,663,308 $ (608,580 ) $ 5,054,728

Note 5 - Convertible Notes

Note 5 - Convertible Notes	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Convertible Debt [Text Block]	Note 5 Convertible Notes March 2017 July 2017 In March 2017, third three March 2017 May 2017, three three In July 2017, third three July 2017 December 2017, three three All notes from the March July 2017 March 31, 2021, $197,000 three September 30, 2023. 10% three June 30, 2021, $197,000 June 30, 2021, Three convertible notes totaling $1,060,000 held by the same investor are past maturity and are currently in default. The Company is negotiating the terms of an extension with the note holder. The notes do not three June 30, 2021, no $1,060,000 June 30, 2021. 8% Convertible Promissory Note dated February 28, 2019 On February 28, 2019, August 28, 2020, On May 28, 2019, February 28, 2019. On July 12, 2019, July 12, 2019, The Company evaluated the modification under the guidance in ASC 470 50 10% On August 1, 2019, On October 23, 2019, October 23, 2019 We evaluated the modification under the guidance in ASC 470 50 10% 2nd March 31, 2020. On November 27, 2019, “2nd 2nd We evaluated the modification under the guidance in ASC 470 50 2nd 10% 2nd 2nd On December 16, 2019, On December 29, 2020, November 30, 2020. During the quarter ended March 31, 2021, March 31, 2021, June 30, 2021. no 8% April 23, 2019 On April 23, 2019, April 22, 2020. During the year ended March 31, 2020, October 30, 2019, November 18, 2019, On April 22, 2020, 10% On May 20, 2020, July 14, 2020, On November 20, 2020, December 8, 2020. December 8, 2020, December 9, 2020, not December 16, 2020, December 18, 2020, no December 2020 $575,000 6% On December 18, 2020, 19 March 31, 2021, three December 2021, December 2023. At June 30, 2021, three June 30, 2021,	Note 6 Convertible Notes March 2017 July 2017 In March 2017, third three March 2017 May 2017, three three In July 2017, third three July 2017 December 2017, three three All notes from the March July 2017 March 31, 2021, $197,000 three September 30, 2023. 10% March 31, 2021, $197,000 March 31, 2021, Three convertible notes totaling $1,060,000 held by the same investor are past maturity and are currently in default. The Company is negotiating the terms of an extension with the note holder. The notes do not March 31, 2021, $1,060,000 March 31, 2021. 8% Convertible Promissory Note dated February 28, 2019 On February 28, 2019, August 28, 2020, On May 28, 2019, February 28, 2019. On July 12, 2019, July 12, 2019, The Company evaluated the modification under the guidance in ASC 470 50 10% On August 1, 2019, On October 23, 2019, October 23, 2019 We evaluated the modification under the guidance in ASC 470 50 10% 2nd March 31, 2020. On November 27, 2019, “2nd 2nd We evaluated the modification under the guidance in ASC 470 50 2nd 10% 2nd 2nd On December 16, 2019, On December 29, 2020, 14 November 30, 2020. During the quarter ended March 31, 2021, March 31, 2021. During the year ended March 31, 2021, no 8% April 23, 2019 On April 23, 2019, April 22, 2020. During the year ended March 31, 2020, October 30, 2019, November 18, 2019, On April 22, 2020, 10% On May 20, 2020, July 14, 2020, On November 20, 2020, 14 December 8, 2020. December 8, 2020, December 9, 2020, not December 16, 2020, December 18, 2020, no During the year ended March 31, 2021, $209,292 December 2020 $575,000 6% On December 18, 2020, 19 March 31, 2021, three December 2021, December 2023. At March 31, 2021, March 31, 2021,

Note 6 - Capital Transactions

Note 6 - Capital Transactions	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 6 Capital Transactions Sale of Common Stock and Exercise of Warrants On April 1, 2020, $.05 July 18, 2021, September 30, 2021 three three June 30, 2021,the	Note 9 Capital Transactions Year Ended March 31, 2021 On April 1, 2020, $.05 March 31, 2021, During the year ended March 31, 2021, one ten During the year ended March 31, 2021, three three 6 On November 16, 2020, November 16, 2025, June 1, 2023. On December 7, 2020, ten On December 15, 2020, ten one third one third one one third two March 31, 2021. March 31, 2021. On December 15, 2020, On January 2, 2021, January 2, 2024. December 11, 2020 October 1, 2023, During the quarter ended March 31, 2021, 6 On February 8, 2021, December 2019 three At March 31, 2021, Year Ended March 31, 2020 Stock Issued for Debt Conversions During the year ended March 31, 2020, On May 28, 2019, February 28, 2019 ( 6 On August 1, 2019, On December 16, 2019, During the year ended March 31, 2020, October 30, 2019, November 18, 2019, two March 31, 2020. Exercise of Warrants for Stock During the year ended March 31, 2020, In order to encourage the exercise of approximately 70.5 million warrants issued to investors in private placements of convertible notes and common stock having exercise prices ranging between $0.65 and $0.30, the Company effected a temporary decrease in the exercise price of the warrants to $0.10 per share until July 11, 2019. July 12, 2019, August 30, 2019, July 31, 2019, December 31, 2019. In order to encourage the further exercise of the warrants, the Company effected a temporary decrease in the exercise price of the warrants to $0.03-$.05 per share beginning in December 2019. Issuance of Stock for Services During the year ended March 31, 2020, Warrants Outstanding Presented below is a summary of the Company’s warrant activity, exclusive of warrants held by employees (see Note 10 March 31, 2021 2020: Warrants Outstanding Number of Shares Exercise Price Outstanding at March 31, 2019 99,790,989 Warrants issued 7,622,780 $0.30 Warrants exercised (17,563,000 ) 0.03550.1010 Warrants expired/cancelled (5,312,608 ) 0.5002.0000 Outstanding at March 31, 2020 84,538,161 Warrants issued 43,493,809 $0.10 Warrants exercised (35,798,809 ) 0.03000.03535 Warrants expired/cancelled (6,390,125 ) 0.6000.9090 Outstanding at March 31, 2021 85,843,036

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 7 Commitments and Contingencies On April 22, 2020, May 20, 2020, July 14, 2020, December 16, 2020 5 On April 22, 2020, September 17, 2020, From time to time, the Company may not	Note 11 Commitments and Contingencies On September 18, 2017, five five 50% $500,000 three August 4, 2020, first $250,000 twelve September 30, 2020, twelve August 24, 2020, no 14 An individual filed a Charge of Discrimination with the Nevada Equal Rights Commission ("NERC") against the Company on April 2, 2019, May 11, 2021. On April 22, 2020, May 20, 2020, July 14, 2020, December 16, 2020, 6 On April 22, 2020, September 17, 2020, From time to time, the Company may not

Note 8 - Related Party Transact

Note 8 - Related Party Transactions	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 8 Related Party Transactions As of June 30, 2021	Note 12 As of March 31, 2021, On September 1, 2019, 9 January 2, 2021, On November 16, 2020, March 31, 2021. March 31, 2020, In connection with the sale of membership interest in GB Sciences Louisiana, LLC, the Company issued a note payable in the amount of $151,923 to John Davis, the Company's former General Counsel and President of GB Sciences Louisiana, LLC, for unpaid compensation and bonuses. The note matured upon receipt of the first August 4, 2020, first 14

Note 9 - Sale of Membership Int

Note 9 - Sale of Membership Interests in Nevada Subsidiaries	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Nevada Subsidiaries [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 9 Sale of Membership Interests in Nevada Subsidiaries On November 15, 2019, March 24, 2020, 30 On July 24, 2020, "July 24 July 24 4 On December 29, 2020, one three not July 24 July 24 three $325,000, $4,000,000 The Omnibus Amendment also amends the Management Services Agreement to provide that no November 30, 2020. June 30, 2021, three 36 30 On May 11, 2021, December 31, 2021, $4,000,000 June 30, 2021. The sale is expected to close upon the successful transfer of the Nevada cultivation and production licenses. The transfer of cannabis licenses in the State of Nevada was subject to an indefinite moratorium beginning in October 2019. July 21, 2020, 90 19 The Company also holds a Nevada license for cultivation of medical marijuana located in Sandy Valley, Nevada (the “Nopah License”). The license is owned by the Company’s wholly owned subsidiary, GB Sciences Nopah, LLC ("Nopah"). Operations have not November 27, 2019, August 10, 2020, October 23, 2017 ( 4 Because the moratorium on license transfers has been lifted, the Company determined that the Teco Facility and Nopah Facility qualify for presentation as discontinued operations, and the income, assets, and cash flows of the Teco Subsidiaries and GB Sciences Nopah, LLC have been reclassified as discontinued operations for all periods presented in the Company's consolidated financial statements.	Note 14 100% On November 15, 2019, 5 On March 24, 2020, 30 On July 24, 2020, "July 24 July 24 July 24 March 31, 2021, July 24 5 On December 29, 2020, one three not July 24 July 24 three $325,000, The Omnibus Amendment also amends the Management Services Agreement to provide that no November 30, 2020. March 31, 2021, three 36 30 The sale is expected to close upon the successful transfer of the Nevada cultivation and production licenses. The transfer of cannabis licenses in the State of Nevada was subject to an indefinite moratorium beginning in October 2019. July 21, 2020, 90 19 The Company also holds a Nevada license for cultivation of medical marijuana located in Sandy Valley, Nevada (the “Nopah License”). The license is owned by the Company’s wholly owned subsidiary, GB Sciences Nopah, LLC ("Nopah"). Operations have not November 27, 2019, August 10, 2020, October 23, 2017 ( 5 Because the moratorium on license transfers has been lifted, the Company determined that the Teco Facility and Nopah Facility qualify for presentation as discontinued operations, and the income, assets, and cash flows of the Teco Subsidiaries and GB Sciences Nopah, LLC have been reclassified as discontinued operations for all periods presented in the Company's consolidated financial statements.

Note 10 - Subsequent Events

Note 10 - Subsequent Events	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	Note 10 Subsequent Events Capital Transactions On July 2, 2021, July 1, 2022 December 2020.	Note 16 Subsequent Events On May 11, 2021, December 31, 2021. On June 14, 2021,

Note 1 - Background and Nature

Note 1 - Background and Nature of Operations	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	Note 1 Background and Significant Accounting Policies GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) is a phytomedical research and biopharmaceutical drug development company whose goal is to create patented formulations of plant-inspired, complex therapeutic mixtures for the prescription drug market that target a variety of medical conditions. The Company is engaged in the research and development of plant-based medicines and plans to produce plant-inspired, complex therapeutic mixtures based on its portfolio of intellectual property. Through its wholly owned Canadian subsidiary, GBS Global Biopharma, Inc. (“GBSGB”), the Company is engaged in the research and development of plant-based medicines, primarily cannabinoid medicines, with virtual operations in North America and Europe. GBSGB’s assets include a portfolio of intellectual property containing both proprietary cannabinoid-containing formulations and our AI-enabled drug discovery platform, as well as critical research contracts and key supplier arrangements. GBSGB’s intellectual property covers a range of medical conditions and several programs are in the pre-clinical animal stage of development including Parkinson’s disease, neuropathic pain, and cardiovascular therapeutic programs. GBSGB runs a lean drug development program and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses through strategic partnerships with Universities and Contract Research Organizations (“CROs”). GBSGB’s intellectual property portfolio includes five nine one 35 Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2022. March 31, 2021 not 10 March 31, 2021. Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. In particular, the assets, liabilities, profit and loss, and cash flows of GB Sciences Nevada LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC, have been separated from the comparative period amounts to conform to the current period presentation as discontinued operations as the result of the pending sale of the Company's Nevada operations. The reclassifications had no Discontinued Operations See Note 3. Long-Lived Assets We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not June 30, 2021. Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, 00 27, No. 98 5 first 718 The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source is part of discontinued operations and derives from sales of cannabis and cannabis products, distinct physical goods. Under ASC 606, may may one 606 not Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company operates in the State-licensed cannabis industry through the Nevada Subsidiaries, it is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E. Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 160,314,865 and 164,049,941 potentially dilutive common shares at June 30, 2021 March 31, 2021, not Recent Accounting Pronouncements Standards Not In May 2021, No. 2021 04, 2021 04 April 1, 2022. 2021 04 not On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2024. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not	Note 1 Business GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) is a phytomedical research and biopharmaceutical drug development company whose goal is to create patented formulations of plant-inspired, complex therapeutic mixtures for the prescription drug market that target a variety of medical conditions. The Company is engaged in the research and development of plant-based medicines and plans to produce plant-inspired, complex therapeutic mixtures based on its portfolio of intellectual property. Through its wholly owned Canadian subsidiary, GBS Global Biopharma, Inc. (“GBSGB”), the Company is engaged in the research and development of plant-based medicines, primarily cannabinoid medicines, with virtual operations in North America and Europe. GBSGB’s assets include a portfolio of intellectual property containing both proprietary cannabinoid-containing formulations and our AI-enabled drug discovery platform, as well as critical research contracts and key supplier arrangements. GBSGB’s intellectual property covers a range of medical conditions and several programs are in the pre-clinical animal stage of development including Parkinson’s disease, neuropathic pain, and cardiovascular therapeutic programs. GBSGB runs a lean drug development program and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses through strategic partnerships with Universities and Contract Research Organizations (“CROs”). GBSGB’s intellectual property portfolio includes five nine one 35 We were incorporated in the State of Delaware on April 4, 2001, March 28, 2008, On April 4, 2014, December 12, 2016, Effective April 8, 2018, August 15, 2019, 400,000,000 Recent Developments Sale of Membership Interest in GB Sciences Louisiana, LLC On November 15, 2019, December 16, 2020, 13 Convertible Note Payable to Iliad Research and Trading, L.P. On April 23, 2019, April 22, 2020, July 14, 2020, On November 20, 2020, December 8, 2020, 6 Intellectual Property Portfolio On October 14th, 2020, In Silico in silico On September 23rd, no January 31, 2018 December 8, 2020, 10,857,107. On April 7th, 2020, May 19, 2020, 10,653,640. On May 12th, 2020, July 14, 2020, 10,709,670. Planned Divestiture of Nevada Cannabis Operations On November 15, 2019, March 24, 2020, 14 On November 27, 2019, August 10, 2020, October 23, 2017, 14 The sales of the Teco and Nopah Subsidiaries are expected to close upon the successful transfer of the Nevada cannabis cultivation and production licenses held by those subsidiaries. The transfer of cannabis licenses in the State of Nevada was subject to an indefinite moratorium beginning in October 2019. July 21, 2020, 90 19

Note 2 - Going Concern_2

Note 2 - Going Concern	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 2 Going Concern The Company’s financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $104,681,665 at June 30, 2021. June 30, 2021, March 31, 2021, three June 30, 2021, three June 30, 2020. Management has been able, thus far, to finance the losses through a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no Furthermore, Management believes the COVID- 19 may three June 30, 2020, not 19 In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying financial statements do not may	Note 2 The Company’s consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $103,886,232 at March 31, 2021. March 31, 2021, March 31, 2020. March 31, 2021, March 31, 2020. Management has been able, thus far, to finance the losses through a public offering, private placements of debt and equity, and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no Furthermore, Management believes the COVID- 19 may not 19 In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying consolidated financial statements do not may

Note 3 - Basis of Presentation

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3 Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. The subsidiaries of the Company are: Continuing Operations: GBS Global Biopharma, Inc. ECRX, Inc. The PhAROS Institute, LLC GB Sciences Texas, LLC Discontinued Operations: GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC GB Sciences Nopah, LLC Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. In particular, the assets, liabilities, income, and cash flows of GB Sciences Nevada LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC, have been separated from the comparative period amounts to conform to the current period presentation as discontinued operations as the result of the pending sale of the Company's Nevada operations. The reclassifications had no Discontinued Operations See Note 4. Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three - Level 1 - Level 2 - Level 3 The carrying value of cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value, primarily due to the short-term nature of the instruments. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three March 31, 2021 2020. Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on aging and subsequent collections. Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first Indefinite-Lived Intangible Assets Our indefinite-lived intangible assets primarily represent the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also include the acquisition cost of a cannabis production license with an indefinite life. We amortize our finite-lived intangible assets over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. During the year ended March 31, 2020, not March 31, 2020, Operating Lease Right-of-Use Asset and Liability The Company determines if an arrangement is a lease at inception and has lease agreements for office facilities, equipment, and other space and assets with non-cancelable lease terms. Certain real estate and property leases, and various other operating leases are measured on the balance sheet with a lease liability and right-of-use asset ("ROU"). ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the New Lease Standard. Lease payments do not Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of twelve not Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets: 3-8 years for machinery and equipment, and leasehold improvements are amortized over the shorter of the estimated useful lives or the underlying lease term. Property under finance leases and related obligations are initially recorded at an amount equal to the present value of future minimum lease payments computed on the basis of the Company’s incremental borrowing rate, and depreciation is recorded on a straight-line basis and is included within depreciation and amortization expense. Repairs and maintenance expenditures which do not Long-Lived Assets Property and equipment comprise a significant portion of our total assets from discontinued operations. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not During the year ended March 31, 2020, 100% 14 not 3 820. $4.0M Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, Debt with Conversion and Other Options 00 27, Application of Issue No. 98 5 first 718 Compensation Stock Compensation The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source is part of discontinued operations and derives from sales of cannabis and cannabis products, distinct physical goods. Under ASC 606, may may one 606 not Research and Development Costs Research and development costs are expensed as incurred. During the years ended March 31, 2021 2020, Equity-Based Compensation The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 718 no may may may Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company operates in the State-licensed cannabis industry, it is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E. Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 164,049,941 and 158,404,020 potentially dilutive common shares at March 31, 2021 2020, not Recent Accounting Pronouncements Recently Adopted Standards In August 2018, No. 2018 13, December 15, 2019, April 1, 2020, not Standards Not In May 2021, No. 2021 04, 2021 04 April 1, 2022. 2021 04 On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2024. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not

Note 4 - Discontinued Operation

Note 4 - Discontinued Operations	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	Note 3 Discontinued Operations Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. The Company has included its subsidiaries GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC in discontinued operations due to the pending sale of the Company's Nevada cultivation and extraction facilities 9 The assets and liabilities associated with discontinued operations included in our condensed consolidated balance sheets as of June 30, 2021 March 31, 2021 June 30, 2021 March 31, 2021 Continuing Discontinued Total Continuing Discontinued Total ASSETS CURRENT ASSETS Cash $ 582,971 $ 112,696 $ 695,667 $ 793,040 $ 352,593 $ 1,145,633 Accounts receivable, net - 643,594 643,594 - 400,175 400,175 Inventory, net - 1,462,009 1,462,009 - 1,689,304 1,689,304 Prepaid and other current assets 296,081 30,458 326,539 256,251 52,492 308,743 TOTAL CURRENT ASSETS 879,052 2,248,757 3,127,809 1,049,291 2,494,564 3,543,855 Property and equipment, net 21,895 4,736,272 4,758,167 25,022 4,876,247 4,901,269 Intangible assets, net 1,797,920 571,264 2,369,184 1,706,762 571,264 2,278,026 Deposits and other noncurrent assets - 75,469 75,469 - 82,904 82,904 TOTAL ASSETS $ 2,698,867 $ 7,631,762 $ 10,330,629 $ 2,781,075 $ 8,024,979 $ 10,806,054 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,463,806 $ 385,320 $ 1,849,126 $ 1,412,459 $ 509,477 $ 1,921,936 Accrued interest 521,145 49,211 570,356 493,741 49,211 542,952 Accrued expenses 1,031,003 122,714 1,153,717 957,946 105,421 1,063,367 Notes payable, net 3,619,186 485,000 4,104,186 3,594,804 485,000 4,079,804 Indebtedness to related parties 84,913 - 84,913 84,913 - 84,913 Income tax payable - 793,292 793,292 - 761,509 761,509 Finance lease obligations, current - 152,250 152,250 - 143,967 143,967 TOTAL CURRENT LIABILITIES 6,720,053 1,987,787 8,707,840 6,543,863 2,054,585 8,598,448 Convertible notes payable 305,877 - 305,877 292,410 - 292,410 Finance lease obligations, long term - 3,347,363 3,347,363 - 3,389,124 3,389,124 TOTAL LIABILITIES $ 7,025,930 $ 5,335,150 $ 12,361,080 $ 6,836,273 $ 5,443,709 $ 12,279,982 Discontinued Operations - Revenues and Expenses The revenues and expenses associated with discontinued operations included in our condensed consolidated statements of operations for the three June 30, 2021 2020 For the Three Months Ended June 30, 2021 2020 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 1,342,586 $ 1,342,586 $ - $ 551,197 $ 551,197 Cost of goods sold - (1,219,041 ) (1,219,041 ) - (491,795 ) (491,795 ) Gross profit/(loss) - 123,545 123,545 - 59,402 59,402 General and administrative expenses 493,405 84,078 577,483 515,253 289,455 804,708 INCOME/(LOSS) FROM OPERATIONS (493,405 ) 39,467 (453,938 ) (515,253 ) (230,053 ) (745,306 ) OTHER EXPENSE Interest expense (65,254 ) (102,331 ) (167,585 ) (662,370 ) (132,943 ) (795,313 ) Debt default penalty - - - (286,059 ) - (286,059 ) Other income/(expense) - 20,889 20,889 (11,182 ) - (11,182 ) Total other expense (65,254 ) (81,442 ) (146,696 ) (959,611 ) (132,943 ) (1,092,554 ) LOSS BEFORE INCOME TAXES (558,659 ) (41,975 ) (600,634 ) (1,474,864 ) (362,996 ) (1,837,860 ) Income tax expense - (31,783 ) (31,783 ) - (8,840 ) (8,840 ) NET LOSS $ (558,659 ) $ (73,758 ) $ (632,417 ) $ (1,474,864 ) $ (371,836 ) $ (1,846,700 ) Discontinued Operations - Inventory Raw materials consist of supplies, materials, and consumables used in the cultivation and extraction processes. Work-in-progress includes live plants and cannabis in the drying, curing, and trimming processes. Finished goods includes completed cannabis flower, trim, and extracts in bulk and packaged forms. Inventory is included in current assets from discontinued operations in the Company's unaudited condensed consolidated balance sheets at June 30, 2021 March 31, 2021. June 30, 2021 March 31, 2021 Raw materials $ 112,857 $ 86,076 Work in progress 814,166 743,844 Finished goods 601,807 866,195 Subtotal 1,528,830 1,696,115 Allowance to reduce inventory to net realizable value (66,821 ) (6,811 ) Total inventory, net $ 1,462,009 $ 1,689,304 Discontinued Operations - Leases The Company evaluates all finance and operating leases, and they are measured on the balance sheet with a lease liability and right-of-use asset (“ROU”) at inception. ROU assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 not The Company's only remaining lease commitment is a finance lease for the Teco Facility, which is classified as discontinued operations in the Company's unaudited condensed consolidated financial statements. This lease has a remaining non-cancelable term that ends December 31, 2025 December 31, 2030. Finance leases are included in property and equipment (long term assets from discontinued operations), finance lease obligations, short term (current liabilities from discontinued operations), and finance lease obligations, long term (long term liabilities from discontinued operations), on the unaudited condensed consolidated balance sheets. During the three June 30, 2021, The future minimum lease payments of lease liabilities as of June 30, 2021, Year Ending March 31, Finance Leases 2022 (9 months) $ 409,235 2023 560,625 2024 577,444 2025 594,767 2026 612,610 Thereafter 3,168,492 Total minimum lease payments 5,923,173 Less: Amount representing interest (2,423,560 ) Present value of minimum lease payments 3,499,613 Less: Current maturities of capital lease obligations (152,250 ) Long-term capital lease obligations $ 3,347,363 Discontinued Operations - 8% Line of Credit dated November 27, 2019 In connection with the Binding Letter of Intent dated November 27, 2019 ( 9 not March 31, 2021, December 29, 2020, no November 30, 2020. June 30, 2021	Note 4 Discontinued Operations Discontinued operations comprise those activities that were disposed of during the period, or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. The Company has included its subsidiaries GB Sciences Louisiana, LLC, GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC in discontinued operations due to the sale of the Company's Louisiana cultivation and extraction facility (Note 13 14 There were no assets and liabilities from discontinued operations attributable to GB Sciences Louisiana, LLC at March 31, 2021 2020. March 31, 2021 2020 March 31, 2021 March 31, 2020 Continuing Discontinued Nevada Subsidiaries Total Continuing Discontinued Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 793,040 $ 352,593 $ 1,145,633 $ 2,406 $ 149,360 $ 151,766 Accounts receivable, net - 400,175 400,175 - 117,967 117,967 Inventory, net - 1,689,304 1,689,304 - 1,445,839 1,445,839 Prepaid and other current assets 256,251 52,492 308,743 18,776 42,109 60,885 Note receivable - - - 5,224,423 - 5,224,423 TOTAL CURRENT ASSETS 1,049,291 2,494,564 3,543,855 5,245,605 1,755,275 7,000,880 Property and equipment, net 25,022 4,876,247 4,901,269 37,821 5,496,012 5,533,833 Intangible assets, net 1,706,762 571,264 2,278,026 1,128,702 571,264 1,699,966 Deposits and other noncurrent assets - 82,904 82,904 - 91,504 91,504 Operating lease right-of-use assets, net - - - - 26,685 26,685 TOTAL ASSETS $ 2,781,075 $ 8,024,979 $ 10,806,054 $ 6,412,128 $ 7,940,740 $ 14,352,868 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,412,459 $ 509,477 $ 1,921,936 $ 1,913,049 $ 646,865 $ 2,559,914 Accrued interest 493,741 49,211 542,952 366,865 30,787 397,652 Accrued expenses 957,946 105,421 1,063,367 813,618 74,394 888,012 Notes and convertible notes payable, net 3,594,804 485,000 4,079,804 5,054,728 480,000 5,534,728 Indebtedness to related parties 84,913 - 84,913 586,512 - 586,512 Note payable to related party - - - 151,923 - 151,923 Income tax payable - 761,509 761,509 - 592,982 592,982 Finance lease obligations, current - 143,967 143,967 - 166,769 166,769 Operating lease obligations, current - - - - 7,265 7,265 TOTAL CURRENT LIABILITIES 6,543,863 2,054,585 8,598,448 8,886,695 1,999,062 10,885,757 Convertible notes payable, net 292,410 - 292,410 - - - Operating lease obligations, long term - - - - 22,515 22,515 Finance lease obligations, long term - 3,389,124 3,389,124 - 3,533,090 3,533,090 TOTAL LIABILITIES $ 6,836,273 $ 5,443,709 $ 12,279,982 $ 8,886,695 $ 5,554,667 $ 14,441,362 The revenues and expenses associated with discontinued operations included in our consolidated statements of operations for the years ended March 31, 2021 2020, For the Year Ended March 31, For the Year Ended March 31, 2021 2020 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 4,110,456 $ 4,110,456 $ - $ 3,689,697 $ 3,689,697 Cost of goods sold - (3,506,722 ) (3,506,722 ) - (4,576,627 ) (4,576,627 ) Gross profit (loss) - 603,734 603,734 - (886,930 ) (886,930 ) General and administrative expenses 2,001,617 276,986 2,278,603 5,741,514 2,034,612 7,776,126 Loss on impairment of long-lived assets - - - - 4,645,054 4,645,054 LOSS FROM OPERATIONS (2,001,617 ) 326,748 (1,674,869 ) (5,741,514 ) (7,566,596 ) (13,308,110 ) OTHER INCOME/(EXPENSE) Gain/(loss) on extinguishment 467,872 - 467,872 (216,954 ) - (216,954 ) Gain on settlement of accounts payable 422,414 54,958 477,372 - - - Gain on deconsolidation - - - 4,393,242 - 4,393,242 Interest expense (1,285,460 ) (486,481 ) (1,771,941 ) (1,109,031 ) (694,313 ) (1,803,344 ) Loss on modification of line of credit (650,000 ) - (650,000 ) - - - Loss on modification of note receivable - - - (1,895,434 ) - (1,895,434 ) Debt default penalty (286,059 ) - (286,059 ) - - - Other expense - (118,875 ) (118,875 ) (179,368 ) (14,880 ) (194,248 ) TOTAL OTHER INCOME/(EXPENSE) (1,331,233 ) (550,398 ) (1,881,631 ) 992,455 (709,193 ) 283,262 NET LOSS BEFORE INCOME TAXES (3,332,850 ) (223,650 ) (3,556,500 ) (4,749,059 ) (8,275,789 ) (13,024,848 ) Income tax expense - (168,527 ) (168,527 ) - (86,837 ) (86,837 ) NET LOSS $ (3,332,850 ) $ (392,177 ) $ (3,725,027 ) $ (4,749,059 ) $ (8,362,626 ) $ (13,111,685 ) The components of revenues and expenses associated with discontinued operations included in our consolidated statements of operations for the years ended March 31, 2021 2020 For the Year Ended March 31, For the Year Ended March 31, 2021 2020 Nevada Louisiana Total Nevada Louisiana Total Sales revenue $ 4,110,456 $ - $ 4,110,456 $ 3,120,620 $ 569,077 $ 3,689,697 Cost of goods sold (3,506,722 ) - (3,506,722 ) (4,002,083 ) (574,544 ) (4,576,627 ) Gross profit (loss) 603,734 - 603,734 (881,463 ) (5,467 ) (886,930 ) General and administrative expenses 276,986 - 276,986 741,999 1,292,613 2,034,612 Loss on impairment of long-lived assets - - - 4,645,054 - 4,645,054 LOSS FROM OPERATIONS 326,748 - 326,748 (6,268,516 ) (1,298,080 ) (7,566,596 ) OTHER INCOME/(EXPENSE) Gain on settlement of accounts payable 54,958 - 54,958 - - - Interest expense (486,481 ) - (486,481 ) (516,173 ) (178,140 ) (694,313 ) Other expense (118,875 ) - (118,875 ) (14,880 ) - (14,880 ) TOTAL OTHER INCOME/(EXPENSE) (550,398 ) - (550,398 ) (531,053 ) (178,140 ) (709,193 ) NET LOSS BEFORE INCOME TAXES (223,650 ) - (223,650 ) (6,799,569 ) (1,476,220 ) (8,275,789 ) Income tax expense (168,527 ) - (168,527 ) (86,837 ) - (86,837 ) NET LOSS $ (392,177 ) $ - $ (392,177 ) $ (6,886,406 ) $ (1,476,220 ) $ (8,362,626 ) Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on aging and subsequent collections. During the year ended March 31, 2021, March 31, 2021 2020. Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first Raw materials consist of supplies, materials, and consumables used in the cultivation and extraction processes. Work-in-progress includes live plants and cannabis in the drying, curing, and trimming processes. Finished goods includes completed cannabis flower, trim, and extracts in bulk and packaged forms. Inventory is included in current assets from discontinued operations in the Company's consolidated balance sheets at March 31, 2021 2020. March 31, 2021 March 31, 2020 Raw materials $ 86,076 $ 91,465 Work in progress 743,844 1,166,511 Finished goods 866,195 466,319 Subtotal 1,696,115 1,724,295 Allowance to reduce inventory to NRV (6,811 ) (278,456 ) Total inventory, net $ 1,689,304 $ 1,445,839 Deposits and Noncurrent Assets Deposits and noncurrent assets from discontinued operations were $82,904 and $91,504 at March 31, 2021 2020, March 31, 2021 2020. Leases In February 2016, 2016 02, 842 Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the standard. Lease payments do not April 1, 2019. not The Company adopted the New Lease Standard using the modified retrospective transition approach as of the effective date as permitted by the amendments in ASU 2018 11, 842 not April 1, 2019. The Company determines if an arrangement is a lease at inception and has had lease agreements for warehouses, office facilities, and equipment. As a result of the adoption of ASC 842 April 1, 2019, All of the Company's lease commitments previously recorded as operating leases have terminated as of March 31, 2021. March 31, 2021, March 31, 2021 2020. December 31, 2025 December 31, 2030. Operating leases are included in discontinued operations as operating lease right-of-use assets, operating lease obligations, current, and operating lease obligations, long term on the Company's balance sheets. Finance leases are included in property and equipment, finance lease obligations, current, and finance lease obligations, long term, on the Company's balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. The rates used to discount finance leases previously recorded as capital leases range from 10.2% to 11.5%. Operating leases were discounted at a rate of 17.0%. Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 not The lease costs recorded in the Company's financial statements for the years ended March 31, 2021 2020 March 31, Classification on the Statements of Operations 2021 2020 Discontinued operations: Finance leases - amortization of ROU assets Loss from discontinued operations $ 154,699 $ 252,973 Finance leases - interest on lease liabilities Loss from discontinued operations 414,993 426,374 Operating leases Loss from discontinued operations 3,243 13,648 Total lease cost, discontinued operations 572,935 692,995 Operating leases, continuing operations General and administrative expense - 61,658 Total lease cost $ 572,935 $ 754,653 The future minimum lease payments of lease liabilities, including the costs of the lease extension, classified as discontinued operations at March 31, 2021, Year Ending March 31, Finance Leases 2022 $ 544,296 2023 560,625 2024 577,444 2025 594,767 2026 612,610 Thereafter 3,168,492 Total minimum lease payments 6,058,234 Less: Amount representing interest (2,525,143 ) Present value of minimum lease payments 3,533,091 Less: Current maturities of capital lease obligations (143,967 ) Long-term capital lease obligations $ 3,389,124

Note 5 - Notes Payable and Line

Note 5 - Notes Payable and Line of Credit	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 4 Notes Payable and Line of Credit 0% October 23, 2017 On October 23, 2017, one three January 1, 2018. To date, the Company has made principal payments totaling $330,555 and the principal balance of the note was $369,445 at June 30, 2021. June 30, 2021, On August 10, 2020, 9 July 31, 2021, no no 8% July 24, 2020 On July 24, 2020, "July 24 may 8% February 28, 2019. July 24 July 24 may 9 On December 29, 2020, three $325,000 July 24 July 24 one not November 30, 2020. not July 24 March 31, 2021 ( two $325,000 $325,000 July 24 June 30, 2021, $325,000 March 31, 2021, June 30, 2021. June 30, 2021. Summary of Notes and Convertible Notes Payable As of June 30, 2021, As of June 30, 2021 Short-Term Notes Payable Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 4) $ 369,445 $ - $ 369,445 8% Line of Credit dated November 27, 2019 (Note 3) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 4) 1,025,000 - 1,025,000 6% Convertible promissory notes payable (Note 5) 1,060,000 - 1,060,000 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 5) 1,111,863 - 1,111,863 6% Convertible notes payable due January 18, 2022 (Note 5) 325,000 (272,122 ) 52,878 Total short-term notes and convertible notes payable 4,376,308 (272,122 ) 4,104,186 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short-term notes payable classified as continuing operations $ 3,891,308 $ (272,122 ) $ 3,619,186 6% Convertible promissory notes payable due September 30, 2023 (Note 5) 197,000 (37,204 ) 159,796 6% Convertible note payable due December 31, 2023 (Note 5) 250,000 (103,919 ) 146,081 Total long-term notes payable classified as continuing operations $ 447,000 $ (141,123 ) $ 305,877	Note 5 Notes Payable and Line of Credit 0% October 23, 2017 On October 23, 2017, one three January 1, 2018. To date, the Company has made principal payments totaling $330,555 and the principal balance of the note was $369,445 at March 31, 2021. March 31, 2021, March 31, 2021, On August 10, 2020, 14 July 31, 2021, no no 8% November 27, 2019 In connection with the Binding Letter of Intent dated November 27, 2019 ( 14 not March 31, 2021, March 31, 2021, March 31, 2021. 8% May 7, 2020 On May 7, 2020, first March 31, 2021, October 5, 2020, 8% July 24, 2020 On July 24, 2020, "July 24 may 8% February 28, 2019. July 24 July 24 may 14 On December 29, 2020, three $325,000 July 24 July 24 one not July 24 two $325,000 $325,000 July 24 $325,000 March 31, 2021. March 31, 2021. Summary of Notes Payable As of March 31, 2021, As of March 31, 2021 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ - $ 369,445 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 5) 1,025,000 - 1,025,000 6% Convertible promissory notes payable (Note 6) 1,060,000 - 1,060,000 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,111,863 - 1,111,863 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 (296,504 ) 28,496 Total short-term notes and convertible notes payable 4,376,308 (296,504 ) 4,079,804 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 3,891,308 $ (296,504 ) $ 3,594,804 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (40,561 ) $ 156,439 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (114,029 ) 135,971 Total long term convertible notes payable classified as continuing operations $ 447,000 $ (154,590 ) $ 292,410 As of March 31, 2020, As of March 31, 2020 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ (13,929 ) $ 355,516 8% Line of Credit dated November 27, 2019 (Note 5) 480,000 - 480,000 6% Convertible promissory notes payable (Note 6) 1,257,000 (155,340 ) 1,101,660 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,271,863 (409,481 ) 862,382 8% Convertible Promissory Note dated April 23, 2019 (Note 6) 2,765,000 (29,830 ) 2,735,170 Total short term notes and convertible notes payable 6,143,308 (608,580 ) 5,534,728 Less: Notes payable classified as discontinued operations (480,000 ) - (480,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 5,663,308 $ (608,580 ) $ 5,054,728

Note 6 - Convertible Notes

Note 6 - Convertible Notes	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Convertible Debt [Text Block]	Note 5 Convertible Notes March 2017 July 2017 In March 2017, third three March 2017 May 2017, three three In July 2017, third three July 2017 December 2017, three three All notes from the March July 2017 March 31, 2021, $197,000 three September 30, 2023. 10% three June 30, 2021, $197,000 June 30, 2021, Three convertible notes totaling $1,060,000 held by the same investor are past maturity and are currently in default. The Company is negotiating the terms of an extension with the note holder. The notes do not three June 30, 2021, no $1,060,000 June 30, 2021. 8% Convertible Promissory Note dated February 28, 2019 On February 28, 2019, August 28, 2020, On May 28, 2019, February 28, 2019. On July 12, 2019, July 12, 2019, The Company evaluated the modification under the guidance in ASC 470 50 10% On August 1, 2019, On October 23, 2019, October 23, 2019 We evaluated the modification under the guidance in ASC 470 50 10% 2nd March 31, 2020. On November 27, 2019, “2nd 2nd We evaluated the modification under the guidance in ASC 470 50 2nd 10% 2nd 2nd On December 16, 2019, On December 29, 2020, November 30, 2020. During the quarter ended March 31, 2021, March 31, 2021, June 30, 2021. no 8% April 23, 2019 On April 23, 2019, April 22, 2020. During the year ended March 31, 2020, October 30, 2019, November 18, 2019, On April 22, 2020, 10% On May 20, 2020, July 14, 2020, On November 20, 2020, December 8, 2020. December 8, 2020, December 9, 2020, not December 16, 2020, December 18, 2020, no December 2020 $575,000 6% On December 18, 2020, 19 March 31, 2021, three December 2021, December 2023. At June 30, 2021, three June 30, 2021,	Note 6 Convertible Notes March 2017 July 2017 In March 2017, third three March 2017 May 2017, three three In July 2017, third three July 2017 December 2017, three three All notes from the March July 2017 March 31, 2021, $197,000 three September 30, 2023. 10% March 31, 2021, $197,000 March 31, 2021, Three convertible notes totaling $1,060,000 held by the same investor are past maturity and are currently in default. The Company is negotiating the terms of an extension with the note holder. The notes do not March 31, 2021, $1,060,000 March 31, 2021. 8% Convertible Promissory Note dated February 28, 2019 On February 28, 2019, August 28, 2020, On May 28, 2019, February 28, 2019. On July 12, 2019, July 12, 2019, The Company evaluated the modification under the guidance in ASC 470 50 10% On August 1, 2019, On October 23, 2019, October 23, 2019 We evaluated the modification under the guidance in ASC 470 50 10% 2nd March 31, 2020. On November 27, 2019, “2nd 2nd We evaluated the modification under the guidance in ASC 470 50 2nd 10% 2nd 2nd On December 16, 2019, On December 29, 2020, 14 November 30, 2020. During the quarter ended March 31, 2021, March 31, 2021. During the year ended March 31, 2021, no 8% April 23, 2019 On April 23, 2019, April 22, 2020. During the year ended March 31, 2020, October 30, 2019, November 18, 2019, On April 22, 2020, 10% On May 20, 2020, July 14, 2020, On November 20, 2020, 14 December 8, 2020. December 8, 2020, December 9, 2020, not December 16, 2020, December 18, 2020, no During the year ended March 31, 2021, $209,292 December 2020 $575,000 6% On December 18, 2020, 19 March 31, 2021, three December 2021, December 2023. At March 31, 2021, March 31, 2021,

Note 7 - Property and Equipment

Note 7 - Property and Equipment	3 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 7 Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of the asset or, in the case of leasehold improvements amortized over the lesser of the useful life of the asset or the underlying lease term. We recorded depreciation expense of $34,555 and $541,462 on a consolidated basis for the years ended year ended March 31, 2021 2020, March 31, 2021 2020, March 31, 2021 Continuing Operations Discontinued Operations Total Furniture and fixtures $ - $ - $ - Computer and software 151,748 - 151,748 Machinery and equipment 619,631 289,035 908,666 Leaseholds - 3,455,600 3,455,600 Construction in progress - 21,069 21,069 Finance lease right-of-use asset - 1,663,013 1,663,013 771,379 5,428,717 6,200,097 Less accumulated depreciation and amortization (746,357 ) (552,471 ) (1,298,828 ) Property and Equipment, Net $ 25,022 $ 4,876,247 $ 4,901,269 During the year ended March 31, 2020, 14 not 3 820.

Note 8 - Income Taxes

Note 8 - Income Taxes	3 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 8 Income Taxes The Company files income tax returns in the U.S. federal jurisdiction. The Company operates in the state of Nevada, which does not The Company’s effective tax rate was -3.6% and 0.0% for the years ended March 31, 2021 2020, Income tax expense was $168,527 for the year ended March 31, 2021, March 31, 2018 March 31, 2021 March 31, 2018 March 31, 2020. March 31, 2018 March 31, 2020. March 31, 2021 2020. Because the Company operates in the State-licensed cannabis industry, it is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E. At March 31, 2021 2020 2025 2039. March 31, 2019 no may 50% The provision for income taxes included in discontinued operations is different than would result from applying the U.S. statutory rate to profit before taxes for the reasons set forth in the following reconciliation: 2021 2020 Tax benefit computed at U.S. statutory rates $ (697,040 ) $ (2,178,478 ) Increases (decreases) in taxes resulting from: IRC Section 280E 173,045 202,877 Other permanent items 14,407 22,948 Change in valuation allowance 26,720 1,952,653 Adjustments to valuation of deferred tax assets 603,319 - Total provision for income taxes 120,451 - Penalties and interest on prior year tax liabilities 48,076 86,837 Total income tax expense $ 168,527 $ 86,837 The tax effects of the primary temporary differences giving rise to the Company’s deferred tax assets and liabilities are as follows for the year ended March 31, 2021 2020: 2021 2020 Deferred tax assets: Stock based compensation $ 3,131,344 $ 2,943,816 Net operating loss carryforward 10,460,788 10,625,357 Impairment of long-lived assets 975,461 975,461 Depreciation and Amortization expense (458,938 ) (324,707 ) Other temporary items 220,795 136,243 Total deferred tax assets 14,329,450 14,356,170 Less valuation allowance (14,329,450 ) (14,356,170 ) Net deferred tax asset $ - $ - Deferred tax assets are evaluated by considering historical levels of income, estimates of future taxable income and the impact of tax planning strategies. The Company continues to evaluate its deferred tax asset valuation allowance on a quarterly basis. The Company concluded that, as of March 31, 2021, not not The Company believes that the tax positions taken in its tax returns would be sustained upon examination by taxing authorities. The Company files income tax returns in the U.S. federal jurisdiction and other required state jurisdictions. The Company's periodic tax returns filed in 2018

Note 9 - Capital Transactions

Note 9 - Capital Transactions	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 6 Capital Transactions Sale of Common Stock and Exercise of Warrants On April 1, 2020, $.05 July 18, 2021, September 30, 2021 three three June 30, 2021,the	Note 9 Capital Transactions Year Ended March 31, 2021 On April 1, 2020, $.05 March 31, 2021, During the year ended March 31, 2021, one ten During the year ended March 31, 2021, three three 6 On November 16, 2020, November 16, 2025, June 1, 2023. On December 7, 2020, ten On December 15, 2020, ten one third one third one one third two March 31, 2021. March 31, 2021. On December 15, 2020, On January 2, 2021, January 2, 2024. December 11, 2020 October 1, 2023, During the quarter ended March 31, 2021, 6 On February 8, 2021, December 2019 three At March 31, 2021, Year Ended March 31, 2020 Stock Issued for Debt Conversions During the year ended March 31, 2020, On May 28, 2019, February 28, 2019 ( 6 On August 1, 2019, On December 16, 2019, During the year ended March 31, 2020, October 30, 2019, November 18, 2019, two March 31, 2020. Exercise of Warrants for Stock During the year ended March 31, 2020, In order to encourage the exercise of approximately 70.5 million warrants issued to investors in private placements of convertible notes and common stock having exercise prices ranging between $0.65 and $0.30, the Company effected a temporary decrease in the exercise price of the warrants to $0.10 per share until July 11, 2019. July 12, 2019, August 30, 2019, July 31, 2019, December 31, 2019. In order to encourage the further exercise of the warrants, the Company effected a temporary decrease in the exercise price of the warrants to $0.03-$.05 per share beginning in December 2019. Issuance of Stock for Services During the year ended March 31, 2020, Warrants Outstanding Presented below is a summary of the Company’s warrant activity, exclusive of warrants held by employees (see Note 10 March 31, 2021 2020: Warrants Outstanding Number of Shares Exercise Price Outstanding at March 31, 2019 99,790,989 Warrants issued 7,622,780 $0.30 Warrants exercised (17,563,000 ) 0.03550.1010 Warrants expired/cancelled (5,312,608 ) 0.5002.0000 Outstanding at March 31, 2020 84,538,161 Warrants issued 43,493,809 $0.10 Warrants exercised (35,798,809 ) 0.03000.03535 Warrants expired/cancelled (6,390,125 ) 0.6000.9090 Outstanding at March 31, 2021 85,843,036

Note 10 - Employee Benefit Plan

Note 10 - Employee Benefit Plan	3 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	Note 10 Employee Benefit Plan Share-Based Employee Compensation On February 6, 2008, 2007 “2007 2007 may 2014 June 30, 2015, 8 April 6, 2018, 2014 2018 October 25, 2018, 8 2018 March 31, 2021. Compensation Expense For the years ended March 31, 2021 2020, March 31, 2021. Fair Value The closing price of the Company's stock on the date of grant is used as the fair value for issuances of restricted stock. The fair value of stock options granted is estimated as of the grant date using the Black-Scholes option pricing model. The following range of assumptions in the Black-Scholes option pricing model was used to determine fair value: Year Ended March 31, 2021 March 31, 2020 Weighted-average volatility 127 % N/A Expected term (in years) 10 N/A Risk-free interest rate 0.93 % N/A Expected volatilities used for award valuation are based on historical volatility of the Company's common stock. The risk-free interest rate for periods equal to the expected term of an award is based on Federal Reserve yields for U.S. Treasury securities. Stock Options A summary of employee option activity, including warrants issued to employees, as of March 31, 2021 2020, Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Employee options and warrants Options Price $ Life (years) Value ($) Outstanding at March 31, 2019 12,583,334 $ 0.28 7.18 $ 43,000 Granted - Exercised - Forfeited (1,600,000 ) $ 0.27 Outstanding at March 31, 2020 10,983,334 $ 0.28 6.02 $ - Granted 6,750,000 $ 0.045 Exercised - Forfeited - Outstanding at March 31, 2021 17,733,334 $ 0.11 6.80 $ 172,000 Fully vested and expected to vest at March 31, 2021 17,733,334 $ 0.11 Exercisable at March 31, 2021 15,566,668 $ 0.12 The table below sets forth nonemployee option activity for the years ended March 31, 2021 2020: Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Nonemployee options Options Price $ Life (years) Value ($) Outstanding at March 31, 2019 2,383,000 $ 0.27 7.76 $ 492,250 Granted - Exercised - Forfeited - Outstanding at March 31, 2020 2,383,000 $ 0.27 6.75 $ - Granted 3,500,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2021 5,883,000 $ 0.14 8.11 $ 35,000 Fully vested and expected to vest at March 31, 2021 5,883,000 $ 0.14 Exercisable at March 31, 2021 5,883,000 $ 0.14 Restricted stock awards No restricted stock awards were granted during the years ended March 31, 2021 2020.

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 7 Commitments and Contingencies On April 22, 2020, May 20, 2020, July 14, 2020, December 16, 2020 5 On April 22, 2020, September 17, 2020, From time to time, the Company may not	Note 11 Commitments and Contingencies On September 18, 2017, five five 50% $500,000 three August 4, 2020, first $250,000 twelve September 30, 2020, twelve August 24, 2020, no 14 An individual filed a Charge of Discrimination with the Nevada Equal Rights Commission ("NERC") against the Company on April 2, 2019, May 11, 2021. On April 22, 2020, May 20, 2020, July 14, 2020, December 16, 2020, 6 On April 22, 2020, September 17, 2020, From time to time, the Company may not

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 8 Related Party Transactions As of June 30, 2021	Note 12 As of March 31, 2021, On September 1, 2019, 9 January 2, 2021, On November 16, 2020, March 31, 2021. March 31, 2020, In connection with the sale of membership interest in GB Sciences Louisiana, LLC, the Company issued a note payable in the amount of $151,923 to John Davis, the Company's former General Counsel and President of GB Sciences Louisiana, LLC, for unpaid compensation and bonuses. The note matured upon receipt of the first August 4, 2020, first 14

Note 13 - Sale of 50% Membershi

Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC	12 Months Ended
	Mar. 31, 2021
GB Sciences Louisiana, LLC, Sale of Equity [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 13 Sale of 50% On November 15, 2019, The Wellcana note bore interest at a rate of 5% per annum and payments were due beginning June 1, 2020 December 1, 2021. November 15, 2019: November 15, 2019 Note Receivable Note Payments June 1, 2020 $ 500,000 September 1, 2020 750,000 December 1, 2020 1,000,000 March 1, 2020 1,250,000 June 1, 2021 1,500,000 September 1, 2021 1,500,000 December 1, 2021 1,500,000 Total proceeds 8,000,000 Discount on note receivable (1,389,408 ) Net present value $ 6,610,592 Upon close of the sale on November 15, 2019, As of Gain on Deconsolidation November 15, 2019 Present value of promissory note $ 6,610,592 Carrying amount of non-controlling interest 8,707,651 Total 15,318,243 Carrying amount of assets 14,715,798 Carrying amount of liabilities (3,790,797 ) Net assets deconsolidated 10,925,001 Gain on deconsolidation $ 4,393,242 On August 24, 2020, October 15, 2020, 11 no September 1, 2020, As a result of the August 24, 2020 March 31, 2020 August 24, 2020 Modification March 31, 2020 Total cash payments to be made by October 15, 2020 $ 4,900,000 Liabilities to be forgiven upon receipt of October 15, 2020 payment 324,423 Total receivable (as modified) 5,224,423 Carrying value of note receivable as of March 31, 2020 6,969,720 Accrued interest as of March 31, 2020 150,137 Total amount receivable (prior to modification) 7,119,857 Loss on modification of note receivable $ (1,895,434 ) The Company received payments from Wellcana totaling $550,000 in August September 2020, On October 15, 2020, October 15, 2020, December 8, 2020. $4,350,000 December 8, 2020. October 24, 2020, October 29, 2020. On December 8, 2020, December 8, 2020, not $4,350,000 December 16, 2020, The Company's statements of operations and cash flows for the year ended March 31, 2020 November 15, 2019,

Note 14 - Sale of 100% Membersh

Note 14 - Sale of 100% Membership Interests in Nevada Subsidiaries	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Nevada Subsidiaries [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 9 Sale of Membership Interests in Nevada Subsidiaries On November 15, 2019, March 24, 2020, 30 On July 24, 2020, "July 24 July 24 4 On December 29, 2020, one three not July 24 July 24 three $325,000, $4,000,000 The Omnibus Amendment also amends the Management Services Agreement to provide that no November 30, 2020. June 30, 2021, three 36 30 On May 11, 2021, December 31, 2021, $4,000,000 June 30, 2021. The sale is expected to close upon the successful transfer of the Nevada cultivation and production licenses. The transfer of cannabis licenses in the State of Nevada was subject to an indefinite moratorium beginning in October 2019. July 21, 2020, 90 19 The Company also holds a Nevada license for cultivation of medical marijuana located in Sandy Valley, Nevada (the “Nopah License”). The license is owned by the Company’s wholly owned subsidiary, GB Sciences Nopah, LLC ("Nopah"). Operations have not November 27, 2019, August 10, 2020, October 23, 2017 ( 4 Because the moratorium on license transfers has been lifted, the Company determined that the Teco Facility and Nopah Facility qualify for presentation as discontinued operations, and the income, assets, and cash flows of the Teco Subsidiaries and GB Sciences Nopah, LLC have been reclassified as discontinued operations for all periods presented in the Company's consolidated financial statements.	Note 14 100% On November 15, 2019, 5 On March 24, 2020, 30 On July 24, 2020, "July 24 July 24 July 24 March 31, 2021, July 24 5 On December 29, 2020, one three not July 24 July 24 three $325,000, The Omnibus Amendment also amends the Management Services Agreement to provide that no November 30, 2020. March 31, 2021, three 36 30 The sale is expected to close upon the successful transfer of the Nevada cultivation and production licenses. The transfer of cannabis licenses in the State of Nevada was subject to an indefinite moratorium beginning in October 2019. July 21, 2020, 90 19 The Company also holds a Nevada license for cultivation of medical marijuana located in Sandy Valley, Nevada (the “Nopah License”). The license is owned by the Company’s wholly owned subsidiary, GB Sciences Nopah, LLC ("Nopah"). Operations have not November 27, 2019, August 10, 2020, October 23, 2017 ( 5 Because the moratorium on license transfers has been lifted, the Company determined that the Teco Facility and Nopah Facility qualify for presentation as discontinued operations, and the income, assets, and cash flows of the Teco Subsidiaries and GB Sciences Nopah, LLC have been reclassified as discontinued operations for all periods presented in the Company's consolidated financial statements.

Note 15 - Concentrations

Note 15 - Concentrations	3 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 15 Concentrations For the year ended March 31, 2021, March 31, 2021, March 31, 2021. March 31, 2021 March 31, 2020,

Note 16 - Subsequent Events

Note 16 - Subsequent Events	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	Note 10 Subsequent Events Capital Transactions On July 2, 2021, July 1, 2022 December 2020.	Note 16 Subsequent Events On May 11, 2021, December 31, 2021. On June 14, 2021,

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2022. March 31, 2021 not 10 March 31, 2021.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single	Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. The subsidiaries of the Company are: Continuing Operations: GBS Global Biopharma, Inc. ECRX, Inc. The PhAROS Institute, LLC GB Sciences Texas, LLC Discontinued Operations: GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC GB Sciences Nopah, LLC Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. In particular, the assets, liabilities, profit and loss, and cash flows of GB Sciences Nevada LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC, have been separated from the comparative period amounts to conform to the current period presentation as discontinued operations as the result of the pending sale of the Company's Nevada operations. The reclassifications had no	Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. In particular, the assets, liabilities, income, and cash flows of GB Sciences Nevada LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC, have been separated from the comparative period amounts to conform to the current period presentation as discontinued operations as the result of the pending sale of the Company's Nevada operations. The reclassifications had no
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations See Note 3.	Discontinued Operations See Note 4.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not June 30, 2021.	Long-Lived Assets Property and equipment comprise a significant portion of our total assets from discontinued operations. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not During the year ended March 31, 2020, 100% 14 not 3 820. $4.0M
Inventory, Policy [Policy Text Block]	Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first	Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first
Debt, Policy [Policy Text Block]	Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, 00 27, No. 98 5 first 718 The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.	Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, Debt with Conversion and Other Options 00 27, Application of Issue No. 98 5 first 718 Compensation Stock Compensation The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source is part of discontinued operations and derives from sales of cannabis and cannabis products, distinct physical goods. Under ASC 606, may may one 606 not	Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source is part of discontinued operations and derives from sales of cannabis and cannabis products, distinct physical goods. Under ASC 606, may may one 606 not
Income Tax, Policy [Policy Text Block]	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company operates in the State-licensed cannabis industry through the Nevada Subsidiaries, it is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E.	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company operates in the State-licensed cannabis industry, it is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E.
Earnings Per Share, Policy [Policy Text Block]	Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 160,314,865 and 164,049,941 potentially dilutive common shares at June 30, 2021 March 31, 2021, not	Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 164,049,941 and 158,404,020 potentially dilutive common shares at March 31, 2021 2020, not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Standards Not In May 2021, No. 2021 04, 2021 04 April 1, 2022. 2021 04 not On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2024. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not	Recent Accounting Pronouncements Recently Adopted Standards In August 2018, No. 2018 13, December 15, 2019, April 1, 2020, not Standards Not In May 2021, No. 2021 04, 2021 04 April 1, 2022. 2021 04 On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2024. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not
Fair Value of Financial Instruments, Policy [Policy Text Block]		Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three - Level 1 - Level 2 - Level 3 The carrying value of cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value, primarily due to the short-term nature of the instruments.
Cash and Cash Equivalents, Policy [Policy Text Block]		Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three March 31, 2021 2020.
Accounts Receivable [Policy Text Block]		Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on aging and subsequent collections.
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]		Indefinite-Lived Intangible Assets Our indefinite-lived intangible assets primarily represent the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also include the acquisition cost of a cannabis production license with an indefinite life. We amortize our finite-lived intangible assets over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. During the year ended March 31, 2020, not March 31, 2020,
Lessee, Leases [Policy Text Block]		Operating Lease Right-of-Use Asset and Liability The Company determines if an arrangement is a lease at inception and has lease agreements for office facilities, equipment, and other space and assets with non-cancelable lease terms. Certain real estate and property leases, and various other operating leases are measured on the balance sheet with a lease liability and right-of-use asset ("ROU"). ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the New Lease Standard. Lease payments do not Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of twelve not
Property, Plant and Equipment, Policy [Policy Text Block]		Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets: 3-8 years for machinery and equipment, and leasehold improvements are amortized over the shorter of the estimated useful lives or the underlying lease term. Property under finance leases and related obligations are initially recorded at an amount equal to the present value of future minimum lease payments computed on the basis of the Company’s incremental borrowing rate, and depreciation is recorded on a straight-line basis and is included within depreciation and amortization expense. Repairs and maintenance expenditures which do not
Research and Development Expense, Policy [Policy Text Block]		Research and Development Costs Research and development costs are expensed as incurred. During the years ended March 31, 2021 2020,
Share-based Payment Arrangement [Policy Text Block]		Equity-Based Compensation The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 718 no may may may

Note 3 - Discontinued Operati_2

Note 3 - Discontinued Operations (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	June 30, 2021 March 31, 2021 Continuing Discontinued Total Continuing Discontinued Total ASSETS CURRENT ASSETS Cash $ 582,971 $ 112,696 $ 695,667 $ 793,040 $ 352,593 $ 1,145,633 Accounts receivable, net - 643,594 643,594 - 400,175 400,175 Inventory, net - 1,462,009 1,462,009 - 1,689,304 1,689,304 Prepaid and other current assets 296,081 30,458 326,539 256,251 52,492 308,743 TOTAL CURRENT ASSETS 879,052 2,248,757 3,127,809 1,049,291 2,494,564 3,543,855 Property and equipment, net 21,895 4,736,272 4,758,167 25,022 4,876,247 4,901,269 Intangible assets, net 1,797,920 571,264 2,369,184 1,706,762 571,264 2,278,026 Deposits and other noncurrent assets - 75,469 75,469 - 82,904 82,904 TOTAL ASSETS $ 2,698,867 $ 7,631,762 $ 10,330,629 $ 2,781,075 $ 8,024,979 $ 10,806,054 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,463,806 $ 385,320 $ 1,849,126 $ 1,412,459 $ 509,477 $ 1,921,936 Accrued interest 521,145 49,211 570,356 493,741 49,211 542,952 Accrued expenses 1,031,003 122,714 1,153,717 957,946 105,421 1,063,367 Notes payable, net 3,619,186 485,000 4,104,186 3,594,804 485,000 4,079,804 Indebtedness to related parties 84,913 - 84,913 84,913 - 84,913 Income tax payable - 793,292 793,292 - 761,509 761,509 Finance lease obligations, current - 152,250 152,250 - 143,967 143,967 TOTAL CURRENT LIABILITIES 6,720,053 1,987,787 8,707,840 6,543,863 2,054,585 8,598,448 Convertible notes payable 305,877 - 305,877 292,410 - 292,410 Finance lease obligations, long term - 3,347,363 3,347,363 - 3,389,124 3,389,124 TOTAL LIABILITIES $ 7,025,930 $ 5,335,150 $ 12,361,080 $ 6,836,273 $ 5,443,709 $ 12,279,982 For the Three Months Ended June 30, 2021 2020 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 1,342,586 $ 1,342,586 $ - $ 551,197 $ 551,197 Cost of goods sold - (1,219,041 ) (1,219,041 ) - (491,795 ) (491,795 ) Gross profit/(loss) - 123,545 123,545 - 59,402 59,402 General and administrative expenses 493,405 84,078 577,483 515,253 289,455 804,708 INCOME/(LOSS) FROM OPERATIONS (493,405 ) 39,467 (453,938 ) (515,253 ) (230,053 ) (745,306 ) OTHER EXPENSE Interest expense (65,254 ) (102,331 ) (167,585 ) (662,370 ) (132,943 ) (795,313 ) Debt default penalty - - - (286,059 ) - (286,059 ) Other income/(expense) - 20,889 20,889 (11,182 ) - (11,182 ) Total other expense (65,254 ) (81,442 ) (146,696 ) (959,611 ) (132,943 ) (1,092,554 ) LOSS BEFORE INCOME TAXES (558,659 ) (41,975 ) (600,634 ) (1,474,864 ) (362,996 ) (1,837,860 ) Income tax expense - (31,783 ) (31,783 ) - (8,840 ) (8,840 ) NET LOSS $ (558,659 ) $ (73,758 ) $ (632,417 ) $ (1,474,864 ) $ (371,836 ) $ (1,846,700 )	March 31, 2021 March 31, 2020 Continuing Discontinued Nevada Subsidiaries Total Continuing Discontinued Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 793,040 $ 352,593 $ 1,145,633 $ 2,406 $ 149,360 $ 151,766 Accounts receivable, net - 400,175 400,175 - 117,967 117,967 Inventory, net - 1,689,304 1,689,304 - 1,445,839 1,445,839 Prepaid and other current assets 256,251 52,492 308,743 18,776 42,109 60,885 Note receivable - - - 5,224,423 - 5,224,423 TOTAL CURRENT ASSETS 1,049,291 2,494,564 3,543,855 5,245,605 1,755,275 7,000,880 Property and equipment, net 25,022 4,876,247 4,901,269 37,821 5,496,012 5,533,833 Intangible assets, net 1,706,762 571,264 2,278,026 1,128,702 571,264 1,699,966 Deposits and other noncurrent assets - 82,904 82,904 - 91,504 91,504 Operating lease right-of-use assets, net - - - - 26,685 26,685 TOTAL ASSETS $ 2,781,075 $ 8,024,979 $ 10,806,054 $ 6,412,128 $ 7,940,740 $ 14,352,868 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,412,459 $ 509,477 $ 1,921,936 $ 1,913,049 $ 646,865 $ 2,559,914 Accrued interest 493,741 49,211 542,952 366,865 30,787 397,652 Accrued expenses 957,946 105,421 1,063,367 813,618 74,394 888,012 Notes and convertible notes payable, net 3,594,804 485,000 4,079,804 5,054,728 480,000 5,534,728 Indebtedness to related parties 84,913 - 84,913 586,512 - 586,512 Note payable to related party - - - 151,923 - 151,923 Income tax payable - 761,509 761,509 - 592,982 592,982 Finance lease obligations, current - 143,967 143,967 - 166,769 166,769 Operating lease obligations, current - - - - 7,265 7,265 TOTAL CURRENT LIABILITIES 6,543,863 2,054,585 8,598,448 8,886,695 1,999,062 10,885,757 Convertible notes payable, net 292,410 - 292,410 - - - Operating lease obligations, long term - - - - 22,515 22,515 Finance lease obligations, long term - 3,389,124 3,389,124 - 3,533,090 3,533,090 TOTAL LIABILITIES $ 6,836,273 $ 5,443,709 $ 12,279,982 $ 8,886,695 $ 5,554,667 $ 14,441,362 For the Year Ended March 31, For the Year Ended March 31, 2021 2020 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 4,110,456 $ 4,110,456 $ - $ 3,689,697 $ 3,689,697 Cost of goods sold - (3,506,722 ) (3,506,722 ) - (4,576,627 ) (4,576,627 ) Gross profit (loss) - 603,734 603,734 - (886,930 ) (886,930 ) General and administrative expenses 2,001,617 276,986 2,278,603 5,741,514 2,034,612 7,776,126 Loss on impairment of long-lived assets - - - - 4,645,054 4,645,054 LOSS FROM OPERATIONS (2,001,617 ) 326,748 (1,674,869 ) (5,741,514 ) (7,566,596 ) (13,308,110 ) OTHER INCOME/(EXPENSE) Gain/(loss) on extinguishment 467,872 - 467,872 (216,954 ) - (216,954 ) Gain on settlement of accounts payable 422,414 54,958 477,372 - - - Gain on deconsolidation - - - 4,393,242 - 4,393,242 Interest expense (1,285,460 ) (486,481 ) (1,771,941 ) (1,109,031 ) (694,313 ) (1,803,344 ) Loss on modification of line of credit (650,000 ) - (650,000 ) - - - Loss on modification of note receivable - - - (1,895,434 ) - (1,895,434 ) Debt default penalty (286,059 ) - (286,059 ) - - - Other expense - (118,875 ) (118,875 ) (179,368 ) (14,880 ) (194,248 ) TOTAL OTHER INCOME/(EXPENSE) (1,331,233 ) (550,398 ) (1,881,631 ) 992,455 (709,193 ) 283,262 NET LOSS BEFORE INCOME TAXES (3,332,850 ) (223,650 ) (3,556,500 ) (4,749,059 ) (8,275,789 ) (13,024,848 ) Income tax expense - (168,527 ) (168,527 ) - (86,837 ) (86,837 ) NET LOSS $ (3,332,850 ) $ (392,177 ) $ (3,725,027 ) $ (4,749,059 ) $ (8,362,626 ) $ (13,111,685 ) For the Year Ended March 31, For the Year Ended March 31, 2021 2020 Nevada Louisiana Total Nevada Louisiana Total Sales revenue $ 4,110,456 $ - $ 4,110,456 $ 3,120,620 $ 569,077 $ 3,689,697 Cost of goods sold (3,506,722 ) - (3,506,722 ) (4,002,083 ) (574,544 ) (4,576,627 ) Gross profit (loss) 603,734 - 603,734 (881,463 ) (5,467 ) (886,930 ) General and administrative expenses 276,986 - 276,986 741,999 1,292,613 2,034,612 Loss on impairment of long-lived assets - - - 4,645,054 - 4,645,054 LOSS FROM OPERATIONS 326,748 - 326,748 (6,268,516 ) (1,298,080 ) (7,566,596 ) OTHER INCOME/(EXPENSE) Gain on settlement of accounts payable 54,958 - 54,958 - - - Interest expense (486,481 ) - (486,481 ) (516,173 ) (178,140 ) (694,313 ) Other expense (118,875 ) - (118,875 ) (14,880 ) - (14,880 ) TOTAL OTHER INCOME/(EXPENSE) (550,398 ) - (550,398 ) (531,053 ) (178,140 ) (709,193 ) NET LOSS BEFORE INCOME TAXES (223,650 ) - (223,650 ) (6,799,569 ) (1,476,220 ) (8,275,789 ) Income tax expense (168,527 ) - (168,527 ) (86,837 ) - (86,837 ) NET LOSS $ (392,177 ) $ - $ (392,177 ) $ (6,886,406 ) $ (1,476,220 ) $ (8,362,626 )
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 2021 March 31, 2021 Raw materials $ 112,857 $ 86,076 Work in progress 814,166 743,844 Finished goods 601,807 866,195 Subtotal 1,528,830 1,696,115 Allowance to reduce inventory to net realizable value (66,821 ) (6,811 ) Total inventory, net $ 1,462,009 $ 1,689,304	March 31, 2021 March 31, 2020 Raw materials $ 86,076 $ 91,465 Work in progress 743,844 1,166,511 Finished goods 866,195 466,319 Subtotal 1,696,115 1,724,295 Allowance to reduce inventory to NRV (6,811 ) (278,456 ) Total inventory, net $ 1,689,304 $ 1,445,839
Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]	Year Ending March 31, Finance Leases 2022 (9 months) $ 409,235 2023 560,625 2024 577,444 2025 594,767 2026 612,610 Thereafter 3,168,492 Total minimum lease payments 5,923,173 Less: Amount representing interest (2,423,560 ) Present value of minimum lease payments 3,499,613 Less: Current maturities of capital lease obligations (152,250 ) Long-term capital lease obligations $ 3,347,363	Year Ending March 31, Finance Leases 2022 $ 544,296 2023 560,625 2024 577,444 2025 594,767 2026 612,610 Thereafter 3,168,492 Total minimum lease payments 6,058,234 Less: Amount representing interest (2,525,143 ) Present value of minimum lease payments 3,533,091 Less: Current maturities of capital lease obligations (143,967 ) Long-term capital lease obligations $ 3,389,124

Note 4 - Notes Payable and Li_2

Note 4 - Notes Payable and Line of Credit (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes Tables
Schedule of Debt [Table Text Block]	As of June 30, 2021 Short-Term Notes Payable Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 4) $ 369,445 $ - $ 369,445 8% Line of Credit dated November 27, 2019 (Note 3) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 4) 1,025,000 - 1,025,000 6% Convertible promissory notes payable (Note 5) 1,060,000 - 1,060,000 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 5) 1,111,863 - 1,111,863 6% Convertible notes payable due January 18, 2022 (Note 5) 325,000 (272,122 ) 52,878 Total short-term notes and convertible notes payable 4,376,308 (272,122 ) 4,104,186 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short-term notes payable classified as continuing operations $ 3,891,308 $ (272,122 ) $ 3,619,186 6% Convertible promissory notes payable due September 30, 2023 (Note 5) 197,000 (37,204 ) 159,796 6% Convertible note payable due December 31, 2023 (Note 5) 250,000 (103,919 ) 146,081 Total long-term notes payable classified as continuing operations $ 447,000 $ (141,123 ) $ 305,877	As of March 31, 2021 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ - $ 369,445 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 5) 1,025,000 - 1,025,000 6% Convertible promissory notes payable (Note 6) 1,060,000 - 1,060,000 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,111,863 - 1,111,863 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 (296,504 ) 28,496 Total short-term notes and convertible notes payable 4,376,308 (296,504 ) 4,079,804 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 3,891,308 $ (296,504 ) $ 3,594,804 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (40,561 ) $ 156,439 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (114,029 ) 135,971 Total long term convertible notes payable classified as continuing operations $ 447,000 $ (154,590 ) $ 292,410 As of March 31, 2020 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ (13,929 ) $ 355,516 8% Line of Credit dated November 27, 2019 (Note 5) 480,000 - 480,000 6% Convertible promissory notes payable (Note 6) 1,257,000 (155,340 ) 1,101,660 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,271,863 (409,481 ) 862,382 8% Convertible Promissory Note dated April 23, 2019 (Note 6) 2,765,000 (29,830 ) 2,735,170 Total short term notes and convertible notes payable 6,143,308 (608,580 ) 5,534,728 Less: Notes payable classified as discontinued operations (480,000 ) - (480,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 5,663,308 $ (608,580 ) $ 5,054,728

Note 4 - Discontinued Operati_2

Note 4 - Discontinued Operations (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	June 30, 2021 March 31, 2021 Continuing Discontinued Total Continuing Discontinued Total ASSETS CURRENT ASSETS Cash $ 582,971 $ 112,696 $ 695,667 $ 793,040 $ 352,593 $ 1,145,633 Accounts receivable, net - 643,594 643,594 - 400,175 400,175 Inventory, net - 1,462,009 1,462,009 - 1,689,304 1,689,304 Prepaid and other current assets 296,081 30,458 326,539 256,251 52,492 308,743 TOTAL CURRENT ASSETS 879,052 2,248,757 3,127,809 1,049,291 2,494,564 3,543,855 Property and equipment, net 21,895 4,736,272 4,758,167 25,022 4,876,247 4,901,269 Intangible assets, net 1,797,920 571,264 2,369,184 1,706,762 571,264 2,278,026 Deposits and other noncurrent assets - 75,469 75,469 - 82,904 82,904 TOTAL ASSETS $ 2,698,867 $ 7,631,762 $ 10,330,629 $ 2,781,075 $ 8,024,979 $ 10,806,054 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,463,806 $ 385,320 $ 1,849,126 $ 1,412,459 $ 509,477 $ 1,921,936 Accrued interest 521,145 49,211 570,356 493,741 49,211 542,952 Accrued expenses 1,031,003 122,714 1,153,717 957,946 105,421 1,063,367 Notes payable, net 3,619,186 485,000 4,104,186 3,594,804 485,000 4,079,804 Indebtedness to related parties 84,913 - 84,913 84,913 - 84,913 Income tax payable - 793,292 793,292 - 761,509 761,509 Finance lease obligations, current - 152,250 152,250 - 143,967 143,967 TOTAL CURRENT LIABILITIES 6,720,053 1,987,787 8,707,840 6,543,863 2,054,585 8,598,448 Convertible notes payable 305,877 - 305,877 292,410 - 292,410 Finance lease obligations, long term - 3,347,363 3,347,363 - 3,389,124 3,389,124 TOTAL LIABILITIES $ 7,025,930 $ 5,335,150 $ 12,361,080 $ 6,836,273 $ 5,443,709 $ 12,279,982 For the Three Months Ended June 30, 2021 2020 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 1,342,586 $ 1,342,586 $ - $ 551,197 $ 551,197 Cost of goods sold - (1,219,041 ) (1,219,041 ) - (491,795 ) (491,795 ) Gross profit/(loss) - 123,545 123,545 - 59,402 59,402 General and administrative expenses 493,405 84,078 577,483 515,253 289,455 804,708 INCOME/(LOSS) FROM OPERATIONS (493,405 ) 39,467 (453,938 ) (515,253 ) (230,053 ) (745,306 ) OTHER EXPENSE Interest expense (65,254 ) (102,331 ) (167,585 ) (662,370 ) (132,943 ) (795,313 ) Debt default penalty - - - (286,059 ) - (286,059 ) Other income/(expense) - 20,889 20,889 (11,182 ) - (11,182 ) Total other expense (65,254 ) (81,442 ) (146,696 ) (959,611 ) (132,943 ) (1,092,554 ) LOSS BEFORE INCOME TAXES (558,659 ) (41,975 ) (600,634 ) (1,474,864 ) (362,996 ) (1,837,860 ) Income tax expense - (31,783 ) (31,783 ) - (8,840 ) (8,840 ) NET LOSS $ (558,659 ) $ (73,758 ) $ (632,417 ) $ (1,474,864 ) $ (371,836 ) $ (1,846,700 )	March 31, 2021 March 31, 2020 Continuing Discontinued Nevada Subsidiaries Total Continuing Discontinued Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 793,040 $ 352,593 $ 1,145,633 $ 2,406 $ 149,360 $ 151,766 Accounts receivable, net - 400,175 400,175 - 117,967 117,967 Inventory, net - 1,689,304 1,689,304 - 1,445,839 1,445,839 Prepaid and other current assets 256,251 52,492 308,743 18,776 42,109 60,885 Note receivable - - - 5,224,423 - 5,224,423 TOTAL CURRENT ASSETS 1,049,291 2,494,564 3,543,855 5,245,605 1,755,275 7,000,880 Property and equipment, net 25,022 4,876,247 4,901,269 37,821 5,496,012 5,533,833 Intangible assets, net 1,706,762 571,264 2,278,026 1,128,702 571,264 1,699,966 Deposits and other noncurrent assets - 82,904 82,904 - 91,504 91,504 Operating lease right-of-use assets, net - - - - 26,685 26,685 TOTAL ASSETS $ 2,781,075 $ 8,024,979 $ 10,806,054 $ 6,412,128 $ 7,940,740 $ 14,352,868 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,412,459 $ 509,477 $ 1,921,936 $ 1,913,049 $ 646,865 $ 2,559,914 Accrued interest 493,741 49,211 542,952 366,865 30,787 397,652 Accrued expenses 957,946 105,421 1,063,367 813,618 74,394 888,012 Notes and convertible notes payable, net 3,594,804 485,000 4,079,804 5,054,728 480,000 5,534,728 Indebtedness to related parties 84,913 - 84,913 586,512 - 586,512 Note payable to related party - - - 151,923 - 151,923 Income tax payable - 761,509 761,509 - 592,982 592,982 Finance lease obligations, current - 143,967 143,967 - 166,769 166,769 Operating lease obligations, current - - - - 7,265 7,265 TOTAL CURRENT LIABILITIES 6,543,863 2,054,585 8,598,448 8,886,695 1,999,062 10,885,757 Convertible notes payable, net 292,410 - 292,410 - - - Operating lease obligations, long term - - - - 22,515 22,515 Finance lease obligations, long term - 3,389,124 3,389,124 - 3,533,090 3,533,090 TOTAL LIABILITIES $ 6,836,273 $ 5,443,709 $ 12,279,982 $ 8,886,695 $ 5,554,667 $ 14,441,362 For the Year Ended March 31, For the Year Ended March 31, 2021 2020 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 4,110,456 $ 4,110,456 $ - $ 3,689,697 $ 3,689,697 Cost of goods sold - (3,506,722 ) (3,506,722 ) - (4,576,627 ) (4,576,627 ) Gross profit (loss) - 603,734 603,734 - (886,930 ) (886,930 ) General and administrative expenses 2,001,617 276,986 2,278,603 5,741,514 2,034,612 7,776,126 Loss on impairment of long-lived assets - - - - 4,645,054 4,645,054 LOSS FROM OPERATIONS (2,001,617 ) 326,748 (1,674,869 ) (5,741,514 ) (7,566,596 ) (13,308,110 ) OTHER INCOME/(EXPENSE) Gain/(loss) on extinguishment 467,872 - 467,872 (216,954 ) - (216,954 ) Gain on settlement of accounts payable 422,414 54,958 477,372 - - - Gain on deconsolidation - - - 4,393,242 - 4,393,242 Interest expense (1,285,460 ) (486,481 ) (1,771,941 ) (1,109,031 ) (694,313 ) (1,803,344 ) Loss on modification of line of credit (650,000 ) - (650,000 ) - - - Loss on modification of note receivable - - - (1,895,434 ) - (1,895,434 ) Debt default penalty (286,059 ) - (286,059 ) - - - Other expense - (118,875 ) (118,875 ) (179,368 ) (14,880 ) (194,248 ) TOTAL OTHER INCOME/(EXPENSE) (1,331,233 ) (550,398 ) (1,881,631 ) 992,455 (709,193 ) 283,262 NET LOSS BEFORE INCOME TAXES (3,332,850 ) (223,650 ) (3,556,500 ) (4,749,059 ) (8,275,789 ) (13,024,848 ) Income tax expense - (168,527 ) (168,527 ) - (86,837 ) (86,837 ) NET LOSS $ (3,332,850 ) $ (392,177 ) $ (3,725,027 ) $ (4,749,059 ) $ (8,362,626 ) $ (13,111,685 ) For the Year Ended March 31, For the Year Ended March 31, 2021 2020 Nevada Louisiana Total Nevada Louisiana Total Sales revenue $ 4,110,456 $ - $ 4,110,456 $ 3,120,620 $ 569,077 $ 3,689,697 Cost of goods sold (3,506,722 ) - (3,506,722 ) (4,002,083 ) (574,544 ) (4,576,627 ) Gross profit (loss) 603,734 - 603,734 (881,463 ) (5,467 ) (886,930 ) General and administrative expenses 276,986 - 276,986 741,999 1,292,613 2,034,612 Loss on impairment of long-lived assets - - - 4,645,054 - 4,645,054 LOSS FROM OPERATIONS 326,748 - 326,748 (6,268,516 ) (1,298,080 ) (7,566,596 ) OTHER INCOME/(EXPENSE) Gain on settlement of accounts payable 54,958 - 54,958 - - - Interest expense (486,481 ) - (486,481 ) (516,173 ) (178,140 ) (694,313 ) Other expense (118,875 ) - (118,875 ) (14,880 ) - (14,880 ) TOTAL OTHER INCOME/(EXPENSE) (550,398 ) - (550,398 ) (531,053 ) (178,140 ) (709,193 ) NET LOSS BEFORE INCOME TAXES (223,650 ) - (223,650 ) (6,799,569 ) (1,476,220 ) (8,275,789 ) Income tax expense (168,527 ) - (168,527 ) (86,837 ) - (86,837 ) NET LOSS $ (392,177 ) $ - $ (392,177 ) $ (6,886,406 ) $ (1,476,220 ) $ (8,362,626 )
Lease, Cost [Table Text Block]	March 31, Classification on the Statements of Operations 2021 2020 Discontinued operations: Finance leases - amortization of ROU assets Loss from discontinued operations $ 154,699 $ 252,973 Finance leases - interest on lease liabilities Loss from discontinued operations 414,993 426,374 Operating leases Loss from discontinued operations 3,243 13,648 Total lease cost, discontinued operations 572,935 692,995 Operating leases, continuing operations General and administrative expense - 61,658 Total lease cost $ 572,935 $ 754,653
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 2021 March 31, 2021 Raw materials $ 112,857 $ 86,076 Work in progress 814,166 743,844 Finished goods 601,807 866,195 Subtotal 1,528,830 1,696,115 Allowance to reduce inventory to net realizable value (66,821 ) (6,811 ) Total inventory, net $ 1,462,009 $ 1,689,304	March 31, 2021 March 31, 2020 Raw materials $ 86,076 $ 91,465 Work in progress 743,844 1,166,511 Finished goods 866,195 466,319 Subtotal 1,696,115 1,724,295 Allowance to reduce inventory to NRV (6,811 ) (278,456 ) Total inventory, net $ 1,689,304 $ 1,445,839
Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]	Year Ending March 31, Finance Leases 2022 (9 months) $ 409,235 2023 560,625 2024 577,444 2025 594,767 2026 612,610 Thereafter 3,168,492 Total minimum lease payments 5,923,173 Less: Amount representing interest (2,423,560 ) Present value of minimum lease payments 3,499,613 Less: Current maturities of capital lease obligations (152,250 ) Long-term capital lease obligations $ 3,347,363	Year Ending March 31, Finance Leases 2022 $ 544,296 2023 560,625 2024 577,444 2025 594,767 2026 612,610 Thereafter 3,168,492 Total minimum lease payments 6,058,234 Less: Amount representing interest (2,525,143 ) Present value of minimum lease payments 3,533,091 Less: Current maturities of capital lease obligations (143,967 ) Long-term capital lease obligations $ 3,389,124

Note 5 - Notes Payable and Li_2

Note 5 - Notes Payable and Line of Credit (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes Tables
Schedule of Debt [Table Text Block]	As of June 30, 2021 Short-Term Notes Payable Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 4) $ 369,445 $ - $ 369,445 8% Line of Credit dated November 27, 2019 (Note 3) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 4) 1,025,000 - 1,025,000 6% Convertible promissory notes payable (Note 5) 1,060,000 - 1,060,000 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 5) 1,111,863 - 1,111,863 6% Convertible notes payable due January 18, 2022 (Note 5) 325,000 (272,122 ) 52,878 Total short-term notes and convertible notes payable 4,376,308 (272,122 ) 4,104,186 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short-term notes payable classified as continuing operations $ 3,891,308 $ (272,122 ) $ 3,619,186 6% Convertible promissory notes payable due September 30, 2023 (Note 5) 197,000 (37,204 ) 159,796 6% Convertible note payable due December 31, 2023 (Note 5) 250,000 (103,919 ) 146,081 Total long-term notes payable classified as continuing operations $ 447,000 $ (141,123 ) $ 305,877	As of March 31, 2021 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ - $ 369,445 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 5) 1,025,000 - 1,025,000 6% Convertible promissory notes payable (Note 6) 1,060,000 - 1,060,000 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,111,863 - 1,111,863 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 (296,504 ) 28,496 Total short-term notes and convertible notes payable 4,376,308 (296,504 ) 4,079,804 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 3,891,308 $ (296,504 ) $ 3,594,804 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (40,561 ) $ 156,439 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (114,029 ) 135,971 Total long term convertible notes payable classified as continuing operations $ 447,000 $ (154,590 ) $ 292,410 As of March 31, 2020 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ (13,929 ) $ 355,516 8% Line of Credit dated November 27, 2019 (Note 5) 480,000 - 480,000 6% Convertible promissory notes payable (Note 6) 1,257,000 (155,340 ) 1,101,660 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,271,863 (409,481 ) 862,382 8% Convertible Promissory Note dated April 23, 2019 (Note 6) 2,765,000 (29,830 ) 2,735,170 Total short term notes and convertible notes payable 6,143,308 (608,580 ) 5,534,728 Less: Notes payable classified as discontinued operations (480,000 ) - (480,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 5,663,308 $ (608,580 ) $ 5,054,728

Note 7 - Property and Equipme_2

Note 7 - Property and Equipment (Tables)	3 Months Ended
	Jun. 30, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, 2021 Continuing Operations Discontinued Operations Total Furniture and fixtures $ - $ - $ - Computer and software 151,748 - 151,748 Machinery and equipment 619,631 289,035 908,666 Leaseholds - 3,455,600 3,455,600 Construction in progress - 21,069 21,069 Finance lease right-of-use asset - 1,663,013 1,663,013 771,379 5,428,717 6,200,097 Less accumulated depreciation and amortization (746,357 ) (552,471 ) (1,298,828 ) Property and Equipment, Net $ 25,022 $ 4,876,247 $ 4,901,269

Note 8 - Income Taxes (Tables)

Note 8 - Income Taxes (Tables)	3 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2021 2020 Tax benefit computed at U.S. statutory rates $ (697,040 ) $ (2,178,478 ) Increases (decreases) in taxes resulting from: IRC Section 280E 173,045 202,877 Other permanent items 14,407 22,948 Change in valuation allowance 26,720 1,952,653 Adjustments to valuation of deferred tax assets 603,319 - Total provision for income taxes 120,451 - Penalties and interest on prior year tax liabilities 48,076 86,837 Total income tax expense $ 168,527 $ 86,837
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2021 2020 Deferred tax assets: Stock based compensation $ 3,131,344 $ 2,943,816 Net operating loss carryforward 10,460,788 10,625,357 Impairment of long-lived assets 975,461 975,461 Depreciation and Amortization expense (458,938 ) (324,707 ) Other temporary items 220,795 136,243 Total deferred tax assets 14,329,450 14,356,170 Less valuation allowance (14,329,450 ) (14,356,170 ) Net deferred tax asset $ - $ -

Note 9 - Capital Transactions (

Note 9 - Capital Transactions (Tables)	3 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants Outstanding Number of Shares Exercise Price Outstanding at March 31, 2019 99,790,989 Warrants issued 7,622,780 $0.30 Warrants exercised (17,563,000 ) 0.03550.1010 Warrants expired/cancelled (5,312,608 ) 0.5002.0000 Outstanding at March 31, 2020 84,538,161 Warrants issued 43,493,809 $0.10 Warrants exercised (35,798,809 ) 0.03000.03535 Warrants expired/cancelled (6,390,125 ) 0.6000.9090 Outstanding at March 31, 2021 85,843,036

Note 10 - Employee Benefit Pl_2

Note 10 - Employee Benefit Plan (Tables)	3 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended March 31, 2021 March 31, 2020 Weighted-average volatility 127 % N/A Expected term (in years) 10 N/A Risk-free interest rate 0.93 % N/A
Schedule of Stock Options Roll Forward [Table Text Block]	Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Employee options and warrants Options Price $ Life (years) Value ($) Outstanding at March 31, 2019 12,583,334 $ 0.28 7.18 $ 43,000 Granted - Exercised - Forfeited (1,600,000 ) $ 0.27 Outstanding at March 31, 2020 10,983,334 $ 0.28 6.02 $ - Granted 6,750,000 $ 0.045 Exercised - Forfeited - Outstanding at March 31, 2021 17,733,334 $ 0.11 6.80 $ 172,000 Fully vested and expected to vest at March 31, 2021 17,733,334 $ 0.11 Exercisable at March 31, 2021 15,566,668 $ 0.12 Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Nonemployee options Options Price $ Life (years) Value ($) Outstanding at March 31, 2019 2,383,000 $ 0.27 7.76 $ 492,250 Granted - Exercised - Forfeited - Outstanding at March 31, 2020 2,383,000 $ 0.27 6.75 $ - Granted 3,500,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2021 5,883,000 $ 0.14 8.11 $ 35,000 Fully vested and expected to vest at March 31, 2021 5,883,000 $ 0.14 Exercisable at March 31, 2021 5,883,000 $ 0.14

Note 13 - Sale of 50% Members_2

Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Notes Tables
Schedule of Note Receivable with Imputed Interest [Table Text Block]		November 15, 2019 Note Receivable Note Payments June 1, 2020 $ 500,000 September 1, 2020 750,000 December 1, 2020 1,000,000 March 1, 2020 1,250,000 June 1, 2021 1,500,000 September 1, 2021 1,500,000 December 1, 2021 1,500,000 Total proceeds 8,000,000 Discount on note receivable (1,389,408 ) Net present value $ 6,610,592
Schedule of Deconsolidation [Table Text Block]	As of Gain on Deconsolidation November 15, 2019 Present value of promissory note $ 6,610,592 Carrying amount of non-controlling interest 8,707,651 Total 15,318,243 Carrying amount of assets 14,715,798 Carrying amount of liabilities (3,790,797 ) Net assets deconsolidated 10,925,001 Gain on deconsolidation $ 4,393,242
Schedule of Gain (Loss) on Notes Receivable Modification [Table Text Block]	August 24, 2020 Modification March 31, 2020 Total cash payments to be made by October 15, 2020 $ 4,900,000 Liabilities to be forgiven upon receipt of October 15, 2020 payment 324,423 Total receivable (as modified) 5,224,423 Carrying value of note receivable as of March 31, 2020 6,969,720 Accrued interest as of March 31, 2020 150,137 Total amount receivable (prior to modification) 7,119,857 Loss on modification of note receivable $ (1,895,434 )

Note 1 - Background and Signi_2

Note 1 - Background and Significant Accounting Policies (Details Textual) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2021USD ($)shares	Mar. 31, 2021shares	Mar. 31, 2020shares
Number of Operating Segments	1
Impairment, Long-Lived Asset, Held-for-Use, Total | $	$ 0
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares	160,314,865	164,049,941	158,404,020

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021	Mar. 31, 2020
Retained Earnings (Accumulated Deficit), Ending Balance	$ (104,681,665)		$ (103,886,232)	$ (97,387,205)
Working Capital (Deficit)	(5,580,031)		(5,054,593)	(3,884,877)
Net Cash Provided by (Used in) Operating Activities, Total	(636,583)	$ (323,845)	(2,185,220)	(4,479,713)
Discontinued Operations [Member]
Working Capital (Deficit)	(260,970)		$ (439,979)	$ (243,787)
Net Cash Provided by (Used in) Operating Activities, Total	$ (2,954)	$ (235,779)

Note 3 - Discontinued Operati_3

Note 3 - Discontinued Operations (Details Textual) - USD ($)	3 Months Ended	12 Months Ended		16 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2021	Nov. 27, 2019
Proceeds from Lines of Credit, Total		$ 375,000	$ 0
Line of Credit [Member]
Debt Instrument, Interest Rate, Stated Percentage						8.00%
Line of Credit Facility, Maximum Borrowing Capacity						$ 470,000
Proceeds from Lines of Credit, Total				$ 485,000	$ 485,000
Line of Credit Facility, Maximum Borrowing Capacity, Increased				15,000	15,000
Long-term Line of Credit, Total	$ 485,000	485,000		485,000	485,000
Interest Payable	49,211	38,767		$ 38,767	$ 38,767
Discontinued Operations [Member]
Finance Lease Costs	140,258
Finance Lease, Interest Expense	101,583	414,993	426,374
Finance Lease, Right-of-Use Asset, Amortization	$ 38,675	$ 154,699	$ 252,973
Maximum [Member]
Lessee, Finance Lease, Discount Rate	11.50%	11.50%		11.50%	11.50%

Note 3 - Discontinued Operati_4

Note 3 - Discontinued Operations - Discontinued Operations (Details) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021	Mar. 31, 2020
Cash	$ 582,971		$ 793,040	$ 2,406
Prepaid and other current assets	296,081		256,251	18,776
TOTAL CURRENT ASSETS	3,127,809		3,543,855	7,000,880
Property and equipment, net	21,895		25,022	37,821
Intangible assets, net	1,797,920		1,706,762	1,128,702
TOTAL ASSETS	10,330,629		10,806,054	14,352,868
Accounts payable	1,463,806		1,412,459	1,913,049
Accrued interest	521,145		493,741	366,865
Accrued expenses	1,031,003		957,946	813,618
Notes payable, net			3,594,804	5,054,728
Indebtedness to related parties	84,913		84,913	586,512
Income tax payable			761,509	592,982
TOTAL CURRENT LIABILITIES	8,707,840		8,598,448	10,885,757
Convertible notes payable	305,877		292,410	0
TOTAL LIABILITIES	12,361,080		12,279,982	14,441,362
Sales revenue	0	$ 0	0	0
Cost of goods sold	0	0	0	0
Gross profit	0	0	0	0
General and administrative expenses	493,405	515,253	2,001,617	5,741,514
Interest expense	(65,254)	(662,370)	(1,285,460)	(1,109,031)
Debt default penalty	0	(286,059)	(286,059)	0
Other expense	0	11,182	0	179,368
Total other expense	(65,254)	(959,611)	(1,331,233)	992,455
Income tax expense	0	0	0	0
NET LOSS	(73,758)	(371,836)	(392,177)	(8,362,626)
Continuing Operations [Member]
Cash	582,971		793,040	2,406
Accounts receivable, net	0		0	0
Inventory, net	0		0	0
Prepaid and other current assets	296,081		256,251	18,776
TOTAL CURRENT ASSETS	879,052		1,049,291	5,245,605
Property and equipment, net	21,895		25,022	37,821
Intangible assets, net	1,797,920		1,706,762	1,128,702
Deposits and other noncurrent assets	0		0	0
TOTAL ASSETS	2,698,867		2,781,075	6,412,128
Accounts payable	1,463,806		1,412,459	1,913,049
Accrued interest	521,145		493,741	366,865
Accrued expenses	1,031,003		957,946	813,618
Notes payable, net	3,619,186		3,594,804	5,054,728
Indebtedness to related parties	84,913		84,913	586,512
Income tax payable	0		0	0
Finance lease obligations, current	0		0	0
TOTAL CURRENT LIABILITIES	6,720,053		6,543,863	8,886,695
Convertible notes payable	305,877		292,410	0
Finance lease obligations, long term	0		0	0
TOTAL LIABILITIES	7,025,930		6,836,273	8,886,695
Sales revenue	0	0	0	0
Cost of goods sold	0	0	0	0
Gross profit	0	0	0	0
General and administrative expenses	493,405	515,253	2,001,617	5,741,514
INCOME/(LOSS) FROM OPERATIONS	(493,405)	(515,253)	(2,001,617)	(5,741,514)
Interest expense	(65,254)	(662,370)	(1,285,460)	(1,109,031)
Debt default penalty	0	(286,059)	(286,059)	0
Other expense	0	(11,182)
Total other expense	(65,254)	(959,611)	(1,331,233)	992,455
LOSS BEFORE INCOME TAXES	(558,659)	(1,474,864)	(3,332,850)	(4,749,059)
Income tax expense	0	0	0	0
NET LOSS	(558,659)	(1,474,864)	(3,332,850)	(4,749,059)
Discontinued Operations [Member]
Cash	112,696		352,593	149,360
Accounts receivable, net	643,594		400,175	117,967
Inventory, net	1,462,009		1,689,304	1,445,839
Prepaid and other current assets	30,458		52,492	42,109
TOTAL CURRENT ASSETS	2,248,757		2,494,564	1,755,275
Property and equipment, net	4,736,272		4,876,247	5,496,012
Intangible assets, net	571,264		571,264	571,264
Deposits and other noncurrent assets	75,469		82,904	91,504
TOTAL ASSETS	7,631,762		8,024,979	7,940,740
Accounts payable	385,320		509,477	646,865
Accrued interest	49,211		49,211	30,787
Accrued expenses	122,714		105,421	74,394
Notes payable, net	485,000		485,000	480,000
Indebtedness to related parties	0		0	0
Income tax payable	793,292		761,509	592,982
Finance lease obligations, current	152,250		143,967	166,769
TOTAL CURRENT LIABILITIES	1,987,787		2,054,585	1,999,062
Convertible notes payable	0		0	0
Finance lease obligations, long term	3,347,363		3,389,124	3,533,090
TOTAL LIABILITIES	5,335,150		5,443,709	5,554,667
Sales revenue	1,342,586	551,197	4,110,456	3,689,697
Cost of goods sold	(1,219,041)	(491,795)	(3,506,722)	(4,576,627)
Gross profit	123,545	59,402	603,734	(886,930)
General and administrative expenses	84,078	289,455	276,986	2,034,612
INCOME/(LOSS) FROM OPERATIONS	39,467	(230,053)	326,748	(7,566,596)
Interest expense	(102,331)	(132,943)	(486,481)	(694,313)
Debt default penalty	0	0	0	0
Other expense	20,889	0
Total other expense	(81,442)	(132,943)	(550,398)	(709,193)
LOSS BEFORE INCOME TAXES	(41,975)	(362,996)	(223,650)	(8,275,789)
Income tax expense	(31,783)	(8,840)	(168,527)	(86,837)
NET LOSS	(73,758)	(371,836)	(392,177)	(8,362,626)
Segment, Continuing and Discontinued Operations [Member]
Cash	695,667		1,145,633	151,766
Accounts receivable, net	643,594		400,175	117,967
Inventory, net	1,462,009		1,689,304	1,445,839
Prepaid and other current assets	326,539		308,743	60,885
TOTAL CURRENT ASSETS	3,127,809		3,543,855	7,000,880
Property and equipment, net	4,758,167		4,901,269	5,533,833
Intangible assets, net	2,369,184		2,278,026	1,699,966
Deposits and other noncurrent assets	75,469		82,904	91,504
TOTAL ASSETS	10,330,629		10,806,054	14,352,868
Accounts payable	1,849,126		1,921,936	2,559,914
Accrued interest	570,356		542,952	397,652
Accrued expenses	1,153,717		1,063,367	888,012
Notes payable, net	4,104,186		4,079,804	5,534,728
Indebtedness to related parties	84,913		84,913	586,512
Income tax payable	793,292		761,509	592,982
Finance lease obligations, current	152,250		143,967	166,769
TOTAL CURRENT LIABILITIES	8,707,840		8,598,448	10,885,757
Convertible notes payable	305,877		292,410	0
Finance lease obligations, long term	3,347,363		3,389,124	3,533,090
TOTAL LIABILITIES	12,361,080		12,279,982	14,441,362
Sales revenue	1,342,586	551,197	4,110,456	3,689,697
Cost of goods sold	(1,219,041)	(491,795)	(3,506,722)	(4,576,627)
Gross profit	123,545	59,402	603,734	(886,930)
General and administrative expenses	577,483	804,708	2,278,603	7,776,126
INCOME/(LOSS) FROM OPERATIONS	(453,938)	(745,306)	(1,674,869)	(13,308,110)
Interest expense	(167,585)	(795,313)	(1,771,941)	(1,803,344)
Debt default penalty	0	(286,059)	(286,059)	0
Other expense	20,889	(11,182)
Total other expense	(146,696)	(1,092,554)	(1,881,631)	283,262
LOSS BEFORE INCOME TAXES	(600,634)	(1,837,860)	(3,556,500)	(13,024,848)
Income tax expense	(31,783)	(8,840)	(168,527)	(86,837)
NET LOSS	$ (632,417)	$ (1,846,700)	$ (3,725,027)	$ (13,111,685)

Note 3 - Discontinued Operati_5

Note 3 - Discontinued Operations - Schedule of Inventory (Details) - Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] - USD ($)	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020
Raw materials	$ 112,857	$ 86,076	$ 91,465
Work in progress	814,166	743,844	1,166,511
Finished goods	601,807	866,195	466,319
Subtotal	1,528,830	1,696,115	1,724,295
Allowance to reduce inventory to net realizable value	(66,821)	(6,811)	(278,456)
Total inventory, net	$ 1,462,009	$ 1,689,304	$ 1,445,839

Note 3 - Discontinued Operati_6

Note 3 - Discontinued Operations - Future Minimum Lease Payments (Details) - Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] - USD ($)	Jun. 30, 2021	Mar. 31, 2021
2022 (9 months)	$ 409,235
2023	560,625	$ 544,296
2024	577,444	560,625
2025	594,767	577,444
2026	612,610	594,767
Thereafter	3,168,492	3,168,492
Total minimum lease payments, finance leases	5,923,173	6,058,234
Less: Amount representing interest, finance leases	(2,423,560)	(2,525,143)
Present value of minimum lease payments, finance leases	3,499,613	3,533,091
Less: Current maturities of capital lease obligations, finance leases	(152,250)	(143,967)
Long-term capital lease obligations, finance leases	$ 3,347,363	$ 3,389,124

Note 4 - Notes Payable and Li_3

Note 4 - Notes Payable and Line of Credit (Details Textual) - USD ($)	Dec. 29, 2020	Oct. 23, 2017	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Jun. 30, 2021	Aug. 10, 2020	Jul. 24, 2020	Mar. 24, 2020	Nov. 27, 2019	Nov. 15, 2019
Notes Payable, Current, Total				$ 3,594,804	$ 5,054,728	$ 3,594,804
Gain (Loss) on Amendment to Line of Credit				(650,000)	$ 0
The July 24 Note [Member]
Gain (Loss) on Amendment to Line of Credit	$ (650,000)
Teco [Member]
Financing Receivable, after Allowance for Credit Loss, Total										$ 4,000,000		$ 4,000,000
Disposal Group, Including Discontinued Operation, Consideration			$ 4,000,000	4,000,000		4,000,000	$ 4,000,000
Teco [Member] | The July 24 Note [Member]
Financing Receivable, after Allowance for Credit Loss, Total	3,025,000		1,025,000	1,025,000		1,025,000	1,025,000
Increase (Decrease) in Notes Receivable, Current	975,000
Notes Receivable, Maximum Allowed Prepayments On Note	325,000
Disposal Group, Including Discontinued Operation, Consideration	4,000,000
Gain (Loss) on Amendment to Line of Credit	$ (650,000)			(650,000)
Notes Receivable, Additional Advances			50,000	50,000
Interest Payable			58,495				58,495
The July 24 Note [Member]
Debt Instrument, Interest Rate, Stated Percentage									8.00%
The July 24 Note [Member] | Revolving Credit Facility [Member]
Debt Instrument, Interest Rate, Stated Percentage									8.00%
Line of Credit Facility, Maximum Borrowing Capacity									$ 500,000
The July 24 Note [Member] | Teco [Member]
Financing Receivable, after Allowance for Credit Loss, Total									$ 4,000,000
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding									3
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage		0.00%						0.00%			0.00%
Debt Instrument, Face Amount		$ 700,000
Debt Instrument, Term (Year)		3 years
Debt Instrument, Present Value		$ 521,067
Receivable with Imputed Interest, Effective Yield (Interest Rate)		20.30%
Debt Instrument, Unamortized Discount, Total		$ 178,933	0	0		0	0
Repayments of Debt						330,555	330,555
Notes Payable, Current, Total			$ 369,445	$ 369,445		$ 369,445	$ 369,445
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | Membership Interest Purchase Agreement for Sale of Interest in GB Sciences Nopah, LLC [Member]
Debt Instrument, Principal Balance After Reduction Upon Close of Disposition								$ 190,272
Debt Instrument, Penalty Rate Waived Upon Closing of Disposition								15.00%
Nevada Medical Marijuana Production License Agreement [Member]
Payments to Acquire License		$ 500,000
Nevada Medical Marijuana Production License Agreement [Member] | Production License [Member]
Ownership of Licence		100.00%
Nevada Medical Marijuana Production License Agreement [Member] | Cultivation License [Member]
Ownership of Licence		100.00%

Note 4 - Notes Payable and Li_4

Note 4 - Notes Payable and Line of Credit - Schedule of Debt Payable (Details) - USD ($)	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020	Oct. 23, 2017
Discount, short-term notes payable	$ (272,122)	$ (296,504)	$ (608,580)
Discount, long-term notes payable	(141,123)	(154,590)	0
Promissory Note [Member]
Face value, short term notes and convertible notes payable classified as continuing operations	447,000	447,000
Discount, long-term notes payable		(154,590)
Carrying Value, long-term notes payable		292,410
Total long-term notes payable classified as continuing operations	447,000	447,000
Total long-term notes payable classified as continuing operations	(141,123)
Carrying Value, long-term notes payable	305,877
The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]
Face Value, short-term notes payable				$ 700,000
The 6 % Note Payable Dated September 30, 2023 [Member] | Convertible Debt [Member]
Face Value, short-term notes payable	197,000	197,000
Discount, long-term notes payable	(37,204)	(40,561)
Carrying Value, long-term notes payable	159,796	156,439
The 6 % Note Payable Dated December 31, 2023 [Member] | Convertible Debt [Member]
Face Value, short-term notes payable	250,000	250,000
Discount, long-term notes payable	(103,919)	(114,029)
Carrying Value, long-term notes payable	146,081	135,971
Convertible Notes Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Face Value, short-term notes payable	369,445	369,445	369,445
Discount, short-term notes payable	0	0	(13,929)
Carrying Value, short-term notes payable	369,445	369,445	355,516
Convertible Notes Payable [Member] | The 6% Note Payable Due November 30, 2018 [Member]
Face Value, short-term notes payable	1,060,000	1,060,000	1,257,000
Discount, short-term notes payable	0	0	(155,340)
Carrying Value, short-term notes payable	1,060,000	1,060,000	1,101,660
Convertible Notes Payable [Member] | The 6% Notes Payable Due January 18, 2022 [Member]
Face Value, short-term notes payable	325,000	325,000
Discount, short-term notes payable	(272,122)	(296,504)
Carrying Value, short-term notes payable	52,878	28,496
Line of Credit [Member] | The 8% Line of Credit Dated November 27, 2019 [Member]
Face Value, short-term notes payable	485,000	485,000	480,000
Discount, short-term notes payable	0	0	0
Carrying Value, short-term notes payable	485,000	485,000	480,000
Line of Credit [Member] | The 8% Line of Credit Dated July 24, 2020 [Member]
Face Value, short-term notes payable	1,025,000	1,025,000
Discount, short-term notes payable	0	0
Carrying Value, short-term notes payable	1,025,000	1,025,000
Senior Secured Convertible Promissory Note [Member] | The Amended 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Face Value, short-term notes payable	1,111,863	1,111,863	1,271,863
Discount, short-term notes payable	0	0	(409,481)
Carrying Value, short-term notes payable	1,111,863	1,111,863	862,382
Promissory Note [Member]
Face Value, short-term notes payable	4,376,308	4,376,308	6,143,308
Discount, short-term notes payable	(272,122)	(296,504)	(608,580)
Carrying Value, short-term notes payable	4,104,186	4,079,804	5,534,728
Less: Notes payable classified as discontinued operations, face value	(485,000)	(485,000)	(480,000)
Less: Notes payable classified as discontinued operations, discount	0	0	0
Less: Notes payable classified as discontinued operations, carrying value	(485,000)	(485,000)	(480,000)
Face value, short term notes and convertible notes payable classified as continuing operations	3,891,308	3,891,308	5,663,308
Discount, short-term notes payable classified as continuing operations	(272,122)	(296,504)	(608,580)
Total short-term notes payable classified as continuing operations	3,619,186	3,594,804	5,054,728
Total long-term notes payable classified as continuing operations	$ 3,891,308	$ 3,891,308	$ 5,663,308

Note 5 - Convertible Notes (Det

Note 5 - Convertible Notes (Details Textual)	Dec. 16, 2020USD ($)	Jul. 14, 2020USD ($)	Apr. 22, 2020USD ($)	Dec. 16, 2019USD ($)$ / sharesshares	Nov. 27, 2019USD ($)$ / shares	Nov. 18, 2019USD ($)$ / sharesshares	Oct. 30, 2019USD ($)$ / sharesshares	Oct. 23, 2019USD ($)$ / shares	Aug. 01, 2019USD ($)$ / sharesshares	Jul. 12, 2019USD ($)$ / shares	May 28, 2019USD ($)$ / sharesshares	Apr. 23, 2019USD ($)$ / shares	Feb. 28, 2019USD ($)$ / shares	Jul. 31, 2017USD ($)$ / shares	Mar. 31, 2017USD ($)$ / shares	Jun. 30, 2021USD ($)	Mar. 31, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)	May 31, 2017USD ($)$ / sharesshares	Mar. 31, 2021USD ($)$ / shares	Dec. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2021USD ($)$ / sharesshares	Mar. 31, 2020USD ($)shares	Dec. 18, 2020$ / shares	Dec. 09, 2020USD ($)	Nov. 20, 2020USD ($)	Dec. 31, 2019USD ($)
Class of Warrant or Right, Issued During Period (in shares) | shares																						43,493,809	7,622,780
Amortization of Debt Discount (Premium)																$ 37,849		$ 510,885				$ 776,122	$ 1,150,995
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares																							7,583,333
Gain (Loss) on Extinguishment of Debt, Total																						467,872	$ (216,954)
Induced Conversion of Convertible Debt Expense																						0	127,059
Proceeds from Convertible Debt																0		$ 150,000				725,000	2,630,000
Convertible Notes Payable, Current																3,619,186	$ 3,594,804			$ 3,594,804		3,594,804
Debt Instrument, Unamortized Discount, Current																272,122	296,504			296,504		296,504	608,580
Convertible Notes Payable, Noncurrent																305,877	292,410			292,410		292,410	0
Debt Instrument, Unamortized Discount, Noncurrent																141,123	154,590			154,590		154,590	0
Repayment of Iliad Note [Member] | Judicial Ruling [Member]
Debt Instrument, Debt Default, Interest Rate Penalty		15.00%
Litigation Settlement, Amount Awarded to Other Party		$ 3,264,594
Litigation Settlement, Amount Final Settlement																									$ 3,006,015	$ 3,006,015
Litigation Settlement, One Time Required Payment																									25,000
Litigation Settlement, Weekly Required Payment																									$ 25,000
Litigation Settlement, Payment	$ 3,006,015
Teco [Member]
Disposal Group, Including Discontinued Operation, Consideration																4,000,000	4,000,000			4,000,000		4,000,000
Convertible Debt [Member]
Debt Instrument, Extended Amount																	197,000			197,000		197,000
Interest Expense, Debt, Total																15,856						208,779
Amortization of Debt Discount (Premium)																244,129						139,253
Interest Payable																	228,373			228,373		228,373
Debt Instrument, Debt Default, Amount																1,060,000	$ 1,060,000			$ 1,060,000		$ 1,060,000
Warrants Issued in March 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Number of Warrants															4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares															$ 0.60				$ 0.60
Warrants and Rights Outstanding, Term (Year)															3 years				3 years
Class of Warrant or Right, Issued (in shares) | shares																			8,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares																			1
Warrants Issued In March 2017 and July 2017 Convertible Note Offerings [Member]
Debt Instrument, Convertible, Number of Warrants														4,000
Class of Warrant or Right, Issued During Period (in shares) | shares																						788,000
Warrants Related to July 2017 Convertible Note Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares														$ 0.65							$ 0.60
Warrants and Rights Outstanding, Term (Year)																					3 years
Class of Warrant or Right, Issued (in shares) | shares																					28,804,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares																					1
Warrants Issued in September 30, 2023, Convertible Note Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																	$ 0.10			$ 0.10		$ 0.10
Warrants and Rights Outstanding, Term (Year)																	3 years			3 years		3 years
Warrants and Rights Outstanding																	$ 13,396			$ 13,396		$ 13,396
March And July 2017 Convertible Note Offering [Member] | Convertible Debt [Member]
Debt Instrument, Unamortized Discount, Total																	46,886			46,886		46,886
Debt Instrument, Convertible, Beneficial Conversion Feature																						33,490
Interest Expense, Debt, Total																6,303						28,306
Amortization of Debt Discount (Premium)																3,356						22,412
Interest Payable																47,279	44,332			44,332		44,332
Interest Payable, Accrued Prior to Extinguishments																38,438	38,438			38,438		38,438
The 6 % Convertible Note Payable Dated December 31, 2023 [Member]
Debt Instrument, Interest Rate, Stated Percentage																								6.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares																								$ 0.05
Debt Instrument, Unamortized Discount, Total																	74,750			74,750		74,750
Debt Instrument, Convertible, Beneficial Conversion Feature																						347,000
Interest Expense, Debt, Total																						16,354
Amortization of Debt Discount (Premium)																						11,217
Convertible Notes Payable, Current																	28,496			28,496		28,496
Debt Instrument, Unamortized Discount, Current																	296,504			296,504		296,504
Convertible Notes Payable, Noncurrent																	135,971			135,971		135,971
Debt Instrument, Unamortized Discount, Noncurrent																	114,029			114,029		114,029
The 6 % Convertible Note Payable Dated December 31, 2023 [Member] | Three Investors [Member]
Debt Instrument, Face Amount																	575,000			575,000		575,000
The 6 % Convertible Note Payable Mature in December 2021 [Member] | Three Investors [Member]
Debt Instrument, Face Amount																	325,000			325,000		325,000
The 6 % Convertible Note Payable Mature in December 2023 [Member]
Interest Expense, Debt, Total																24,458
Amortization of Debt Discount (Premium)																15,857
Convertible Notes Payable, Current																52,878
Debt Instrument, Unamortized Discount, Current																272,122
Convertible Notes Payable, Noncurrent																146,081
Debt Instrument, Unamortized Discount, Noncurrent																103,919
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Three Investors [Member]
Debt Instrument, Face Amount																	250,000			250,000		250,000
The 6 Percent Convertible Note Payable Issued With In Money Conversion Features [Member]
Debt Instrument, Face Amount																	425,000			425,000		425,000
Debt Instrument, Unamortized Discount, Total																	$ 74,750			$ 74,750		74,750
Debt Instrument, Convertible, Beneficial Conversion Feature																						347,000
Proceeds from Convertible Debt																						500,250
Convertible Notes Payable [Member]
Debt Instrument, Convertible, Beneficial Conversion Feature																						$ 543,886	829,737
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note															$ 1,000
Debt Instrument, Interest Rate, Stated Percentage															6.00%
Debt Instrument, Face Amount																			$ 2,000,000
Debt Instrument, Term (Year)																			3 years
Debt Instrument, Unamortized Discount, Total																			$ 1,933,693
Debt Instrument, Convertible, Beneficial Conversion Feature																			904,690
Debt Instrument, Convertible, Discount, Fair Value of Warrants																			$ 1,029,003
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments															4,000				8,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares															$ 0.25
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note														$ 1,000
Debt Instrument, Face Amount																					$ 7,201,000
Debt Instrument, Term (Year)														3 years							3 years
Debt Instrument, Unamortized Discount, Total																					$ 7,092,796
Debt Instrument, Convertible, Beneficial Conversion Feature																					3,142,605
Debt Instrument, Convertible, Discount, Fair Value of Warrants																					$ 3,950,191
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments														4,000							28,804,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares														$ 0.25
Convertible Notes Payable [Member] | March And July 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares																	$ 0.10			$ 0.10		$ 0.10
Debt Instrument, Extended Amount																	$ 197,000			$ 197,000		$ 197,000
Convertible Notes Payable, Total																	1,257,000			1,257,000		1,257,000
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage												8.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares						$ 0.0375	$ 0.06					$ 0.17
Debt Instrument, Face Amount												$ 2,765,000											2,765,000
Debt Instrument, Unamortized Discount, Total												265,000
Interest Expense, Debt, Total																				209,292		379,956
Amortization of Debt Discount (Premium)																						29,831
Debt Conversion, Original Debt, Amount						$ 50,000	$ 75,000																125,000
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares						1,333,333	1,250,000
Short-term Debt, Total																							2,735,170
Gain (Loss) on Extinguishment of Debt, Total																						467,872
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total												440,000
Payments for Brokerage Fees												$ 175,000
Induced Conversion of Convertible Debt Expense						$ 62,353	$ 64,706																127,059
Debt Instrument, Debt Default, Interest Rate Penalty			10.00%
Debt Instrument, Debt Default, Interest Expense			$ 9,559
Debt Instrument, Debt Default, Principal Expense			$ 276,500
Debt Instrument, Debt Default, Increase in Principal Amount, Percent			10.00%
Debt Instrument, Unamortized Discount, Current																							29,830
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Judicial Ruling [Member]
Litigation Settlement, Amount Awarded to Other Party		$ 3,264,594																				3,264,594
Promissory Note [Member]
Debt Instrument, Face Amount																4,376,308	4,376,308			4,376,308		4,376,308	6,143,308
Short-term Debt, Total																4,104,186	4,079,804			4,079,804		4,079,804	5,534,728
Debt Instrument, Unamortized Discount, Current																272,122	296,504			296,504		296,504	608,580
Promissory Note [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Interest Rate, Stated Percentage														6.00%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage					8.00%					8.00%			8.00%
Debt Instrument, Face Amount													$ 1,500,000
Debt Instrument, Unamortized Discount, Total				$ 57,551					$ 9,579																		$ 584,842
Debt Instrument, Convertible, Beneficial Conversion Feature								$ 92,796		$ 133,806			$ 176,471
Interest Expense, Debt, Total				584,842																		477,500
Amortization of Debt Discount (Premium)				57,551																		409,481
Interest Payable																144,994
Debt Conversion, Original Debt, Amount				120,000					110,000								160,000						125,000
Debt Instrument, Increase (Decrease), Net, Total				(62,449)	$ 30,000				(100,421)	100,000
Short-term Debt, Total				1,271,863	1,361,863			$ 1,269,067	$ 1,361,863	1,338,057						1,111,863	1,111,863			1,111,863		1,111,863					$ 687,021
Proceeds from Related Party Debt										100,000
Debt Instrument, Increase, Accrued Interest										41,863
Gain (Loss) on Extinguishment of Debt, Total					$ 0					$ (124,158)													$ (92,796)
Long-term Debt, Gross				$ 687,021
Long Term Debt Including Interest																$ 1,256,857	$ 1,256,857			$ 1,256,857		$ 1,256,857
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | CSW Ventures, L.P. [Member]
Debt Instrument, Interest Rate, Stated Percentage											8.00%
Debt Instrument, Unamortized Discount, Total											$ 17,225
Debt Conversion, Original Debt, Amount											170,000
Debt Instrument, Increase (Decrease), Net, Total											(152,775)
Short-term Debt, Total											$ 1,330,000
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | GB Sciences, Nevada, LLC [Member] | Collateral Pledged [Member]
Noncontrolling Interest, Ownership Percentage by Parent													100.00%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments													8,823,529
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares				$ 0.04	$ 0.04			$ 0.08	$ 0.11	$ 0.11			$ 0.17				$ 0.04			$ 0.04		$ 0.04
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares				3,000,000					1,000,000								4,000,000
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member] | CSW Ventures, L.P. [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares											$ 0.17
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares											1,000,000

Note 6 - Capital Transactions (

Note 6 - Capital Transactions (Details Textual) - USD ($)	Jun. 14, 2021	Jul. 12, 2019	Dec. 31, 2019	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021	Mar. 31, 2020	Jul. 18, 2021	Apr. 01, 2020	Jul. 11, 2019
Proceeds from Warrant Exercises				$ 62,660	$ 151,202	$ 1,075,396	$ 1,274,790
Brokerage Fees for Issuance of Common Stock and Warrants				6,266	0
Induced Dividend from Warrant Exercises				$ 0	$ 0	$ 0	$ 0
Exercise of Warrants for Stock, Shares (in shares)							17,563,000
Subsequent Event [Member]
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)	$ 0.03
Proceeds from Warrant Exercises	$ 50,160
Minimum [Member]
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)						$ 0.030	$ 0.035
Maximum [Member]
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)						$ 0.035	$ 0.10
Warrants Issued to Investors in Private Placements [Member]
Class of Warrant or Right, Exercises in Period (in shares)		9,449,750	8,113,250	2,088,667		35,798,809
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)				$ 0.03
Proceeds from Warrant Exercises		$ 850,478	$ 307,249	$ 56,394		$ 968,023
Brokerage Fees for Issuance of Common Stock and Warrants		$ 94,498	22,566	6,266		107,373
Induced Dividend from Warrant Exercises			$ 32,215	163,016		$ 1,591,080
Class of Warrant or Right, Exercised During Period, Intrinsic Value				62,660
Class of Warrant or Right, Issued During Period, Fair Value				$ 100,356
Exercise of Warrants for Stock, Shares (in shares)				2,088,667
Warrants Issued to Investors in Private Placements [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 0.10
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)								1
Warrants and Rights Outstanding, Term (Year)								3 years
Warrants Issued to Investors in Private Placements [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.03						$ 0.03	$ 0.65
Warrants Issued to Investors in Private Placements [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 5						$ 0.05	$ 0.30

Note 7 - Commitments and Cont_2

Note 7 - Commitments and Contingencies (Details Textual) - USD ($)	Dec. 16, 2020	Sep. 17, 2020	Jul. 14, 2020	Apr. 22, 2020
Repayment of Iliad Note [Member] | Judicial Ruling [Member]
Litigation Settlement, Amount Awarded to Other Party			$ 3,264,594
Litigation Settlement, Payment	$ 3,006,015
Payment of Services Provided by Contractor [Member] | Pending Litigation [Member]
Loss Contingency, Damages Sought, Value				$ 73,050
Payment of Services Provided by Contractor [Member] | Settled Litigation [Member]
Payments for Legal Settlements		$ 25,000
Reduction in Cost Basis of Fixed Asset Related to Litigation		$ 48,050

Note 8 - Related Party Transa_2

Note 8 - Related Party Transactions (Details Textual)	Jun. 30, 2021USD ($)
Officers and Directors [Member]
Due to Related Parties, Total	$ 84,913

Note 9 - Sale of Membership I_2

Note 9 - Sale of Membership Interests in Nevada Subsidiaries (Details Textual) - USD ($)	May 11, 2021	Dec. 29, 2020	Aug. 10, 2020	Jul. 24, 2020	Mar. 24, 2020	Nov. 27, 2019	Nov. 15, 2019	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020	Oct. 23, 2017
Proceeds from Divestiture of Businesses								$ 200,000	$ 0
Proceeds from Lines of Credit, Total												$ 375,000	$ 0
Gain (Loss) on Amendment to Line of Credit												(650,000)	0
Payments for Management Fees								150,000
Management Fees Accrued								700,000			$ 700,000
Proceeds from Sale and Collection of Notes Receivable, Total												5,051,923	$ 0
July 24 Note [Member]
Financing Receivable, after Allowance for Credit Loss, Total		$ 975,000
The July 24 Note [Member]
Gain (Loss) on Amendment to Line of Credit		(650,000)
Teco [Member]
Management Fees Accrued										$ 850,000		850,000
Proceeds from Sale and Collection of Notes Receivable, Total								$ 4,000,000				$ 4,000,000
Notes Receivable Term (Year)								3 years				3 years
The July 24 Note [Member]
Debt Instrument, Interest Rate, Stated Percentage				8.00%
The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]
Debt Instrument, Interest Rate, Stated Percentage			0.00%			0.00%								0.00%
AJE Management, LLC [Member] | Secured Debt [Member] | The July 24 Note [Member]
Debt Instrument, Interest Rate, Stated Percentage				8.00%
Proceeds from Lines of Credit, Total										375,000	375,000
Teco [Member]
Sale of Stock, Percentage of Ownership					100.00%		100.00%						100.00%
Proceeds from Divestiture of Businesses	$ 200,000				$ 4,000,000		$ 4,000,000
Financing Receivable, after Allowance for Credit Loss, Total					$ 4,000,000		$ 4,000,000
Notes Receivable, Interest Rate					8.00%		8.00%
Notes Receivable, Term of Monthly Installments (Month)					36 months
Teco [Member] | July 24 Note [Member]
Financing Receivable, after Allowance for Credit Loss, Total		3,025,000
Increase (Decrease) in Notes Receivable, Current		(975,000)		$ (50,000)
Note Receivable, Maximum Allowed Prepayments On Note		325,000
Teco [Member] | The July 24 Note [Member]
Financing Receivable, after Allowance for Credit Loss, Total		3,025,000						$ 1,025,000		$ 1,025,000	$ 1,025,000	$ 1,025,000
Increase (Decrease) in Notes Receivable, Current		975,000
Gain (Loss) on Amendment to Line of Credit		(650,000)										$ (650,000)
Teco [Member] | The July 24 Note [Member]
Financing Receivable, after Allowance for Credit Loss, Total				4,000,000
Teco [Member] | July 24 Note [Member]
Financing Receivable, after Allowance for Credit Loss, Total		$ 4,000,000		$ 4,000,000
Teco [Member]
Sale of Stock, Percentage of Ownership							75.00%
Sale of Stock, Consideration Received on Transaction							$ 3,000,000
GB Sciences Nopah, LLC [Member]
Sale of Stock, Percentage of Ownership						100.00%
Sale of Stock, Consideration Received on Transaction			$ 300,000			$ 300,000
GB Sciences Nopah, LLC [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]
Sale of Stock, Consideration to Be Received By Means of Debt Reduction			$ 300,000			$ 300,000

Note 10 - Subsequent Events (De

Note 10 - Subsequent Events (Details Textual) - The 6% Convertible Promissory Note Due July 1, 2022 [Member] - Subsequent Event [Member]	Jul. 02, 2021USD ($)$ / shares
Debt Instrument, Face Amount | $	$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 0.05

Note 1 - Background and Natur_2

Note 1 - Background and Nature of Operations (Details Textual) - USD ($)	May 11, 2021	Dec. 16, 2020	Jul. 14, 2020	Mar. 24, 2020	Nov. 27, 2019	Nov. 15, 2019	Dec. 08, 2020	Jun. 30, 2021	Jun. 30, 2020	Oct. 15, 2020	Mar. 31, 2021	Mar. 31, 2020	Nov. 20, 2020	Aug. 10, 2020	Aug. 15, 2019	Apr. 23, 2019	Apr. 08, 2018	Mar. 31, 2018
Common Stock, Shares Authorized (in shares)								600,000,000			600,000,000	600,000,000			600,000,000		400,000,000	250,000,000
Proceeds from Divestiture of Businesses								$ 200,000	$ 0
Teco [Member]
Sale of Stock, Percentage of Ownership				100.00%		100.00%						100.00%
Proceeds from Collection of Notes Receivable												$ 4,000,000
Proceeds from Divestiture of Businesses	$ 200,000			$ 4,000,000		$ 4,000,000
Financing Receivable, after Allowance for Credit Loss, Total				$ 4,000,000		$ 4,000,000
Notes Receivable, Interest Rate				8.00%		8.00%
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage																8.00%
Debt Instrument, Face Amount												2,765,000				$ 2,765,000
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Judgment Settlement Agreement [Member]
Litigation Settlement, Amount Agreed to Be Paid to Offended Party													$ 3,006,015
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Judgment Settlement Agreement [Member] | Wellcana Plus LLC [Member]
Payments Received Under Modified Note Receivable							$ 4,150,000
Payments for Legal Settlements, Amount Paid Directly to Offended Party							$ 3,006,015
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Judicial Ruling [Member]
Litigation Settlement, Amount Awarded to Other Party			$ 3,264,594								$ 3,264,594
Convertible Notes Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Face Amount								$ 369,445			$ 369,445	369,445
Wellcana Note [Member]
Proceeds from Collection of Notes Receivable		$ 4,900,000								$ 4,900,000
Financing Receivable, after Allowance for Credit Loss, Total												$ 7,119,857
Wellcana Group, LLC [Member] | GB Sciences Louisiana, LLC, Sale of Equity [Member]
Sale of Stock, Percentage of Ownership						50.01%
Wellcana Plus LLC [Member] | Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Judgment Settlement Agreement [Member]
Litigation Settlement, Amount Agreed to Be Paid to Offended Party, Amount Agreed By Other Counterparty to Be Paid Directly to Offended Party													$ 3,006,015
GB Sciences Nopah, LLC [Member]
Sale of Interest, Percentage of Ownership					100.00%
Sale of Interest, Consideration to Be Received on Transaction														$ 300,000
GB Sciences Nopah, LLC [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage														0.00%
Sale of Interest, Consideration to Be Received on Transaction, Reduction to Balance of Debt Instrument														$ 300,000

Note 2 - Going Concern (Detai_2

Note 2 - Going Concern (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021	Mar. 31, 2020
Retained Earnings (Accumulated Deficit), Ending Balance	$ (104,681,665)		$ (103,886,232)	$ (97,387,205)
Working Capital (Deficit)	(5,580,031)		(5,054,593)	(3,884,877)
Net Cash Provided by (Used in) Operating Activities, Total	(636,583)	$ (323,845)	(2,185,220)	(4,479,713)
Cash Provided by (Used in) Operating Activities, Discontinued Operations	(2,954)	235,779	(118,644)	(2,215,434)
Discontinued Operations [Member]
Working Capital (Deficit)	(260,970)		$ (439,979)	$ (243,787)
Net Cash Provided by (Used in) Operating Activities, Total	$ (2,954)	$ (235,779)

Note 3 - Basis of Presentatio_2

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)	Mar. 24, 2020	Nov. 15, 2019	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Short-term Investments, Total					$ 0
Research and Development Expense, Total				$ 352,274	$ 1,543,397
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)			160,314,865	164,049,941	158,404,020
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)				3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)				8 years
Production License [Member]
Asset Impairment Charges, Total					$ 449,801
Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance					$ 571,264	$ 1,021,067
Teco [Member]
Sale of Stock, Percentage of Ownership	100.00%	100.00%			100.00%
Disposal Group, Including Disconitnued Operation, Estimated Future Undiscounted Cash Flows	$ 8,000,000
Disposal Group, Including Discontinued Operation, Carrying Basis	11,900,000
Disposal Group, Including Disconitnued Operation, Fair Value Disclosure	7,300,000
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down	$ 4,645,054
Disposal Group, Including Discontinued Operation, Discount Rate	17.00%
Proceeds from Collection of Notes Receivable					$ 4,000,000

Note 4 - Discontinued Operati_3

Note 4 - Discontinued Operations (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2021	Jun. 30, 2021	Mar. 31, 2020	Apr. 01, 2019
Lessee, Operating Lease, Discount Rate	17.00%
Minimum [Member]
Lessee, Finance Lease, Discount Rate	10.20%
Maximum [Member]
Lessee, Finance Lease, Discount Rate	11.50%	11.50%
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset				$ 182,624
Operating Lease, Liability, Total				$ 190,173
Discontinued Operations [Member]
Accounts Receivable, Allowance for Credit Loss, Recovery	$ 24,768
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease), Total	(94,912)
Accounts Receivable, Allowance for Credit Loss, Writeoff	70,144
Deposits Assets, Noncurrent	82,904	$ 75,469	$ 91,504
Operating Lease, Right-of-Use Asset	0		$ 26,685
GB Sciences Louisiana, LLC [Member]
Disposal Group, Including Discontinued Operation, Assets, Total	$ 0

Note 4 - Discontinued Operati_4

Note 4 - Discontinued Operations - Discontinued Operations (Details) - USD ($)	Nov. 15, 2019	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021	Mar. 31, 2020
Cash		$ 582,971		$ 793,040	$ 2,406
Prepaid and other current assets		296,081		256,251	18,776
Note receivable				0	5,224,423
TOTAL CURRENT ASSETS		3,127,809		3,543,855	7,000,880
Property and equipment, net		21,895		25,022	37,821
Intangible assets, net		1,797,920		1,706,762	1,128,702
TOTAL ASSETS		10,330,629		10,806,054	14,352,868
Accounts payable		1,463,806		1,412,459	1,913,049
Accrued interest		521,145		493,741	366,865
Accrued expenses		1,031,003		957,946	813,618
Notes payable, net				3,594,804	5,054,728
Indebtedness to related parties		84,913		84,913	586,512
Note payable to related party				0	151,923
Income tax payable				761,509	592,982
TOTAL CURRENT LIABILITIES		8,707,840		8,598,448	10,885,757
Convertible notes payable		305,877		292,410	0
TOTAL LIABILITIES		12,361,080		12,279,982	14,441,362
Sales revenue		0	$ 0	0	0
Cost of goods sold		0	0	0	0
Gross profit		0	0	0	0
General and administrative expenses		493,405	515,253	2,001,617	5,741,514
Gain/(loss) on extinguishment				467,872	(216,954)
Gain on settlement of accounts payable				422,414	0
Gain on deconsolidation	$ 4,393,242			0	4,393,242
Interest expense		(65,254)	(662,370)	(1,285,460)	(1,109,031)
Loss on modification of line of credit				(650,000)	0
Loss on modification of note receivable				0	(1,895,434)
Debt default penalty		0	(286,059)	(286,059)	0
Total other expense		(65,254)	(959,611)	(1,331,233)	992,455
Income tax expense		0	0	0	0
NET LOSS		(73,758)	(371,836)	(392,177)	(8,362,626)
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Inventory, net		1,462,009		1,689,304	1,445,839
Finance lease obligations, current		152,250		143,967
Finance lease obligations, long term		3,347,363		3,389,124
Sales revenue				4,110,456	3,689,697
Cost of goods sold				(3,506,722)	(4,576,627)
Gross profit				603,734	(886,930)
General and administrative expenses				276,986	2,034,612
Loss on impairment of long-lived assets				0	4,645,054
LOSS FROM OPERATIONS				326,748	(7,566,596)
Gain on settlement of accounts payable				54,958	0
Interest expense				(486,481)	(694,313)
Other expense				(118,875)	(14,880)
Total other expense				(550,398)	(709,193)
NET LOSS BEFORE INCOME TAXES				(223,650)	(8,275,789)
Income tax expense				(168,527)	(86,837)
NET LOSS				(392,177)	(8,362,626)
Nevada Subsidiaries [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Sales revenue				4,110,456	3,120,620
Cost of goods sold				(3,506,722)	(4,002,083)
Gross profit				603,734	(881,463)
General and administrative expenses				276,986	741,999
Loss on impairment of long-lived assets				0	4,645,054
LOSS FROM OPERATIONS				326,748	(6,268,516)
Gain on settlement of accounts payable				54,958	0
Interest expense				(486,481)	(516,173)
Other expense				(118,875)	(14,880)
Total other expense				(550,398)	(531,053)
NET LOSS BEFORE INCOME TAXES				(223,650)	(6,799,569)
Income tax expense				(168,527)	(86,837)
NET LOSS				(392,177)	(6,886,406)
GB Sciences Louisiana, LLC [Member]
Gain on deconsolidation	$ 4,393,242
GB Sciences Louisiana, LLC [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Sales revenue				0	569,077
Cost of goods sold				0	(574,544)
Gross profit				0	(5,467)
General and administrative expenses				0	1,292,613
Loss on impairment of long-lived assets				0	0
LOSS FROM OPERATIONS				0	(1,298,080)
Gain on settlement of accounts payable				0	0
Interest expense				0	(178,140)
Other expense				0	0
Total other expense				0	(178,140)
NET LOSS BEFORE INCOME TAXES				0	(1,476,220)
Income tax expense				0	0
NET LOSS				0	(1,476,220)
Continuing Operations [Member]
Cash		582,971		793,040	2,406
Accounts receivable, net		0		0	0
Inventory, net		0		0	0
Prepaid and other current assets		296,081		256,251	18,776
Note receivable				0	5,224,423
TOTAL CURRENT ASSETS		879,052		1,049,291	5,245,605
Property and equipment, net		21,895		25,022	37,821
Intangible assets, net		1,797,920		1,706,762	1,128,702
Deposits and other noncurrent assets		0		0	0
Operating lease right-of-use assets, net				0	0
TOTAL ASSETS		2,698,867		2,781,075	6,412,128
Accounts payable		1,463,806		1,412,459	1,913,049
Accrued interest		521,145		493,741	366,865
Accrued expenses		1,031,003		957,946	813,618
Notes payable, net		3,619,186		3,594,804	5,054,728
Indebtedness to related parties		84,913		84,913	586,512
Note payable to related party				0	151,923
Income tax payable		0		0	0
Finance lease obligations, current		0		0	0
Operating lease obligations, current				0	0
TOTAL CURRENT LIABILITIES		6,720,053		6,543,863	8,886,695
Convertible notes payable		305,877		292,410	0
Operating lease obligations, long term				0	0
Finance lease obligations, long term		0		0	0
TOTAL LIABILITIES		7,025,930		6,836,273	8,886,695
Sales revenue		0	0	0	0
Cost of goods sold		0	0	0	0
Gross profit		0	0	0	0
General and administrative expenses		493,405	515,253	2,001,617	5,741,514
Loss on impairment of long-lived assets				0	0
LOSS FROM OPERATIONS		(493,405)	(515,253)	(2,001,617)	(5,741,514)
Gain/(loss) on extinguishment				467,872	(216,954)
Gain on settlement of accounts payable				422,414	0
Gain on deconsolidation				0	4,393,242
Interest expense		(65,254)	(662,370)	(1,285,460)	(1,109,031)
Loss on modification of line of credit				(650,000)	0
Loss on modification of note receivable				0	(1,895,434)
Debt default penalty		0	(286,059)	(286,059)	0
Other expense				0	(179,368)
Total other expense		(65,254)	(959,611)	(1,331,233)	992,455
NET LOSS BEFORE INCOME TAXES		(558,659)	(1,474,864)	(3,332,850)	(4,749,059)
Income tax expense		0	0	0	0
NET LOSS		(558,659)	(1,474,864)	(3,332,850)	(4,749,059)
Discontinued Operations [Member]
Cash		112,696		352,593	149,360
Accounts receivable, net		643,594		400,175	117,967
Inventory, net		1,462,009		1,689,304	1,445,839
Prepaid and other current assets		30,458		52,492	42,109
Note receivable				0	0
TOTAL CURRENT ASSETS		2,248,757		2,494,564	1,755,275
Property and equipment, net		4,736,272		4,876,247	5,496,012
Intangible assets, net		571,264		571,264	571,264
Deposits and other noncurrent assets		75,469		82,904	91,504
Operating lease right-of-use assets, net				0	26,685
TOTAL ASSETS		7,631,762		8,024,979	7,940,740
Accounts payable		385,320		509,477	646,865
Accrued interest		49,211		49,211	30,787
Accrued expenses		122,714		105,421	74,394
Notes payable, net		485,000		485,000	480,000
Indebtedness to related parties		0		0	0
Note payable to related party				0	0
Income tax payable		793,292		761,509	592,982
Finance lease obligations, current		152,250		143,967	166,769
Operating lease obligations, current				0	7,265
TOTAL CURRENT LIABILITIES		1,987,787		2,054,585	1,999,062
Convertible notes payable		0		0	0
Operating lease obligations, long term				0	22,515
Finance lease obligations, long term		3,347,363		3,389,124	3,533,090
TOTAL LIABILITIES		5,335,150		5,443,709	5,554,667
Sales revenue		1,342,586	551,197	4,110,456	3,689,697
Cost of goods sold		(1,219,041)	(491,795)	(3,506,722)	(4,576,627)
Gross profit		123,545	59,402	603,734	(886,930)
General and administrative expenses		84,078	289,455	276,986	2,034,612
Loss on impairment of long-lived assets				0	4,645,054
LOSS FROM OPERATIONS		39,467	(230,053)	326,748	(7,566,596)
Gain/(loss) on extinguishment				0	0
Gain on settlement of accounts payable				54,958	0
Gain on deconsolidation				0	0
Interest expense		(102,331)	(132,943)	(486,481)	(694,313)
Loss on modification of line of credit				0	0
Loss on modification of note receivable				0	0
Debt default penalty		0	0	0	0
Other expense				(118,875)	(14,880)
Total other expense		(81,442)	(132,943)	(550,398)	(709,193)
NET LOSS BEFORE INCOME TAXES		(41,975)	(362,996)	(223,650)	(8,275,789)
Income tax expense		(31,783)	(8,840)	(168,527)	(86,837)
NET LOSS		(73,758)	(371,836)	(392,177)	(8,362,626)
Segment, Continuing and Discontinued Operations [Member]
Cash		695,667		1,145,633	151,766
Accounts receivable, net		643,594		400,175	117,967
Inventory, net		1,462,009		1,689,304	1,445,839
Prepaid and other current assets		326,539		308,743	60,885
Note receivable				0	5,224,423
TOTAL CURRENT ASSETS		3,127,809		3,543,855	7,000,880
Property and equipment, net		4,758,167		4,901,269	5,533,833
Intangible assets, net		2,369,184		2,278,026	1,699,966
Deposits and other noncurrent assets		75,469		82,904	91,504
Operating lease right-of-use assets, net				0	26,685
TOTAL ASSETS		10,330,629		10,806,054	14,352,868
Accounts payable		1,849,126		1,921,936	2,559,914
Accrued interest		570,356		542,952	397,652
Accrued expenses		1,153,717		1,063,367	888,012
Notes payable, net		4,104,186		4,079,804	5,534,728
Indebtedness to related parties		84,913		84,913	586,512
Note payable to related party				0	151,923
Income tax payable		793,292		761,509	592,982
Finance lease obligations, current		152,250		143,967	166,769
Operating lease obligations, current				0	7,265
TOTAL CURRENT LIABILITIES		8,707,840		8,598,448	10,885,757
Convertible notes payable		305,877		292,410	0
Operating lease obligations, long term				0	22,515
Finance lease obligations, long term		3,347,363		3,389,124	3,533,090
TOTAL LIABILITIES		12,361,080		12,279,982	14,441,362
Sales revenue		1,342,586	551,197	4,110,456	3,689,697
Cost of goods sold		(1,219,041)	(491,795)	(3,506,722)	(4,576,627)
Gross profit		123,545	59,402	603,734	(886,930)
General and administrative expenses		577,483	804,708	2,278,603	7,776,126
Loss on impairment of long-lived assets				0	4,645,054
LOSS FROM OPERATIONS		(453,938)	(745,306)	(1,674,869)	(13,308,110)
Gain/(loss) on extinguishment				467,872	(216,954)
Gain on settlement of accounts payable				477,372	0
Gain on deconsolidation				0	4,393,242
Interest expense		(167,585)	(795,313)	(1,771,941)	(1,803,344)
Loss on modification of line of credit				(650,000)	0
Loss on modification of note receivable				0	(1,895,434)
Debt default penalty		0	(286,059)	(286,059)	0
Other expense				(118,875)	(194,248)
Total other expense		(146,696)	(1,092,554)	(1,881,631)	283,262
NET LOSS BEFORE INCOME TAXES		(600,634)	(1,837,860)	(3,556,500)	(13,024,848)
Income tax expense		(31,783)	(8,840)	(168,527)	(86,837)
NET LOSS		$ (632,417)	$ (1,846,700)	$ (3,725,027)	$ (13,111,685)

Note 4 - Discontinued Operati_5

Note 4 - Discontinued Operations - Schedule of Inventory (Details) - Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] - USD ($)	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020
Raw materials	$ 112,857	$ 86,076	$ 91,465
Work in progress	814,166	743,844	1,166,511
Finished goods	601,807	866,195	466,319
Subtotal	1,528,830	1,696,115	1,724,295
Allowance to reduce inventory to net realizable value	(66,821)	(6,811)	(278,456)
Total inventory, net	$ 1,462,009	$ 1,689,304	$ 1,445,839

Note 4 - Discontinued Operati_6

Note 4 - Discontinued Operations - Lease Costs Recorded in the Company's Financial Statements (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020
Total lease cost, discontinued operations		$ 572,935	$ 754,653
Total lease cost		572,935	754,653
Discontinued Operations [Member]
Finance leases - amortization of ROU assets	$ 38,675	154,699	252,973
Finance leases - interest on lease liabilities	$ 101,583	414,993	426,374
Operating leases		3,243	13,648
Total lease cost, discontinued operations		572,935	692,995
Total lease cost		572,935	692,995
Continuing Operations [Member] | General and Administrative Expense [Member]
Operating leases		$ 0	$ 61,658

Note 4 - Discontinued Operati_7

Note 4 - Discontinued Operations - Future Minimum Lease Payments (Details) - Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] - USD ($)	Jun. 30, 2021	Mar. 31, 2021
2023	$ 560,625	$ 544,296
2024	577,444	560,625
2025	594,767	577,444
2026	612,610	594,767
2026		612,610
Thereafter	3,168,492	3,168,492
Total minimum lease payments, finance leases	5,923,173	6,058,234
Less: Amount representing interest, finance leases	(2,423,560)	(2,525,143)
Present value of minimum lease payments, finance leases	3,499,613	3,533,091
Less: Current maturities of capital lease obligations, finance leases	(152,250)	(143,967)
Long-term capital lease obligations, finance leases	$ 3,347,363	$ 3,389,124

Note 5 - Notes Payable and Li_3

Note 5 - Notes Payable and Line of Credit (Details Textual) - USD ($)	Dec. 29, 2020	Oct. 05, 2020	May 07, 2020	Oct. 23, 2017	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2021	Mar. 31, 2021	Jun. 30, 2021	Aug. 10, 2020	Jul. 24, 2020	May 06, 2020	Mar. 24, 2020	Nov. 27, 2019	Nov. 15, 2019
Notes Payable, Current, Total							$ 3,594,804	$ 5,054,728	$ 3,594,804	$ 3,594,804	$ 3,594,804
Proceeds from Lines of Credit, Total							375,000	0
Payments of Debt Issuance Costs							74,750	175,000
Interest Expense, Debt, Excluding Amortization							0	84,354
Amortization of Debt Discount (Premium)					$ 37,849	$ 510,885	776,122	1,150,995
Gain (Loss) on Amendment to Line of Credit							(650,000)	$ 0
The July 24 Note [Member]
Gain (Loss) on Amendment to Line of Credit	$ (650,000)
Repriced Preexisting Warrants with Convertible Debt Issuance [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			8,002,500
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.04
Warrants and Rights Outstanding			$ 272,085												$ 49,525
Fair Value Adjustment of Warrants			$ 222,560
Line of Credit [Member]
Debt Instrument, Interest Rate, Stated Percentage																	8.00%
Line of Credit Facility, Maximum Borrowing Capacity																	$ 470,000
Proceeds from Lines of Credit, Total									485,000	485,000
Line of Credit Facility, Maximum Borrowing Capacity, Increased									15,000	15,000
Interest Payable					49,211		38,767		38,767	38,767	38,767	$ 49,211
Long-term Line of Credit, Total					485,000		485,000		485,000	485,000	485,000	485,000
Teco [Member]
Financing Receivable, after Allowance for Credit Loss, Total																$ 4,000,000		$ 4,000,000
Disposal Group, Including Discontinued Operation, Consideration					4,000,000		4,000,000		4,000,000	4,000,000	4,000,000	4,000,000
Teco [Member] | The July 24 Note [Member]
Interest Payable					58,495							58,495
Interest and Debt Expense, Total							12,510
Financing Receivable, after Allowance for Credit Loss, Total	3,025,000				1,025,000		1,025,000		1,025,000	1,025,000	1,025,000	1,025,000
Increase (Decrease) in Notes Receivable, Current	975,000
Notes Receivable, Maximum Allowed Prepayments On Note	325,000
Disposal Group, Including Discontinued Operation, Consideration	4,000,000
Gain (Loss) on Amendment to Line of Credit	$ (650,000)						(650,000)
Notes Receivable, Additional Advances					50,000		50,000
The July 24 Note [Member]
Debt Instrument, Interest Rate, Stated Percentage														8.00%
The July 24 Note [Member] | Revolving Credit Facility [Member]
Debt Instrument, Interest Rate, Stated Percentage														8.00%
Line of Credit Facility, Maximum Borrowing Capacity														$ 500,000
The July 24 Note [Member] | Teco [Member]
Financing Receivable, after Allowance for Credit Loss, Total														$ 4,000,000
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding														3
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage				0.00%									0.00%				0.00%
Debt Instrument, Face Amount				$ 700,000
Debt Instrument, Term (Year)				3 years
Debt Instrument, Present Value				$ 521,067
Receivable with Imputed Interest, Effective Yield (Interest Rate)				20.30%
Debt Instrument, Unamortized Discount, Total				$ 178,933	0		0		0	0	0	0
Repayments of Debt											330,555	330,555
Notes Payable, Current, Total					369,445		369,445		369,445	369,445	369,445	$ 369,445
Interest Expense, Debt, Total							13,929
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | Membership Interest Purchase Agreement for Sale of Interest in GB Sciences Nopah, LLC [Member]
Debt Instrument, Principal Balance After Reduction Upon Close of Disposition													$ 190,272
Debt Instrument, Penalty Rate Waived Upon Closing of Disposition													15.00%
Convertible Debt [Member]
Interest Expense, Debt, Total					15,856		208,779
Interest Payable							228,373		$ 228,373	$ 228,373	$ 228,373
Amortization of Debt Discount (Premium)					$ 244,129		139,253
Convertible Debt [Member] | The 8% Note Payable dated May 7, 2020 [Member]
Debt Instrument, Interest Rate, Stated Percentage			8.00%
Debt Instrument, Face Amount			$ 150,000
Debt Instrument, Unamortized Discount, Total			150,000
Proceeds from Issuance of Long-term Debt, Net			135,000
Payments of Debt Issuance Costs			15,000
Repayments of Long-term Debt, Total			$ 8,000,000
Interest and Debt Expense, Total		$ 154,964					154,964
Interest Expense, Debt, Excluding Amortization							4,964
Amortization of Debt Discount (Premium)							$ 150,000
Nevada Medical Marijuana Production License Agreement [Member]
Payments to Acquire License				$ 500,000
Nevada Medical Marijuana Production License Agreement [Member] | Production License [Member]
Ownership of Licence				100.00%
Nevada Medical Marijuana Production License Agreement [Member] | Cultivation License [Member]
Ownership of Licence				100.00%

Note 5 - Notes Payable and Li_4

Note 5 - Notes Payable and Line of Credit - Schedule of Debt Payable (Details) - USD ($)	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020	Apr. 23, 2019	Oct. 23, 2017
Discount, short-term notes payable	$ (272,122)	$ (296,504)	$ (608,580)
Discount, long-term notes payable	(141,123)	(154,590)	0
Promissory Note [Member]
Face value, short term notes and convertible notes payable classified as continuing operations	447,000	447,000
Discount, long-term notes payable		(154,590)
Carrying Value, long-term notes payable		292,410
Total long-term notes payable classified as continuing operations	447,000	447,000
The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]
Face Value, short-term notes payable					$ 700,000
The 6 % Note Payable Dated September 30, 2023 [Member] | Convertible Debt [Member]
Face Value, short-term notes payable	197,000	197,000
Discount, long-term notes payable	(37,204)	(40,561)
Carrying Value, long-term notes payable	159,796	156,439
The 6 % Note Payable Dated December 31, 2023 [Member] | Convertible Debt [Member]
Face Value, short-term notes payable	250,000	250,000
Discount, long-term notes payable	(103,919)	(114,029)
Carrying Value, long-term notes payable	146,081	135,971
Convertible Notes Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Face Value, short-term notes payable	369,445	369,445	369,445
Discount, short-term notes payable	0	0	(13,929)
Carrying Value, short-term notes payable	369,445	369,445	355,516
Convertible Notes Payable [Member] | The 6% Note Payable Due November 30, 2018 [Member]
Face Value, short-term notes payable	1,060,000	1,060,000	1,257,000
Discount, short-term notes payable	0	0	(155,340)
Carrying Value, short-term notes payable	1,060,000	1,060,000	1,101,660
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Face Value, short-term notes payable			2,765,000	$ 2,765,000
Discount, short-term notes payable			(29,830)
Carrying Value, short-term notes payable			2,735,170
Convertible Notes Payable [Member] | The 6% Notes Payable Due January 18, 2022 [Member]
Face Value, short-term notes payable	325,000	325,000
Discount, short-term notes payable	(272,122)	(296,504)
Carrying Value, short-term notes payable	52,878	28,496
Line of Credit [Member] | The 8% Line of Credit Dated November 27, 2019 [Member]
Face Value, short-term notes payable	485,000	485,000	480,000
Discount, short-term notes payable	0	0	0
Carrying Value, short-term notes payable	485,000	485,000	480,000
Line of Credit [Member] | The 8% Line of Credit Dated July 24, 2020 [Member]
Face Value, short-term notes payable	1,025,000	1,025,000
Discount, short-term notes payable	0	0
Carrying Value, short-term notes payable	1,025,000	1,025,000
Senior Secured Convertible Promissory Note [Member] | The Amended 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Face Value, short-term notes payable	1,111,863	1,111,863	1,271,863
Discount, short-term notes payable	0	0	(409,481)
Carrying Value, short-term notes payable	1,111,863	1,111,863	862,382
Promissory Note [Member]
Face Value, short-term notes payable	4,376,308	4,376,308	6,143,308
Discount, short-term notes payable	(272,122)	(296,504)	(608,580)
Carrying Value, short-term notes payable	4,104,186	4,079,804	5,534,728
Less: Notes payable classified as discontinued operations, face value	(485,000)	(485,000)	(480,000)
Less: Notes payable classified as discontinued operations, discount	0	0	0
Less: Notes payable classified as discontinued operations, carrying value	(485,000)	(485,000)	(480,000)
Face value, short term notes and convertible notes payable classified as continuing operations	3,891,308	3,891,308	5,663,308
Total short term notes and convertible notes payable classified as continuing operations	(272,122)	(296,504)	(608,580)
Total short-term notes payable classified as continuing operations	3,619,186	3,594,804	5,054,728
Total long-term notes payable classified as continuing operations	$ 3,891,308	$ 3,891,308	$ 5,663,308

Note 6 - Convertible Notes (Det

Note 6 - Convertible Notes (Details Textual)	Dec. 16, 2020USD ($)	Jul. 14, 2020USD ($)	Apr. 22, 2020USD ($)	Dec. 16, 2019USD ($)$ / sharesshares	Nov. 27, 2019USD ($)$ / shares	Nov. 18, 2019USD ($)$ / sharesshares	Oct. 30, 2019USD ($)$ / sharesshares	Oct. 23, 2019USD ($)$ / shares	Aug. 01, 2019USD ($)$ / sharesshares	Jul. 12, 2019USD ($)$ / shares	May 28, 2019USD ($)$ / sharesshares	Apr. 23, 2019USD ($)$ / shares	Feb. 28, 2019USD ($)$ / shares	Jul. 31, 2017USD ($)$ / shares	Mar. 31, 2017USD ($)$ / shares	Jun. 30, 2021USD ($)	Mar. 31, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)	May 31, 2017USD ($)$ / sharesshares	Mar. 31, 2021USD ($)$ / shares	Dec. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2021USD ($)$ / sharesshares	Mar. 31, 2020USD ($)shares	Dec. 18, 2020$ / shares	Dec. 09, 2020USD ($)	Nov. 20, 2020USD ($)	Dec. 31, 2019USD ($)
Class of Warrant or Right, Issued During Period (in shares) | shares																						43,493,809	7,622,780
Amortization of Debt Discount (Premium)																$ 37,849		$ 510,885				$ 776,122	$ 1,150,995
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares																							7,583,333
Gain (Loss) on Extinguishment of Debt, Total																						467,872	$ (216,954)
Interest Expense, Debt, Excluding Amortization																						0	84,354
Induced Conversion of Convertible Debt Expense																						0	127,059
Proceeds from Convertible Debt																0		$ 150,000				725,000	2,630,000
Convertible Notes Payable, Current																3,619,186	$ 3,594,804			$ 3,594,804		3,594,804
Debt Instrument, Unamortized Discount, Current																272,122	296,504			296,504		296,504	608,580
Convertible Notes Payable, Noncurrent																305,877	292,410			292,410		292,410	0
Debt Instrument, Unamortized Discount, Noncurrent																141,123	154,590			154,590		154,590	0
Repayment of Iliad Note [Member] | Judicial Ruling [Member]
Debt Instrument, Debt Default, Interest Rate Penalty		15.00%
Litigation Settlement, Amount Awarded to Other Party		$ 3,264,594
Litigation Settlement, Amount Final Settlement																									$ 3,006,015	$ 3,006,015
Litigation Settlement, One Time Required Payment																									25,000
Litigation Settlement, Weekly Required Payment																									$ 25,000
Litigation Settlement, Payment	$ 3,006,015
Judgment Settlement Agreement [Member] | Judicial Ruling [Member]
Litigation Settlement, Expense																						25,000
Teco [Member]
Disposal Group, Including Discontinued Operation, Consideration																4,000,000	4,000,000			4,000,000		4,000,000
Convertible Debt [Member]
Debt Instrument, Extended Amount																	197,000			197,000		197,000
Interest Expense, Debt, Total																15,856						208,779
Amortization of Debt Discount (Premium)																244,129						139,253
Interest Payable																	228,373			228,373		228,373
Debt Instrument, Debt Default, Amount																1,060,000	$ 1,060,000			$ 1,060,000		$ 1,060,000
Warrants Issued in March 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Number of Warrants															4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares															$ 0.60				$ 0.60
Warrants and Rights Outstanding, Term (Year)															3 years				3 years
Class of Warrant or Right, Issued (in shares) | shares																			8,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares																			1
Warrants Issued In March 2017 and July 2017 Convertible Note Offerings [Member]
Debt Instrument, Convertible, Number of Warrants														4,000
Class of Warrant or Right, Issued During Period (in shares) | shares																						788,000
Warrants Related to July 2017 Convertible Note Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares														$ 0.65							$ 0.60
Warrants and Rights Outstanding, Term (Year)																					3 years
Class of Warrant or Right, Issued (in shares) | shares																					28,804,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares																					1
Warrants Issued in September 30, 2023, Convertible Note Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																	$ 0.10			$ 0.10		$ 0.10
Warrants and Rights Outstanding, Term (Year)																	3 years			3 years		3 years
Warrants and Rights Outstanding																	$ 13,396			$ 13,396		$ 13,396
March And July 2017 Convertible Note Offering [Member] | Convertible Debt [Member]
Debt Instrument, Unamortized Discount, Total																	46,886			46,886		46,886
Debt Instrument, Convertible, Beneficial Conversion Feature																						33,490
Interest Expense, Debt, Total																6,303						28,306
Amortization of Debt Discount (Premium)																3,356						22,412
Interest Payable																47,279	44,332			44,332		44,332
Interest Payable, Accrued Prior to Extinguishments																38,438	38,438			38,438		38,438
The 6 % Convertible Note Payable Dated December 31, 2023 [Member]
Debt Instrument, Interest Rate, Stated Percentage																								6.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares																								$ 0.05
Debt Instrument, Unamortized Discount, Total																	74,750			74,750		74,750
Debt Instrument, Convertible, Beneficial Conversion Feature																						347,000
Interest Expense, Debt, Total																						16,354
Amortization of Debt Discount (Premium)																						11,217
Convertible Notes Payable, Current																	28,496			28,496		28,496
Debt Instrument, Unamortized Discount, Current																	296,504			296,504		296,504
Convertible Notes Payable, Noncurrent																	135,971			135,971		135,971
Debt Instrument, Unamortized Discount, Noncurrent																	114,029			114,029		114,029
The 6 % Convertible Note Payable Dated December 31, 2023 [Member] | Three Investors [Member]
Debt Instrument, Face Amount																	575,000			575,000		575,000
The 6 % Convertible Note Payable Mature in December 2021 [Member] | Three Investors [Member]
Debt Instrument, Face Amount																	325,000			325,000		325,000
The 6 % Convertible Note Payable Mature in December 2023 [Member]
Interest Expense, Debt, Total																24,458
Amortization of Debt Discount (Premium)																15,857
Convertible Notes Payable, Current																52,878
Debt Instrument, Unamortized Discount, Current																272,122
Convertible Notes Payable, Noncurrent																146,081
Debt Instrument, Unamortized Discount, Noncurrent																103,919
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Three Investors [Member]
Debt Instrument, Face Amount																	250,000			250,000		250,000
The 6 Percent Convertible Note Payable Issued With In Money Conversion Features [Member]
Debt Instrument, Face Amount																	425,000			425,000		425,000
Debt Instrument, Unamortized Discount, Total																	$ 74,750			$ 74,750		74,750
Debt Instrument, Convertible, Beneficial Conversion Feature																						347,000
Proceeds from Convertible Debt																						500,250
Convertible Notes Payable [Member]
Debt Instrument, Convertible, Beneficial Conversion Feature																						$ 543,886	829,737
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note															$ 1,000
Debt Instrument, Interest Rate, Stated Percentage															6.00%
Debt Instrument, Face Amount																			$ 2,000,000
Debt Instrument, Term (Year)																			3 years
Debt Instrument, Unamortized Discount, Total																			$ 1,933,693
Debt Instrument, Convertible, Beneficial Conversion Feature																			904,690
Debt Instrument, Convertible, Discount, Fair Value of Warrants																			$ 1,029,003
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments															4,000				8,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares															$ 0.25
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note														$ 1,000
Debt Instrument, Face Amount																					$ 7,201,000
Debt Instrument, Term (Year)														3 years							3 years
Debt Instrument, Unamortized Discount, Total																					$ 7,092,796
Debt Instrument, Convertible, Beneficial Conversion Feature																					3,142,605
Debt Instrument, Convertible, Discount, Fair Value of Warrants																					$ 3,950,191
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments														4,000							28,804,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares														$ 0.25
Convertible Notes Payable [Member] | March And July 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares																	$ 0.10			$ 0.10		$ 0.10
Debt Instrument, Extended Amount																	$ 197,000			$ 197,000		$ 197,000
Convertible Notes Payable, Total																	1,257,000			1,257,000		1,257,000
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage												8.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares						$ 0.0375	$ 0.06					$ 0.17
Debt Instrument, Face Amount												$ 2,765,000											2,765,000
Debt Instrument, Unamortized Discount, Total												265,000
Interest Expense, Debt, Total																				209,292		379,956
Amortization of Debt Discount (Premium)																						29,831
Debt Conversion, Original Debt, Amount						$ 50,000	$ 75,000																125,000
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares						1,333,333	1,250,000
Short-term Debt, Total																							2,735,170
Gain (Loss) on Extinguishment of Debt, Total																						467,872
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total												440,000
Payments for Brokerage Fees												$ 175,000
Induced Conversion of Convertible Debt Expense						$ 62,353	$ 64,706																127,059
Debt Instrument, Debt Default, Interest Rate Penalty			10.00%
Debt Instrument, Debt Default, Interest Expense			$ 9,559
Debt Instrument, Debt Default, Principal Expense			$ 276,500
Debt Instrument, Debt Default, Increase in Principal Amount, Percent			10.00%
Interest Expense, Debt, Pre-judgment Interest																						140,833
Debt Instrument, Unamortized Discount, Current																							29,830
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Judicial Ruling [Member]
Litigation Settlement, Amount Awarded to Other Party		$ 3,264,594																				3,264,594
Litigation Settlement, Amount Including Interest Expense																	3,473,886			3,473,886		3,473,886
Promissory Note [Member]
Debt Instrument, Face Amount																4,376,308	4,376,308			4,376,308		4,376,308	6,143,308
Short-term Debt, Total																4,104,186	4,079,804			4,079,804		4,079,804	5,534,728
Debt Instrument, Unamortized Discount, Current																272,122	296,504			296,504		296,504	608,580
Promissory Note [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Interest Rate, Stated Percentage														6.00%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage					8.00%					8.00%			8.00%
Debt Instrument, Face Amount													$ 1,500,000
Debt Instrument, Unamortized Discount, Total				$ 57,551					$ 9,579																		$ 584,842
Debt Instrument, Convertible, Beneficial Conversion Feature								$ 92,796		$ 133,806			$ 176,471
Interest Expense, Debt, Total				584,842																		477,500
Amortization of Debt Discount (Premium)				57,551																		409,481
Interest Payable																144,994
Debt Conversion, Original Debt, Amount				120,000					110,000								160,000						125,000
Debt Instrument, Increase (Decrease), Net, Total				(62,449)	$ 30,000				(100,421)	100,000
Short-term Debt, Total				1,271,863	1,361,863			$ 1,269,067	$ 1,361,863	1,338,057						1,111,863	1,111,863			1,111,863		1,111,863					$ 687,021
Proceeds from Related Party Debt										100,000
Debt Instrument, Increase, Accrued Interest										41,863
Gain (Loss) on Extinguishment of Debt, Total					$ 0					$ (124,158)													$ (92,796)
Long-term Debt, Gross				$ 687,021
Interest Expense, Debt, Excluding Amortization																						68,019
Long Term Debt Including Interest																$ 1,256,857	$ 1,256,857			$ 1,256,857		$ 1,256,857
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | CSW Ventures, L.P. [Member]
Debt Instrument, Interest Rate, Stated Percentage											8.00%
Debt Instrument, Unamortized Discount, Total											$ 17,225
Debt Conversion, Original Debt, Amount											170,000
Debt Instrument, Increase (Decrease), Net, Total											(152,775)
Short-term Debt, Total											$ 1,330,000
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | GB Sciences, Nevada, LLC [Member] | Collateral Pledged [Member]
Noncontrolling Interest, Ownership Percentage by Parent													100.00%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments													8,823,529
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares				$ 0.04	$ 0.04			$ 0.08	$ 0.11	$ 0.11			$ 0.17				$ 0.04			$ 0.04		$ 0.04
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares				3,000,000					1,000,000								4,000,000
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member] | CSW Ventures, L.P. [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares											$ 0.17
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares											1,000,000

Note 7 - Property and Equipme_3

Note 7 - Property and Equipment (Details Textual) - USD ($)	Mar. 24, 2020	Nov. 15, 2019	Mar. 31, 2021	Mar. 31, 2020
Depreciation, Total			$ 34,555	$ 541,462
Depreciation, Capitalized to Inventory			532,785	$ 811,508
Teco [Member]
Sale of Stock, Percentage of Ownership	100.00%	100.00%		100.00%
Disposal Group, Including Disconitnued Operation, Estimated Future Undiscounted Cash Flows	$ 8,000,000
Disposal Group, Including Discontinued Operation, Carrying Basis	11,900,000
Disposal Group, Including Disconitnued Operation, Fair Value Disclosure	7,300,000
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down	$ 4,645,054
Disposal Group, Including Discontinued Operation, Discount Rate	17.00%
Discontinued Operations [Member]
Depreciation, Total			21,855	$ 424,501
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down			$ 0	$ 4,645,054

Note 7 - Property and Equipme_4

Note 7 - Property and Equipment - Property and Equipment (Details) - USD ($)	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020
Property and Equipment, Gross		$ 771,379
Property and Equipment, Gross, Including Discontinued Operations		6,200,097
Less accumulated depreciation and amortization		(746,357)
Less accumulated depreciation and amortization, Including Discontinued Operations		(1,298,828)
Property and Equipment, Net	$ 21,895	25,022	$ 37,821
Property and Equipment, Net, Including Discontinued Operations		4,901,269
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Property and Equipment, Gross, Discontinued Operations		5,428,717
Less accumulated depreciation and amortization, Discontinued Operations		(552,471)
Property and Equipment, Net, Discontinued Operations		4,876,247
Furniture and Fixtures [Member]
Property and Equipment, Gross		0
Property and Equipment, Gross, Including Discontinued Operations		0
Furniture and Fixtures [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Property and Equipment, Gross, Discontinued Operations		0
Computer Equipment [Member]
Property and Equipment, Gross		151,748
Property and Equipment, Gross, Including Discontinued Operations		151,748
Computer Equipment [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Property and Equipment, Gross, Discontinued Operations		0
Machinery and Equipment [Member]
Property and Equipment, Gross		619,631
Property and Equipment, Gross, Including Discontinued Operations		908,666
Machinery and Equipment [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Property and Equipment, Gross, Discontinued Operations		289,035
Leaseholds and Leasehold Improvements [Member]
Property and Equipment, Gross		0
Property and Equipment, Gross, Including Discontinued Operations		3,455,600
Leaseholds and Leasehold Improvements [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Property and Equipment, Gross, Discontinued Operations		3,455,600
Construction in Progress [Member]
Property and Equipment, Gross		0
Property and Equipment, Gross, Including Discontinued Operations		21,069
Construction in Progress [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Property and Equipment, Gross, Discontinued Operations		21,069
Finance Lease Right-of-use Asset [Member]
Property and Equipment, Gross		0
Property and Equipment, Gross, Including Discontinued Operations		1,663,013
Finance Lease Right-of-use Asset [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Property and Equipment, Gross, Discontinued Operations		$ 1,663,013

Note 8 - Income Taxes (Details

Note 8 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Effective Income Tax Rate Reconciliation, Percent, Total	(3.60%)	0.00%
Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations, Total	$ 168,527	$ 86,837
Income Tax Reconciliation, Prior Year Tax Penalties	48,076
Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount	486,145
Taxes Payable, Current, Total	761,509	592,982
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	154,914
Operating Loss Carryforwards, Total	51,776,062	$ 50,596,940
Operating Loss Carryforwards, Subject to Expiration	34,481,122
Operating Loss Carryforwards, Not Subject to Expiration	$ 17,294,940

Note 8 - Income Taxes - Reconci

Note 8 - Income Taxes - Reconciliation of Effective Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Tax benefit computed at U.S. statutory rates	$ (697,040)	$ (2,178,478)
IRC Section 280E	173,045	202,877
Other permanent items	14,407	22,948
Change in valuation allowance	26,720	1,952,653
Adjustments to valuation of deferred tax assets	603,319	0
Total provision for income taxes	120,451	0
Penalties and interest on prior year tax liabilities	48,076	86,837
Total income tax expense	$ 168,527	$ 86,837

Note 8 - Income Taxes - Deferre

Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Stock based compensation	$ 3,131,344	$ 2,943,816
Net operating loss carryforward	10,460,788	10,625,357
Impairment of long-lived assets	975,461	975,461
Depreciation and Amortization expense	(458,938)	(324,707)
Other temporary items	220,795	136,243
Total deferred tax assets	14,329,450	14,356,170
Less valuation allowance	(14,329,450)	(14,356,170)
Net deferred tax asset	$ 0	$ 0

Note 9 - Capital Transactions_2

Note 9 - Capital Transactions (Details Textual) - USD ($)	Jan. 02, 2021	Dec. 15, 2020	Dec. 07, 2020	Nov. 16, 2020	Dec. 16, 2019	Nov. 27, 2019	Nov. 18, 2019	Oct. 30, 2019	Aug. 01, 2019	Jul. 12, 2019	May 28, 2019	Dec. 31, 2019	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Jul. 11, 2019	Mar. 31, 2021	Mar. 31, 2020	Feb. 08, 2021	Jan. 01, 2021	Apr. 01, 2020	Oct. 23, 2019	Apr. 23, 2019	Mar. 31, 2019	Feb. 28, 2019
Proceeds from Warrant Exercises													$ 62,660		$ 151,202		$ 1,075,396	$ 1,274,790
Brokerage Fees for Issuance of Common Stock and Warrants													6,266		0
Induced Dividend from Warrant Exercises													0		0		$ 0	$ 0
Class of Warrant or Right, Issued During Period (in shares)																	43,493,809	7,622,780
Class of Warrant or Right, Outstanding (in shares)														85,843,036			85,843,036	84,538,161						99,790,989
Class of Warrant or Right, Expense																	$ 211,000	$ 103,472
Debt Conversion, Converted Instrument, Shares Issued (in shares)																		7,583,333
Induced Conversion of Convertible Debt Expense																	$ 0	$ 127,059
Exercise of Warrants for Stock, Shares (in shares)																		17,563,000
Stock Issued During Period, Shares, Issued for Services (in shares)																		2,100,000
Stock Issued During Period, Value, Issued for Services																		$ 214,000
Share-based Payment Arrangement, Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)																	6,750,000	0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)																	$ 0.045
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)														17,733,334			17,733,334	10,983,334						12,583,334
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)														$ 0.11			$ 0.11	$ 0.28						$ 0.28
Share-based Payment Arrangement, Nonemployee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)																	3,500,000	0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)																	$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)														5,883,000			5,883,000	2,383,000						2,383,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)														$ 0.14			$ 0.14	$ 0.27						$ 0.27
Common Stock [Member]
Induced Dividend from Warrant Exercises													$ 0		$ 0		$ 0	$ 0
Exercise of Warrants for Stock, Shares (in shares)													2,088,667		4,991,084		35,798,809	17,563,000
Stock Issued During Period, Shares, Issued for Services (in shares)																		2,100,000
Stock Issued During Period, Value, Issued for Services																		$ 210
Convertible Debt [Member]
Debt Instrument, Extended Amount														$ 197,000			$ 197,000
March And July 2017 Convertible Note Offering [Member] | Convertible Debt [Member]
Debt Instrument, Unamortized Discount, Total														46,886			$ 46,886
Convertible Notes Payable [Member] | March And July 2017 Convertible Note Offering [Member]
Debt Instrument, Extension Period (Year)																	3 years
Debt Instrument, Extended Amount														$ 197,000			$ 197,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)														$ 0.10			$ 0.10
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Debt Conversion, Original Debt, Amount							$ 50,000	$ 75,000										125,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)							$ 0.0375	$ 0.06															$ 0.17
Debt Conversion, Converted Instrument, Shares Issued (in shares)							1,333,333	1,250,000
Debt Instrument, Interest Rate, Stated Percentage																							8.00%
Debt Instrument, Unamortized Discount, Total																							$ 265,000
Short-term Debt, Total																		2,735,170
Induced Conversion of Convertible Debt Expense							$ 62,353	$ 64,706										127,059
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Debt Conversion, Original Debt, Amount					$ 120,000				$ 110,000					$ 160,000				125,000
Debt Instrument, Interest Rate, Stated Percentage						8.00%				8.00%															8.00%
Debt Instrument, Unamortized Discount, Total					57,551				9,579			$ 584,842
Debt Instrument, Increase (Decrease), Net, Total					(62,449)	$ 30,000			(100,421)	$ 100,000
Short-term Debt, Total					$ 1,271,863	$ 1,361,863			$ 1,361,863	$ 1,338,057		$ 687,021	$ 1,111,863	$ 1,111,863			$ 1,111,863					$ 1,269,067
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | CSW Ventures, L.P. [Member]
Debt Conversion, Original Debt, Amount											$ 170,000
Debt Instrument, Interest Rate, Stated Percentage											8.00%
Debt Instrument, Unamortized Discount, Total											$ 17,225
Debt Instrument, Increase (Decrease), Net, Total											(152,775)
Short-term Debt, Total											$ 1,330,000
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)					$ 0.04	$ 0.04			$ 0.11	$ 0.11				$ 0.04			$ 0.04					$ 0.08			$ 0.17
Debt Conversion, Converted Instrument, Shares Issued (in shares)					3,000,000				1,000,000					4,000,000
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member] | CSW Ventures, L.P. [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)											$ 0.17
Debt Conversion, Converted Instrument, Shares Issued (in shares)											1,000,000
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense		$ 51,050															$ 436,349	$ 287,260
Scientist and Researcher [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)																	3,500,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)																	$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value																	$ 168,000
Scientist and Researcher [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)																	10 years
Former Director [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)				$ 0.03
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)				450,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period Before Modification, Fair Value				$ 4,950
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period After Modification, Fair Value				11,250
Share-based Payment Arrangement, Expense				$ 6,300
Employees and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		3,250,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)		$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value																	$ 156,000
Share-based Payment Arrangement, Expense																	62,000
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount														$ 78,000			$ 78,000
Employees and Directors [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		10 years
Employees and Directors [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		33.33%
Employees and Directors [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		33.33%
Employees and Directors [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		33.33%
Current Employees [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)		$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)		6,050,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period Before Modification, Fair Value		$ 199,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period After Modification, Fair Value		$ 250,650
Warrants Issued to Investors in Private Placements [Member]
Class of Warrant or Right, Exercises in Period (in shares)										9,449,750		8,113,250	2,088,667				35,798,809
Proceeds from Warrant Exercises										$ 850,478		$ 307,249	$ 56,394				$ 968,023
Brokerage Fees for Issuance of Common Stock and Warrants										94,498		22,566	6,266				107,373
Induced Dividend from Warrant Exercises												$ 32,215	$ 163,016				$ 1,591,080
Class of Warrant or Right, Outstanding (in shares)																70,500,000
Exercise of Warrants for Stock, Shares (in shares)													2,088,667
Class of Warrant or Right, Temporarily Reduced Exercise Price of Warrants or Rights (in dollars per share)																$ 0.10
Inducement Dividend, Exercise of Warrants										$ 230,025
Warrants Issued to Investors in Private Placements [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)												$ 0.03				0.65					$ 0.03
Warrants Issued to Investors in Private Placements [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)												$ 5				$ 0.30					$ 0.05
Convertible Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)														$ 0.10			$ 0.10
Class of Warrant or Right, Issued During Period (in shares)																	788,000
Class of Warrant or Right, Extension Period of Securities Called by Warrants or Rights (Year)																	3 years
Warrants and Rights Outstanding														$ 13,396			$ 13,396
Employees and Director Warrants [Member] | Employees and Directors [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.04
Warrants and Rights Outstanding			$ 133,000
Share-based Payment Arrangement, Expense			$ 133,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			3,500,000
Warrants and Rights Outstanding, Term (Year)			10 years
Compensation Warrants Issued to Brokers [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.01
Warrants and Rights Outstanding	$ 367,196																			$ 135,861
Class of Warrant or Right, Outstanding (in shares)	9,424,613
Class of Warrant or Right, Expense	$ 231,335
Compensation Warrants Issued to Brokers [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																				$ 0.25
Compensation Warrants Issued to Brokers [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																				$ 1
Replacement Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																			$ 0.10
Warrants and Rights Outstanding																			$ 1,182,920
Warrants and Rights Outstanding, Term (Year)																			3 years
Class of Warrant or Right, Outstanding (in shares)																			42,705,809
Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)														85,843,036			85,843,036
Warrants [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)														$ 0.01			$ 0.01
Warrants [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)														$ 0.90			$ 0.90

Note 9 - Capital Transactions -

Note 9 - Capital Transactions - Warrant Activity (Details) - $ / shares	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Outstanding (in shares)	84,538,161	99,790,989
Warrants issued (in shares)	43,493,809	7,622,780
Warrants issued, exercise price (in dollars per share)	$ 0.10	$ 0.30
Warrants exercised (in shares)	(35,798,809)	(17,563,000)
Warrants expired/cancelled (in shares)	(6,390,125)	(5,312,608)
Outstanding (in shares)	85,843,036	84,538,161
Minimum [Member]
Warrants exercised, exercise price (in dollars per share)	$ 0.030	$ 0.035
Warrants expired/cancelled, exercise price (in dollars per share)	0.60	0.50
Maximum [Member]
Warrants exercised, exercise price (in dollars per share)	0.035	0.10
Warrants expired/cancelled, exercise price (in dollars per share)	$ 0.90	$ 2

Note 10 - Employee Benefit Pl_3

Note 10 - Employee Benefit Plan (Details Textual) - USD ($)	Dec. 15, 2020	Mar. 31, 2021	Mar. 31, 2020	Oct. 25, 2018	Jun. 30, 2015	Feb. 06, 2008
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)		2,022,443
Class of Warrant or Right, Expense		$ 211,000	$ 103,472
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 78,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		0
Restricted Stock [Member]
Share-based Payment Arrangement, Expense		$ 0
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense	$ 51,050	$ 436,349	$ 287,260
GB Sciences, Inc. 2007 Amended Stock Option Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)						4,500,000
The 2014 Equity Compensation Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)					8,500,000
GB Sciences, Inc 2018 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				10,000,000

Note 10 - Employee Benefit Pl_4

Note 10 - Employee Benefit Plan - Assumptions (Details) - Share-based Payment Arrangement, Option [Member]	12 Months Ended
	Mar. 31, 2021
Weighted-average volatility	127.00%
Expected term (in years) (Year)	10 years
Risk-free interest rate	0.93%

Note 10 - Employee Benefit Pl_5

Note 10 - Employee Benefit Plan - Option Activity (Details) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Employee [Member]
Outstanding, options (in shares)	10,983,334	12,583,334
Outstanding, weighted average exercise price (in dollars per share)	$ 0.28	$ 0.28
Outstanding, weighted average remaining contractual life (Year)	6 years 9 months 18 days	6 years 7 days	7 years 2 months 4 days
Outstanding, aggregate intrinsic value	$ 172,000	$ 0	$ 43,000
Granted, options (in shares)	6,750,000	0
Granted, weighted average exercise price (in dollars per share)	$ 0.045
Exercised, options (in shares)	0	0
Exercised, weighted average exercise price (in dollars per share)
Forfeited, options (in shares)	0	(1,600,000)
Forfeited, weighted average exercise price (in dollars per share)		$ 0.27
Outstanding, options (in shares)	17,733,334	10,983,334	12,583,334
Outstanding, weighted average exercise price (in dollars per share)	$ 0.11	$ 0.28	$ 0.28
Fully vested and expected to vest, options (in shares)	17,733,334
Fully vested and expected to vest, weighted average exercise price (in dollars per share)	$ 0.11
Exercisable, options (in shares)	15,566,668
Exercisable, weighted average exercise price (in dollars per share)	$ 0.12
Share-based Payment Arrangement, Nonemployee [Member]
Outstanding, options (in shares)	2,383,000	2,383,000
Outstanding, weighted average exercise price (in dollars per share)	$ 0.27	$ 0.27
Outstanding, weighted average remaining contractual life (Year)	8 years 1 month 9 days	6 years 9 months	7 years 9 months 3 days
Outstanding, aggregate intrinsic value	$ 35,000	$ 0	$ 492,250
Granted, options (in shares)	3,500,000	0
Granted, weighted average exercise price (in dollars per share)	$ 0.05
Exercised, options (in shares)	0	0
Exercised, weighted average exercise price (in dollars per share)
Forfeited, options (in shares)	0	0
Forfeited, weighted average exercise price (in dollars per share)
Outstanding, options (in shares)	5,883,000	2,383,000	2,383,000
Outstanding, weighted average exercise price (in dollars per share)	$ 0.14	$ 0.27	$ 0.27
Fully vested and expected to vest, options (in shares)	5,883,000
Fully vested and expected to vest, weighted average exercise price (in dollars per share)	$ 0.14
Exercisable, options (in shares)	5,883,000
Exercisable, weighted average exercise price (in dollars per share)	$ 0.14

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual)	Dec. 16, 2020USD ($)	Sep. 17, 2020USD ($)	Aug. 24, 2020USD ($)	Jul. 14, 2020USD ($)	Apr. 22, 2020USD ($)	Sep. 18, 2017USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2021USD ($)
Research and Development Expense, Total							$ 352,274	$ 1,543,397
Repayment of Iliad Note [Member] | Judicial Ruling [Member]
Litigation Settlement, Amount Awarded to Other Party				$ 3,264,594
Litigation Settlement, Payment	$ 3,006,015
Payment of Services Provided by Contractor [Member] | Pending Litigation [Member]
Loss Contingency, Damages Sought, Value					$ 73,050
Payment of Services Provided by Contractor [Member] | Settled Litigation [Member]
Payments for Legal Settlements		$ 25,000
Reduction in Cost Basis of Fixed Asset Related to Litigation		$ 48,050
Agreement With Louisiana State University AgCenter [Member]
Term of Agreement (Year)						5 years	3 years
Option to Renew Agreement, Amount						2
Term of Agreement, Renewal (Year)						5 years
Research and Development Expense, Total						$ 500,000	$ 250,000		$ 750,000
Annual Research Contributions			$ 250,000

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Details Textual) - USD ($)	Jan. 02, 2021	Nov. 16, 2020	Mar. 31, 2021	Mar. 31, 2020
Notes Payable, Related Parties, Current			$ 0	$ 151,923
Ksenia Griswold [Member] | Unpaid Severance Compensation [Member]
Related Party Transaction, Amounts of Transaction	$ 57,000	$ 84,913
Related Party Transaction, Expenses from Transactions with Related Party		20,000
Due to Related Parties, Total	114,159
Other Income	$ 57,159
Leslie Bocskor [Member]
Due to Related Parties, Total		78,245
Payments for Postemployment Benefits		6,500
Salary and Wage, Excluding Cost of Good and Service Sold, Total			44,192	$ 40,192
Leslie Bocskor [Member] | Unpaid Severance Compensation [Member]
Related Party Transaction, Amounts of Transaction		$ 84,745
John Davis [Member]
Notes Payable, Related Parties, Current			$ 151,923

Note 13 - Sale of 50% Members_3

Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC (Details Textual) - USD ($)	Dec. 16, 2020	Dec. 08, 2020	Oct. 29, 2020	Nov. 15, 2019	Sep. 30, 2020	Aug. 31, 2020	Oct. 15, 2020	Jun. 30, 2021	Jun. 30, 2020	Oct. 15, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Aug. 24, 2020	Aug. 23, 2020
Proceeds from Divestiture of Businesses								$ 200,000	$ 0
Receivable with Imputed Interest, Discount				$ 1,389,408
Deconsolidation, Gain (Loss), Amount				4,393,242							$ 0	$ 4,393,242
Repayments of Related Party Debt											$ 151,923	0
Wellcana Note [Member]
Note Receivable, Interest Rate											5.00%
Receivable with Imputed Interest, Discount											$ 1,389,408
Receivable with Imputed Interest, Effective Yield (Interest Rate)											17.00%
Receivable with Imputed Interest, Net Amount, Total				6,610,592							$ 6,610,592
Proceeds from Collection of Notes Receivable	$ 4,900,000									$ 4,900,000
Financing Receivable, after Allowance for Credit Loss, Total												$ 7,119,857
GB Sciences Louisiana, LLC [Member]
Deconsolidation, Gain (Loss), Amount				4,393,242
Wellcana Group, LLC [Member] | GB Sciences Louisiana, LLC [Member]
Proceeds from Divestiture of Businesses				8,000,000
Earnout Payments				$ 8,000,000
Proceeds from Collection of Notes Receivable and Liabilities Forgiveness							$ 5,224,423
Repayments of Related Party Debt						$ 151,923	151,923
Debt Instrument, Decrease, Forgiveness					$ 172,500		172,500
Proceeds from Collection of Notes Receivable	$ 4,150,000					$ 550,000	4,900,000
Note Receivable Satisfied							8,000,000
Annual Research Contribution Commitment to LSU Assumed by Counter Party							250,000
Notes Receivable, Net, Scheduled Payments														$ 500,000	$ 750,000
Financing Receivable, after Allowance for Credit Loss, Total													$ 4,350,000
Notes Receivable, Not Yet Collectible							$ 4,350,000			$ 4,350,000
Notes Receivable, Due Date Extended		$ 4,350,000
Notes Receivable, Amount for Which Proof of Funds is Required		4,350,000
Notes Receivable, Escrow Deposit Required of Other Party		250,000
Notes Receivable, Escrow Payment Received			$ 250,000
Notes Receivable, Escrow Payment Not Yet Received		250,000
Notes Receivable, Retained Amount Not Offset Against Full Balance		$ 50,000
Wellcana Group, LLC [Member] | GB Sciences Louisiana, LLC, Sale of Equity [Member]
Sale of Stock, Percentage of Ownership				50.01%

Note 13 - Sale of 50% Members_4

Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC - Note Receivable (Details) - USD ($)	Mar. 31, 2021	Nov. 15, 2019
Total proceeds		$ 8,000,000
Discount on note receivable		(1,389,408)
Wellcana Note [Member]
June 1, 2020		500,000
September 1, 2020		750,000
December 1, 2020		1,000,000
March 1, 2020		1,250,000
June 1, 2021		1,500,000
September 1, 2021		1,500,000
December 1, 2021		1,500,000
Discount on note receivable	$ (1,389,408)
Net present value	$ 6,610,592	$ 6,610,592

Note 13 - Sale of 50% Members_5

Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC - Deconsolidation (Details) - USD ($)	Nov. 15, 2019	Mar. 31, 2021	Mar. 31, 2020
Gain on deconsolidation	$ 4,393,242	$ 0	$ 4,393,242
GB Sciences Louisiana, LLC [Member]
Present value of promissory note	6,610,592
Carrying amount of non-controlling interest	8,707,651
Total	15,318,243
Carrying amount of assets	14,715,798
Carrying amount of liabilities	(3,790,797)
Net assets deconsolidated	$ 10,925,001

Note 13 - Sale of 50% Members_6

Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC - Loss on Modification of Notes Receivable (Details) - USD ($)	Dec. 16, 2020	Oct. 15, 2020	Mar. 31, 2021	Mar. 31, 2020
Loss on modification of note receivable			$ 0	$ (1,895,434)
Wellcana Note [Member]
Total cash payments to be made by October 15, 2020	$ 4,900,000	$ 4,900,000
Liabilities to be forgiven upon receipt of October 15, 2020 payment		324,423
Total receivable (as modified)		$ 5,224,423
Carrying value of note receivable as of March 31, 2020				6,969,720
Accrued interest as of March 31, 2020				150,137
Total amount receivable (prior to modification)				$ 7,119,857

Note 14 - Sale of 100% Member_2

Note 14 - Sale of 100% Membership Interests in Nevada Subsidiaries (Details Textual)	May 11, 2021USD ($)	Dec. 29, 2020USD ($)	Aug. 10, 2020USD ($)	Jul. 24, 2020USD ($)	Mar. 24, 2020USD ($)	Nov. 27, 2019USD ($)	Nov. 15, 2019USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2021USD ($)	Jun. 30, 2021USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2021USD ($)	Oct. 23, 2017
Proceeds from Divestiture of Businesses								$ 200,000	$ 0
Proceeds from Lines of Credit, Total												$ 375,000	$ 0
Gain (Loss) on Amendment to Line of Credit												(650,000)	0
Management Fees Accrued								700,000			$ 700,000
Proceeds from Sale and Collection of Notes Receivable, Total												5,051,923	$ 0
July 24 Note [Member]
Financing Receivable, after Allowance for Credit Loss, Total		$ 975,000
The July 24 Note [Member]
Gain (Loss) on Amendment to Line of Credit		(650,000)
Teco [Member]
Management Fees Accrued										$ 850,000		850,000		$ 850,000	$ 850,000
Proceeds from Sale and Collection of Notes Receivable, Total								$ 4,000,000				$ 4,000,000
Notes Receivable Term (Year)								3 years				3 years
Teco [Member]
Sale of Stock, Percentage of Ownership					100.00%		100.00%						100.00%
Proceeds from Divestiture of Businesses	$ 200,000				$ 4,000,000		$ 4,000,000
Financing Receivable, after Allowance for Credit Loss, Total					$ 4,000,000		$ 4,000,000
Notes Receivable, Interest Rate					8.00%		8.00%
Notes Receivable, Term of Monthly Installments (Month)					36 months
Teco [Member] | July 24 Note [Member]
Financing Receivable, after Allowance for Credit Loss, Total		3,025,000
Increase (Decrease) in Notes Receivable, Current		(975,000)		$ (50,000)
Note Receivable, Maximum Allowed Prepayments On Note		325,000
Teco [Member] | The July 24 Note [Member]
Financing Receivable, after Allowance for Credit Loss, Total		3,025,000						$ 1,025,000		1,025,000	1,025,000	$ 1,025,000		1,025,000	1,025,000
Increase (Decrease) in Notes Receivable, Current		975,000
Gain (Loss) on Amendment to Line of Credit		(650,000)										$ (650,000)
Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity						$ 470,000
Debt Instrument, Interest Rate, Stated Percentage						8.00%
Proceeds from Lines of Credit, Total														$ 485,000	$ 485,000
Teco Note [Member] | Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity							$ 470,000
The July 24 Note [Member]
Debt Instrument, Interest Rate, Stated Percentage				8.00%
Notes Payable, Total		1,025,000
The July 24 Note [Member] | Teco [Member]
Financing Receivable, after Allowance for Credit Loss, Total				$ 4,000,000
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding				3
The July 24 Note [Member] | Secured Debt [Member] | AJE Management, LLC [Member]
Debt Instrument, Interest Rate, Stated Percentage				8.00%
Proceeds from Lines of Credit, Total										$ 375,000	$ 375,000
July 24 Note [Member] | Teco [Member]
Financing Receivable, after Allowance for Credit Loss, Total		$ 4,000,000		$ 4,000,000
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding				3
The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]
Debt Instrument, Interest Rate, Stated Percentage			0.00%			0.00%										0.00%
Teco [Member]
Sale of Stock, Percentage of Ownership							75.00%
Sale of Stock, Consideration Received on Transaction							$ 3,000,000
Sale of Stock, Additional Earn-out Payments							$ 3,000,000
GB Sciences Nopah, LLC [Member]
Sale of Stock, Percentage of Ownership						100.00%
Sale of Stock, Consideration Received on Transaction			$ 300,000			$ 300,000
GB Sciences Nopah, LLC [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]
Sale of Stock, Consideration to Be Received By Means of Debt Reduction			$ 300,000			$ 300,000

Note 15 - Concentrations (Detai

Note 15 - Concentrations (Details Textual)	3 Months Ended		12 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)
Cash, Uninsured Amount			$ 513,901
Revenues, Total	$ 0	$ 0	$ 0	$ 0
NEVADA
Revenues, Total				3,120,620
LOUISIANA
Revenues, Total				$ 569,077
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Customers			3	2
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer One [Member]
Concentration Risk, Percentage			18.40%	26.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Two [Member]
Concentration Risk, Percentage			16.70%	13.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Three [Member]
Concentration Risk, Percentage			13.30%
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | NEVADA
Concentration Risk, Percentage				85.00%
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | LOUISIANA
Concentration Risk, Percentage				15.00%

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual) - USD ($)	Jun. 14, 2021	May 11, 2021	Mar. 24, 2020	Nov. 15, 2019	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021	Mar. 31, 2020
Proceeds from Divestiture of Businesses					$ 200,000	$ 0
Class of Warrant or Right, Exercised During Period (in shares)							35,798,809	17,563,000
Proceeds from Warrant Exercises					$ 62,660	$ 151,202	$ 1,075,396	$ 1,274,790
Subsequent Event [Member]
Class of Warrant or Right, Exercised During Period (in shares)	1,672,000
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)	$ 0.03
Proceeds from Warrant Exercises	$ 50,160
Teco [Member]
Proceeds from Divestiture of Businesses		$ 200,000	$ 4,000,000	$ 4,000,000
Teco [Member] | Subsequent Event [Member]
Proceeds from Divestiture of Businesses		$ 200,000